false0001107421Q3--12-31http://fasb.org/srt/2026#ChiefExecutiveOfficerMember0001107421us-gaap:ResearchAndDevelopmentExpense2026-07-012026-09-300001107421us-gaap:ResearchAndDevelopmentExpense2025-07-012025-09-300001107421us-gaap:EmployeeStockOptionMember2026-01-012026-09-3000011074212025-07-012025-09-300001107421tcrt:SeriesAOnePreferredStockMemberus-gaap:PreferredStockMember2026-06-300001107421srt:MinimumMember2025-07-012025-09-300001107421tcrt:SeriesAOnePreferredStockMember2026-09-300001107421tcrt:BoardOfDirectorsMembertcrt:ServicesRenderedMember2026-07-012026-09-300001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMemberus-gaap:RoyaltyMember2026-07-012026-09-3000011074212025-01-012025-12-310001107421tcrt:CollaborationAgreementWithSolasiaPharmaKkMember2026-01-012026-09-300001107421tcrt:AdditionalPaidInCapitalCommonStockMember2026-09-300001107421tcrt:SeriesAOneAndSeriesATwoConvertiblePreferredStockMember2026-01-012026-09-300001107421tcrt:NonVestedStockMember2026-01-012026-09-300001107421srt:MinimumMember2025-01-012025-09-300001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMemberus-gaap:RoyaltyMember2025-01-012025-09-300001107421srt:MaximumMember2025-01-012025-09-300001107421us-gaap:RetainedEarningsMember2026-09-300001107421us-gaap:SeriesCPreferredStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMember2026-10-130001107421us-gaap:GeneralAndAdministrativeExpense2026-07-012026-09-300001107421tcrt:AdditionalPaidInCapitalCommonStockMember2025-12-3100011074212026-06-300001107421tcrt:TwoThousandAndTwentyEquityIncentivePlanMembersrt:MaximumMember2025-07-030001107421tcrt:September2026RegisteredDirectOfferingMember2026-09-180001107421us-gaap:CommonStockMembersrt:ScenarioForecastMemberus-gaap:SubsequentEventMembertcrt:TwoThousandTwentyEquityIncentivePlanMember2027-03-310001107421tcrt:AdditionalPaidInCapitalCommonStockMember2025-09-3000011074212025-12-310001107421tcrt:September2026RegisteredDirectOfferingMember2026-09-182026-09-180001107421tcrt:AdditionalPaidInCapitalCommonStockMember2025-07-012025-09-300001107421us-gaap:CommonStockMembertcrt:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:SubsequentEventMember2026-10-130001107421tcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMember2026-10-132026-10-130001107421tcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMemberus-gaap:SeriesBPreferredStockMember2026-10-130001107421tcrt:SeriesAOnePreferredStockMemberus-gaap:PreferredStockMember2025-09-300001107421us-gaap:RetainedEarningsMember2026-07-012026-09-300001107421tcrt:SeriesATwoPreferredStockMember2025-12-310001107421srt:MaximumMember2025-07-012025-09-300001107421us-gaap:PreferredStockMembertcrt:SeriesATwoPreferredStockMember2025-12-310001107421tcrt:TwoThousandAndTwentyEquityIncentivePlanMembersrt:MinimumMember2025-07-030001107421tcrt:PreFundedWarrantsMembertcrt:September2026RegisteredDirectOfferingMember2026-09-210001107421us-gaap:CommonStockMember2024-12-310001107421us-gaap:SeriesCPreferredStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-10-132026-10-130001107421tcrt:SeriesATwoPreferredStockMember2026-01-012026-09-300001107421tcrt:AdditionalPaidInCapitalCommonStockMember2026-07-012026-09-300001107421us-gaap:CommonStockMember2025-09-300001107421tcrt:SeriesA-2PreferredStockMember2026-09-300001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterMember2025-12-310001107421us-gaap:SeriesCPreferredStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMember2026-10-132026-10-130001107421us-gaap:CommonStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-10-130001107421us-gaap:RetainedEarningsMember2025-12-310001107421us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001107421us-gaap:CommonStockMember2026-07-012026-09-3000011074212026-07-220001107421tcrt:AdditionalPaidInCapitalCommonStockMember2025-06-300001107421us-gaap:SeriesCPreferredStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-10-130001107421tcrt:EquityLineOfCreditMember2026-01-012026-09-300001107421us-gaap:RetainedEarningsMember2025-07-012025-09-300001107421us-gaap:RetainedEarningsMember2026-06-300001107421us-gaap:PreferredStockMembertcrt:SeriesATwoPreferredStockMember2025-01-012025-09-300001107421tcrt:SeriesAOnePreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-09-300001107421tcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMembertcrt:SeriesBAndSeriesCNonVotingConvertiblePreferredStockMember2026-10-132026-10-130001107421tcrt:SeriesAOnePreferredStockMember2025-01-012025-09-300001107421tcrt:AdditionalPaidInCapitalCommonStockMember2026-01-012026-09-300001107421us-gaap:CommonStockMember2026-01-012026-09-300001107421tcrt:SeriesAOnePreferredStockMemberus-gaap:PreferredStockMember2025-12-310001107421tcrt:BoardOfDirectorsMemberus-gaap:SubsequentEventMembertcrt:BoardServiceFeesServicesRenderedAndSalaryCompensationMember2026-10-012026-10-010001107421tcrt:EquityLineOfCreditMembersrt:MaximumMember2025-05-012025-05-310001107421us-gaap:GeneralAndAdministrativeExpense2025-01-012025-09-300001107421tcrt:SeriesAOnePreferredStockMember2025-12-310001107421us-gaap:RetainedEarningsMember2025-06-3000011074212025-06-300001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember2004-08-310001107421tcrt:CollaborationAgreementWithSolasiaPharmaKkMember2026-07-012026-09-300001107421tcrt:TwoThousandAndTwentyEquityIncentivePlanMember2026-07-060001107421tcrt:OfferingAndRelatedWarrantExercisesMembertcrt:September2026RegisteredDirectOfferingMember2026-09-2100011074212026-11-1600011074212026-07-222026-07-220001107421tcrt:SeriesAOnePreferredStockMemberus-gaap:PreferredStockMember2025-06-300001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterMember2026-09-300001107421us-gaap:SubsequentEventMember2026-10-132026-10-130001107421us-gaap:PreferredStockMembertcrt:SeriesATwoPreferredStockMember2025-09-300001107421us-gaap:CommonStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-10-142026-10-140001107421us-gaap:GeneralAndAdministrativeExpense2026-01-012026-09-300001107421tcrt:NonVestedStockMember2026-09-300001107421us-gaap:CommonStockMembersrt:ScenarioForecastMembertcrt:TwoThousandTwentyEquityIncentivePlanMember2027-07-3000011074212024-12-310001107421us-gaap:PreferredStockMembertcrt:SeriesATwoPreferredStockMember2026-06-300001107421us-gaap:RetainedEarningsMember2026-01-012026-09-300001107421tcrt:TwoThousandAndTwentyEquityIncentivePlanMember2026-09-300001107421us-gaap:CommonStockMember2025-06-300001107421us-gaap:CommonStockMember2026-09-300001107421tcrt:PreFundedWarrantsMembertcrt:September2026RegisteredDirectOfferingMember2026-09-1800011074212025-01-012025-09-300001107421us-gaap:RetainedEarningsMember2025-09-300001107421us-gaap:CommonStockMember2025-01-012025-09-300001107421tcrt:SeriesATwoPreferredStockMember2026-09-300001107421us-gaap:RetainedEarningsMember2024-12-310001107421us-gaap:PreferredStockMembertcrt:SeriesATwoPreferredStockMember2026-09-3000011074212026-09-300001107421us-gaap:ResearchAndDevelopmentExpense2025-01-012025-09-300001107421tcrt:EquityLineOfCreditMembersrt:MaximumMember2025-05-310001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember2026-09-300001107421us-gaap:CommonStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-10-132026-10-130001107421tcrt:AdditionalPaidInCapitalCommonStockMember2026-06-300001107421us-gaap:WarrantMember2025-01-012025-09-3000011074212026-01-012026-09-300001107421tcrt:BoardOfDirectorsMemberus-gaap:SubsequentEventMembertcrt:BoardServiceFeesServicesRenderedAndSalaryCompensationMember2026-10-010001107421tcrt:EquityPurchaseAgreementMember2025-05-012025-05-310001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMemberus-gaap:RoyaltyMember2025-07-012025-09-300001107421tcrt:SeriesA-1PreferredStockMember2026-09-300001107421tcrt:SeriesA-1AndSeriesA-2ConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2026-10-132026-10-1300011074212025-09-300001107421tcrt:CollaborationAgreementWithSolasiaPharmaKkMember2025-01-012025-09-300001107421us-gaap:CommonStockMember2025-07-012025-09-300001107421tcrt:AdditionalPaidInCapitalCommonStockMember2024-12-310001107421tcrt:CollaborationAgreementWithSolasiaPharmaKkMember2025-07-012025-09-300001107421us-gaap:GeneralAndAdministrativeExpense2025-07-012025-09-300001107421tcrt:BoardOfDirectorsMembertcrt:ServicesRenderedMember2026-01-012026-09-300001107421us-gaap:PreferredStockMembertcrt:SeriesATwoPreferredStockMember2025-06-300001107421us-gaap:WarrantMember2026-01-012026-09-300001107421us-gaap:ResearchAndDevelopmentExpense2026-01-012026-09-300001107421tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMemberus-gaap:RoyaltyMember2026-01-012026-09-300001107421us-gaap:CommonStockMember2026-06-300001107421us-gaap:CommonStockMember2025-12-310001107421tcrt:SeriesAOnePreferredStockMember2026-01-012026-09-300001107421us-gaap:RetainedEarningsMember2025-01-012025-09-300001107421us-gaap:SeriesCPreferredStockMembertcrt:VelarisTherapeuticsIncMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-10-142026-10-140001107421tcrt:SeriesAOnePreferredStockMemberus-gaap:PreferredStockMember2026-09-300001107421us-gaap:SeriesCPreferredStockMembertcrt:FairmountHealthcareFundIILPMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-10-140001107421tcrt:AdditionalPaidInCapitalCommonStockMember2025-01-012025-09-300001107421tcrt:SeriesATwoPreferredStockMember2025-01-012025-09-3000011074212026-07-012026-09-30iso4217:USDxbrli:sharesxbrli:purexbrli:sharesiso4217:USD
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
OR
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number: 001-33038
Alaunos Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
Delaware |
84-1475642 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
501 E. Las Olas Blvd., Suite 300 Fort Lauderdale, FL 33301 (346) 355-4099 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock |
|
TCRT |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large Accelerated Filer |
|
☐ |
|
Accelerated Filer |
|
☐ |
Non-Accelerated Filer |
|
☒ |
|
Smaller Reporting Company |
|
☒ |
|
|
|
|
Emerging Growth Company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 16, 2026, the number of outstanding shares of the registrant's common stock, $0.001 par value, was 4,208,359 shares.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Quarterly Report that are not historical fact, and in some cases can be identified by terms such as: “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” "potential," “will” and other words and terms of similar meaning.
These statements are based on management’s current beliefs and assumptions and on information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:
•our ability to raise substantial additional capital to continue as a going concern and fund our planned operations;
•our ability to successfully advance our preclinical Obesity and Metabolic Disorders Program, including ALN1003, through additional studies, formulation optimization, and manufacturing scale-up for progressing toward IND-enabling activities;
•our ability to enter into partnerships, collaborations or licensing arrangements to support development of our Obesity and Metabolic Disorders Program;
•estimates regarding our expenses, use of cash, cash runway, timing of future cash needs and anticipated capital requirements;
•our ability to license additional intellectual property to support our Obesity and Metabolic Disorders Program or out-license our intellectual property;
•our legacy TCR-T assets and limited ongoing efforts to monetize remaining intellectual property and to comply with our existing license agreements;
•our expectation of developments and projections relating to competition from other pharmaceutical and biotechnology companies or our industry;
•our plans relating to conducting future in vitro testing, in vivo studies, and non-clinical and investigational new drug or IND-enabling activities;
•the anticipated amount, timing and accounting of contract liabilities, milestones and other payments under licensing, collaboration or acquisition agreements, research and development costs and other expenses;
•the expected benefits and risks of the Velaris asset acquisition and the financing, including stockholder approval of the conversion of the Series B and Series C Preferred Stock and related charter amendments, the Paragon option, and the reconstitution of our Board;
•our ability to remain listed on the Nasdaq Capital Market, including compliance with the stockholders’ equity continued listing requirement (minimum $2.5 million), and the minimum bid price requirement ($1.00), and the potential consequences of any delisting; and
•our intellectual property position, including the strength and enforceability of our intellectual property rights.
Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, level of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results, levels of activity or performance of achievements to differ materially from current expectations include, among other things, those described in our Annual Report on Form 10-K under Part I, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Unless the context requires otherwise, references in this Quarterly Report to “Alaunos,” the “Company,” “we,” “us” or “our” refer to Alaunos Therapeutics, Inc.
We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the Alaunos® and hunTR® trademarks as well as the graphic trademark found on our website. Other trademarks, service marks and trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in
this Quarterly Report on Form 10-Q are listed without the ® and symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names.
PART I—FINANCIAL INFORMATION
Item 1. Condensed Financial Statements (unaudited)
Alaunos Therapeutics, Inc.
CONDENSED BALANCE SHEETS
(unaudited)
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2026 |
|
|
2025 |
|
ASSETS: |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
615 |
|
|
$ |
1,385 |
|
Receivables |
|
|
— |
|
|
|
3 |
|
Prepaid expenses and other current assets |
|
|
461 |
|
|
|
600 |
|
Total current assets |
|
|
1,076 |
|
|
|
1,988 |
|
Property and equipment, net |
|
|
66 |
|
|
|
91 |
|
Prepaid expenses and other assets |
|
|
776 |
|
|
|
887 |
|
Total assets |
|
$ |
1,918 |
|
|
$ |
2,966 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
796 |
|
|
$ |
613 |
|
Accrued expenses |
|
|
151 |
|
|
|
200 |
|
Total current liabilities |
|
|
947 |
|
|
|
813 |
|
Total liabilities |
|
$ |
947 |
|
|
$ |
813 |
|
Commitments and contingencies (Note 4) |
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
|
|
Series A-1 preferred stock $0.001 par value; 1,000 shares authorized, 500 shares issued and outstanding at September 30, 2026 and at December 31, 2025, respectively |
|
|
— |
|
|
|
— |
|
Series A-2 preferred stock $0.001 par value; 1,000 shares authorized, 850 shares issued and outstanding at September 30, 2026 and at December 31, 2025, respectively |
|
|
— |
|
|
|
— |
|
Common stock $0.001 par value; 50,000,000 shares authorized, 3,324,697 and 2,349,480 shares issued and outstanding at September 30, 2026 and at December 31, 2025, respectively |
|
|
3 |
|
|
|
2 |
|
Additional paid-in capital |
|
|
928,320 |
|
|
|
926,773 |
|
Accumulated deficit |
|
|
(927,352 |
) |
|
|
(924,622 |
) |
Total stockholders' equity |
|
|
971 |
|
|
|
2,153 |
|
Total liabilities and stockholders' equity |
|
$ |
1,918 |
|
|
$ |
2,966 |
|
The accompanying notes are an integral part of these condensed financial statements.
Alaunos Therapeutics, Inc.
CONDENSED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
2 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
227 |
|
|
|
469 |
|
|
|
1,041 |
|
|
|
1,002 |
|
General and administrative |
|
|
533 |
|
|
|
718 |
|
|
|
1,683 |
|
|
|
2,318 |
|
Total operating expenses |
|
|
760 |
|
|
|
1,187 |
|
|
|
2,724 |
|
|
|
3,320 |
|
Loss from operations |
|
|
(760 |
) |
|
|
(1,187 |
) |
|
|
(2,724 |
) |
|
|
(3,318 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(31 |
) |
Other income (expense), net |
|
|
(12 |
) |
|
|
28 |
|
|
|
(6 |
) |
|
|
66 |
|
Total Other income (expense), net |
|
|
(12 |
) |
|
|
28 |
|
|
|
(6 |
) |
|
|
35 |
|
Net loss |
|
$ |
(772 |
) |
|
$ |
(1,159 |
) |
|
$ |
(2,730 |
) |
|
$ |
(3,283 |
) |
Basic and diluted net loss per share |
|
$ |
(0.31 |
) |
|
$ |
(0.55 |
) |
|
$ |
(1.04 |
) |
|
$ |
(1.84 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
2,604,663 |
|
|
|
2,183,039 |
|
|
|
2,723,590 |
|
|
|
1,822,500 |
|
The accompanying notes are an integral part of these condensed financial statements.
Alaunos Therapeutics, Inc.
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands, except share and per share data)
For the Three Months Ended September 30, 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Series A-1 Preferred Stock |
|
|
Series A-2 Preferred Stock |
|
|
Additional Paid in Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
|
|
Balance at June 30, 2026 |
|
|
2,486,140 |
|
|
$ |
2 |
|
|
|
500 |
|
|
$ |
— |
|
|
|
850 |
|
|
$ |
— |
|
|
$ |
927,230 |
|
|
$ |
(926,580 |
) |
|
$ |
652 |
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
41 |
|
|
|
— |
|
|
|
41 |
|
Shares issued as consideration for board service fees, consulting services and salary |
|
|
71,434 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
134 |
|
|
|
— |
|
|
|
134 |
|
Issuance of common stock in registered direct offering, net of offering cost |
|
|
380,469 |
|
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
915 |
|
|
|
— |
|
|
|
916 |
|
Exercise of prefunded warrants |
|
|
386,654 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(772 |
) |
|
|
(772 |
) |
Balance at September 30, 2026 |
|
|
3,324,697 |
|
|
$ |
3 |
|
|
|
500 |
|
|
$ |
- |
|
|
|
850 |
|
|
$ |
- |
|
|
$ |
928,320 |
|
|
$ |
(927,352 |
) |
|
$ |
971 |
|
For the Nine Months Ended September 30, 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Series A-1 Preferred Stock |
|
|
Series A-2 Preferred Stock |
|
|
Additional Paid in Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
|
|
Balance at January 1, 2026 |
|
|
2,349,480 |
|
|
$ |
2 |
|
|
|
500 |
|
|
$ |
— |
|
|
|
850 |
|
|
$ |
— |
|
|
$ |
926,773 |
|
|
$ |
(924,622 |
) |
|
$ |
2,153 |
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
154 |
|
|
|
— |
|
|
|
154 |
|
Shares issued as consideration for board service fees, consulting services and salary |
|
|
177,496 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
408 |
|
|
|
— |
|
|
|
408 |
|
Issuance of common stock in registered direct offering, net of offering cost |
|
|
380,469 |
|
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
915 |
|
|
|
— |
|
|
|
916 |
|
Exercise of prefunded warrants |
|
|
386,654 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Equity line of credit draw |
|
|
30,598 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
70 |
|
|
|
— |
|
|
|
70 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,730 |
) |
|
|
(2,730 |
) |
Balance at September 30, 2026 |
|
|
3,324,697 |
|
|
$ |
3 |
|
|
|
500 |
|
|
$ |
- |
|
|
|
850 |
|
|
$ |
- |
|
|
$ |
928,320 |
|
|
$ |
(927,352 |
) |
|
$ |
971 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alaunos Therapeutics, Inc.
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands, except share and per share data)
For the Three Months Ended September 30, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Series A-1 Preferred Stock |
|
|
Series A-2 Preferred Stock |
|
|
Additional Paid in Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
|
|
Balance at June 30, 2025 |
|
|
2,074,746 |
|
|
$ |
2 |
|
|
|
500 |
|
|
$ |
— |
|
|
|
850 |
|
|
$ |
— |
|
|
$ |
926,229 |
|
|
$ |
(922,570 |
) |
|
$ |
3,661 |
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
239 |
|
|
|
— |
|
|
|
239 |
|
Shares issued as consideration for board service fees |
|
|
7,450 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
37 |
|
|
|
— |
|
|
|
37 |
|
Shares issued as consideration for services |
|
|
10,775 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
25 |
|
|
|
— |
|
|
|
25 |
|
Exercise of prefunded warrants |
|
|
112,875 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,159 |
) |
|
|
(1,159 |
) |
Balance at September 30, 2025 |
|
|
2,205,846 |
|
|
$ |
2 |
|
|
|
500 |
|
|
$ |
- |
|
|
|
850 |
|
|
$ |
- |
|
|
$ |
926,530 |
|
|
$ |
(923,729 |
) |
|
$ |
2,803 |
|
For the Nine Months Ended September 30, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Series A-1 Preferred Stock |
|
|
Series A-2 Preferred Stock |
|
|
Additional Paid in Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
|
|
Balance at January 1, 2025 |
|
|
1,601,252 |
|
|
$ |
2 |
|
|
|
— |
|
|
$ |
— |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
922,507 |
|
|
$ |
(920,446 |
) |
|
$ |
2,063 |
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
379 |
|
|
|
— |
|
|
|
379 |
|
Shares issued as consideration for board service fees |
|
|
45,719 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
149 |
|
|
|
— |
|
|
|
149 |
|
Stock issued as consideration for services |
|
|
10,775 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
25 |
|
|
|
— |
|
|
|
25 |
|
Sale of Series A-1 preferred stock |
|
|
— |
|
|
|
— |
|
|
|
500 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
500 |
|
|
|
— |
|
|
|
500 |
|
Issuance of common stock in registered direct offering, net of offering cost |
|
|
338,725 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
998 |
|
|
|
— |
|
|
|
998 |
|
Issuance of prefunded warrants in registered direct offering |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
913 |
|
|
|
— |
|
|
|
913 |
|
Reclassification of Warrant Liability to equity |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
209 |
|
|
|
— |
|
|
|
209 |
|
Exercise of prefunded warrants |
|
|
209,375 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Sale of Series A-2 preferred stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
850 |
|
|
|
— |
|
|
|
850 |
|
|
|
— |
|
|
|
850 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(3,283 |
) |
|
|
(3,283 |
) |
Balance at September 30, 2025 |
|
|
2,205,846 |
|
|
$ |
2 |
|
|
|
500 |
|
|
$ |
- |
|
|
|
850 |
|
|
$ |
- |
|
|
$ |
926,530 |
|
|
$ |
(923,729 |
) |
|
$ |
2,803 |
|
The accompanying notes are an integral part of these condensed financial statements.
Alaunos Therapeutics, Inc.
CONDENSED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
Net loss |
|
$ |
(2,730 |
) |
|
$ |
(3,283 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
Depreciation |
|
|
25 |
|
|
|
— |
|
Change in fair value of warrant liability |
|
|
— |
|
|
|
31 |
|
Common stock issued for consulting services rendered, including board fees and salary |
|
|
408 |
|
|
|
174 |
|
Stock-based compensation |
|
|
154 |
|
|
|
379 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Receivables |
|
|
3 |
|
|
|
5 |
|
Prepaid expenses and other current assets |
|
|
250 |
|
|
|
148 |
|
Accounts payable |
|
|
183 |
|
|
|
327 |
|
Accrued expenses |
|
|
(49 |
) |
|
|
(98 |
) |
Net cash flows from operating activities |
|
|
(1,756 |
) |
|
|
(2,317 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
Purchases of property and equipment |
|
|
— |
|
|
|
(97 |
) |
Net cash flows from investing activities |
|
|
— |
|
|
|
(97 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
Proceeds from the issuance of common stock and pre funded warrants, net of offering costs |
|
|
916 |
|
|
|
1,911 |
|
Proceeds from sale of Series A-1 preferred stock |
|
|
— |
|
|
|
500 |
|
Proceeds from sale of Series A-2 preferred stock |
|
|
— |
|
|
|
850 |
|
Proceeds from equity line of credit, net of cost |
|
|
70 |
|
|
|
— |
|
Net cash flows from financing activities |
|
|
986 |
|
|
|
3,261 |
|
Net increase (decrease) in cash and cash equivalents |
|
|
(770 |
) |
|
|
847 |
|
Cash and cash equivalents, beginning of period |
|
|
1,385 |
|
|
|
1,091 |
|
Cash and cash equivalents, end of period |
|
$ |
615 |
|
|
$ |
1,938 |
|
The accompanying notes are an integral part of these condensed financial statements.
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
Overview
Alaunos Therapeutics, Inc., which is referred to herein as “Alaunos,” or the “Company,” is a biopharmaceutical company developing a pipeline of potentially transformative therapies for pulmonary arterial hypertension and related cardiopulmonary disease. The Company was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs.
The Company’s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.
As of September 30, 2026, there were 3,324,697 shares of common stock outstanding, 500 Series A-1 shares of preferred stock outstanding, 850 Series A-2 shares of preferred stock outstanding and an additional 325,852 shares of common stock reserved for issuance pursuant to outstanding stock options and warrants. The Company also has 484,156 shares available for issuance under its 2020 Equity Incentive Plan.
The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.
Recent Developments
On October 13, 2026, the Company acquired Velaris Therapeutics, Inc., a Delaware corporation (“Pre-Acquisition Velaris”), in accordance with the terms of the Agreement and Plan of Merger, dated October 13, 2026 (the “Acquisition Agreement”), by and among the Company, Valkyrie Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), Valkyrie Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Pre-Acquisition Velaris. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Pre-Acquisition Velaris, pursuant to which Pre-Acquisition Velariswas the surviving corporation and became a wholly owned subsidiary of the Company (the “First Merger”). Immediately following the First Merger, Pre-Acquisition Velaris merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity (together with the First Merger, the “Asset Acquisition”). The Asset Acquisition is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
Under the terms of the Acquisition Agreement, following the closing of the Asset Acquisition (the “Closing”), the Company issued to the stockholders of Pre-Acquisition Velaris (i) 105,286 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) and (ii) 33,054 shares of Series C Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), each share of which is, in each case, convertible into 1,000 shares of common stock of the Company, subject to certain conditions. In addition, shares of Series C Preferred Stock issued in respect of outstanding unvested restricted shares of Velaris common stock remain subject to the same vesting terms, and each outstanding option to purchase shares of Velaris common stock was assumed by the Company and converted into an option to purchase shares of common stock, with the number of shares and exercise price adjusted based on the exchange ratio in the Merger Agreement.
In connection with the Asset Acquisition, the Company also entered into a significant private investment in public equity (“PIPE”) transaction. The Company agreed to sell (i) 687,789 shares of common stock at a price of $1.4357 per share and (ii) 243,063 shares of Series C Preferred Stock at a price of $1,435.70 per share in the PIPE for approximately $350 million in gross proceeds. The PIPE closed on October 14, 2026. The Series C Preferred Stock are convertible into Common Stock at a ratio of 1,000 shares of common stock per share of Series C Preferred Stock, subject beneficial‑ownership limitations.
Liquidity and Going Concern
The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations. The Company anticipates that losses will continue for the foreseeable future. As of September 30, 2026, the Company had approximately $0.62 million of cash and cash equivalents. The Company’s accumulated deficit at September 30, 2026 was approximately $927.4 million. These conditions initially raised substantial doubt about the Company’s ability to continue as a going concern.
Subsequent to September 30, 2026, on October 14, 2026, the Company completed a private placement of 687,789 shares of common stock and 243,063 shares of Series C Non-Voting Convertible Preferred Stock, resulting in gross cash proceeds of approximately $350.0 million before deducting placement agent fees and other offering expenses. See Note 9. Subsequent Events for additional information regarding the financing.
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
Management evaluated the Company’s ability to continue as a going concern based on information available through the date these financial statements were issued, including the completed financing and the Company’s updated cash flow forecast. Based on this evaluation, management concluded that the Company’s existing cash resources, including the net proceeds from the financing, are sufficient to fund its planned operations and meet its obligations as they become due for at least one year from the issuance date of these financial statements.
The Company’s cash flow forecast is based on assumptions regarding future expenditures and operating requirements, and actual results could differ materially. The Company may require additional financing to support activities beyond the forecast period or changes to its operating plans.
Basis of Presentation
The accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 31, 2026 and as amended by Amendment No. 1 filed with the SEC on April 30, 2026 (collectively, the “2025 Annual Report”),
The results disclosed in the condensed statements of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full fiscal year 2026.
Use of Estimates
The preparation of condensed financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.
Nasdaq Stockholders' Equity Deficiency Notice
On April 9, 2026, the Company received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders equity, as reported in its 2025 Annual Report, did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholder equity be at least $2.5 million. In its 2025 Annual Report Form 10-K, the Company reported stockholders’ equity of $2.2 million, and, as a result, did not satisfy Nasdaq Listing Rule 5550(b)(1) at that time.
Subsequent to September 30, 2026, the Company completed the PIPE on October 14, 2026, generating approximately $350.0 million in gross proceeds before placement agent fees and other offering expenses. In connection with the PIPE, Fairmount Healthcare Fund II, L.P. provided a limited waiver of cash-settlement rights covering 6,268 shares of Series C Preferred Stock, representing approximately $9.0 million. Before the PIPE, on October 5, 2026, the Company had received a written notice from the Listing Qualifications staff of Nasdaq informing the Company that its securities were subject to delisting due to its continued non-compliance with Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”) unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company had timely submitted a plan to regain compliance and then timely requested a hearing, which was scheduled for November 10, 2026. On October 21, 2026, the Company disclosed its determination that the financing, including the effect of the waiver, had restored compliance with the Stockholders’ Equity Requirement.
On October 22, 2026, the Company received a letter from Nasdaq’s Office of General Counsel confirming that Nasdaq staff had determined that the Company had regained compliance with the Stockholders’ Equity Requirement. Nasdaq closed the matter and cancelled the November 10, 2026 hearing. The Company’s common stock continues to be listed and traded on the Nasdaq Capital Market.
Nasdaq will continue to monitor the Company’s compliance. If the Company does not evidence compliance when it files its Annual Report on Form 10-K for the year ending December 31, 2026, it may be subject to delisting. The September 30, 2026 balance sheet precedes the Asset Acquisition and the PIPE and therefore does not reflect their effects on stockholders’ equity. See Note 9. Subsequent
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
Events and Part II, Item 1A, “Risk Factors,” for additional information.
Nasdaq Minimum Market Value Requirement
On July 22, 2026, the SEC’s Division of Trading and Markets, acting pursuant to delegated authority, approved a Nasdaq rule change that would require companies listed on the Nasdaq Capital Market to maintain a market value of listed securities (“MVLS”) of at least $5.0 million. Under the approved rule, a company whose MVLS remains below $5.0 million for 30 consecutive business days would be subject to an immediate staff delisting determination without an automatic compliance period. On July 29, 2026, following the filing of notices of intention to petition for review, the SEC automatically stayed the approval order pending further Commission action. As of the date these condensed financial statements were issued, the stay remained in effect. The Company cannot predict the timing or outcome of the SEC’s review, whether or when the rule will become operative, or the implementation and measurement procedures that may apply if the stay is lifted.
2.Summary of Significant Accounting Policies
Certain of our accounting estimates are important to the portrayal of our financial condition, since they require management to make difficult, complex or subjective judgments, some of which may relate to matters that are inherently uncertain. Estimates are susceptible to material changes as a result of changes in facts and circumstances. Management believes that clinical trial expenses and other research and development expenses, collaboration agreements, fair value measurements of share-based arrangements, and income taxes are its most critical accounting estimates. Our accounting policies are discussed in detail in Note 2. Summary of Significant Accounting Policies in the audited financial statements included in the 2025 Annual Report. There have been no material changes in those policies since the filing of the 2025 Annual Report.
Basic earnings per share of common stock is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method, unless the effect on net earnings per share is antidilutive. The following have been excluded from the calculation of dilutive earnings per share, as the effect was antidilutive:
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
|
2026 |
|
|
2025 |
|
Common stock options |
|
|
219,400 |
|
|
|
225,550 |
|
Warrants |
|
|
106,452 |
|
|
|
168,751 |
|
Series A-1 Preferred Stock |
|
|
209,499 |
|
|
|
189,847 |
|
Series A-2 Preferred Stock |
|
|
214,581 |
|
|
|
194,453 |
|
|
|
|
749,932 |
|
|
|
778,601 |
|
The following table shows the net loss attributable to common stockholders after including undeclared cumulative preferred dividends used to calculate the basic and diluted earnings per share, as shown on the statement of operations (See Note 5. Equity - Series A-1 and A-2 Preferred Stock Cumulative Dividends):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Net loss |
|
$ |
(772 |
) |
|
$ |
(1,159 |
) |
|
$ |
(2,730 |
) |
|
$ |
(3,283 |
) |
Preferred dividends |
|
|
(38 |
) |
|
|
(42 |
) |
|
|
(109 |
) |
|
|
(62 |
) |
Net loss attributable to common stockholders |
|
$ |
(810 |
) |
|
$ |
(1,201 |
) |
|
$ |
(2,839 |
) |
|
$ |
(3,345 |
) |
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
4.Commitments and Contingencies
License Agreements
License Agreement and Research and Development Agreement —The University of Texas MD Anderson Cancer Center
In 2015, the Company, together with Precigen, entered into a license agreement (the “MD Anderson License”) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer (“NK”) Cells, and TCRs.
In 2015, the Company, Precigen and MD Anderson entered into the 2015 R&D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs.
As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&D Agreement. At various times, the Company amended the 2015 R&D Agreement to extend the term until December 31, 2026 and in 2019 entered into the 2019 R&D Agreement, pursuant to which the Company agreed to collaborate with respect to the TCR program.
The 2019 R&D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&D Agreement following written notice of a material breach.The 2019 R&D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.
During the reporting period, the Company continued to engage with M.D. Anderson Cancer Center to wind down the TCR trials. The parties completed the final reconciliation of amounts due under the related R&D agreements, and the Company received the final invoice during the second quarter of 2025. Amounts due to MD Anderson and recorded in accounts payable were $0 and $143 as of September 30, 2026 and December 31, 2025, respectively.
On November 4, 2025, the Office of the Attorney General of Texas, on behalf of MD Anderson, issued a demand for payment. On December 17, 2025, the Company entered into a Settlement and Release Agreement with MD Anderson to resolve the matter. Pursuant to the agreement, the Company agreed to pay $285 in six installments through May 30, 2026, in full satisfaction of the outstanding invoices. The agreement also provides for mutual general releases, subject to customary exceptions, including for breach of the settlement agreement and certain ongoing matters such as Protocol 2006-0676.
As of September 30, 2026, the Company had paid the aggregate settlement amount of $285, all required installments had been satisfied, and no amounts remained outstanding to MD Anderson under the settlement agreement.
Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System
In August 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.
Under the terms of the agreement, the Company may be required to make payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis, could total up to an additional $4.5 million. In addition, the Licensors are entitled to receive low single digit royalties on net sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the three and nine months ended September 30, 2026 and 2025, the Company did not incur any milestone expenses or royalty expenses under this agreement.
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
Collaboration Agreement with Solasia Pharma K.K.
In 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended in 2014 to include an exclusive worldwide license and further amended in 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.
As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia.
During the three and nine months ended September 30, 2026, the Company earned no collaboration revenue under this agreement. During the three and nine months ended September 30, 2025, the Company earned collaboration revenue of $0 and $2, respectively, under this agreement.
Insurance Contract
During 2023, the Company entered into an insurance arrangement covering certain risks, for which the premium had been fully prepaid, with coverage effective over a six-year period. Accordingly, the Company began amortizing the prepaid expense related to the contract. The Company has classified the prepaid contract between its current portion and long-term portion. As of September 30, 2026, $222 is included in prepaid expenses and other current assets and $776 is included in prepaid expense and other non-current assets in the accompanying condensed balance sheet.
Sales Tax Contingency
The Company is subject to examination by certain state and local taxing authorities related to sales and use tax matters. The Company records a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. As of September 30, 2026, the Company has recorded an estimated liability of $57 related to these matters. In addition, the Company may be exposed to additional loss; however, the Company cannot reasonably estimate the amount or range of additional loss at this time.
Equity Incentive Plan and Share Registration
On July 6, 2026, the Company registered an additional 1,000,000 shares of common stock for issuance under the Alaunos Therapeutics, Inc. 2020 Equity Incentive Plan by filing a Registration Statement on Form S-8. The increase in shares available for issuance under the plan from 130,745 shares to 1,130,745 shares was previously approved by the Company’s stockholders on July 3, 2025.
Shares Issued for Services
During the three and nine months ended September 30, 2026, the Company issued an aggregate of 71,434 and 177,496 shares of its common stock, respectively, to members of the board of directors, an employee and consultants in lieu of cash consideration for services rendered. The aggregate fair value of the shares issued was approximately $134 and $408, respectively.
Series A-1 and A-2 Preferred Stock Cumulative Dividends
Cumulative dividends on the Company’s Series A-1 and Series A-2 Convertible Preferred Stock accrue at 10% per annum and compound quarterly by increasing the liquidation preference. Undeclared cumulative dividends are not recorded as a liability. Because the Company reported a net loss for the periods presented, cumulative preferred dividends increased the net loss attributable to common stockholders in the earnings-per-share calculation. As of September 30, 2026, undeclared cumulative dividends totaled $78 for Series A-1 and $114 for Series A-2.
Equity Line of Credit
In May 2025, the Company entered into an equity purchase agreement with Mast Hill Fund, L.P. establishing an equity line of credit
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
(the “Equity Line of Credit”), pursuant to which the Company has the right, but not the obligation, to sell up to $25.0 million of shares of its common stock over a period of up to 24 months, subject to certain conditions and limitations. The purchase price for shares sold under the Equity Line of Credit is generally based on 97% of the applicable volume-weighted average price of the Company’s common stock, subject to the terms, volume limitations, minimum pricing provisions and beneficial ownership limitations set forth in the underlying equity purchase agreement.
During the nine months ended September 30, 2026, the Company sold an aggregate of 30,598 shares of common stock under the Equity Line of Credit for gross proceeds of approximately $74. The Company incurred approximately $4 of transaction costs and fees associated with these sales, resulting in net cash proceeds of approximately $70. All sales under the Equity Line of Credit during the nine months ended September 30, 2026 occurred during the three months ended June 30, 2026.
Transaction costs directly attributable to the issuance of the shares were recorded as a reduction of additional paid-in capital. In addition, a proportionate amount of previously deferred issuance costs associated with the Equity Line of Credit was recognized as a reduction of the proceeds from the shares issued under the facility.
September 2026 Registered Direct Offering
On September 18, 2026, the Company entered into a securities purchase agreement with certain accredited investors for the issuance and sale of 380,469 shares of common stock at a purchase price of $1.46 per share and pre-funded warrants to purchase 386,654 shares of common stock at a purchase price of $1.459 per pre-funded warrant. The offering closed on September 21, 2026 and was conducted pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-289748) and a related prospectus supplement.
The Company received aggregate gross proceeds of approximately $1.12 million and net proceeds of approximately $0.92 million, after deducting placement agent fees and other estimated offering expenses totaling approximately $0.20 million. Dawson James Securities, Inc. acted as the exclusive placement agent and received a cash fee equal to 8% of the aggregate gross proceeds, together with reimbursement of certain expenses. The Company intends to use the net proceeds for general corporate purposes, including working capital.
The pre-funded warrants were immediately exercisable at an exercise price of $0.001 per share and had no expiration date. The warrants permitted cashless exercise if an effective registration statement or current prospectus was unavailable for the issuance or resale of the underlying shares. Exercise was subject to a beneficial ownership limitation of 4.99%, or 9.99% at the purchaser’s election, subject to adjustment in accordance with the warrant terms.
On September 21, 2026, all 386,654 pre-funded warrants were exercised, resulting in the issuance of 386,654 additional shares of common stock. Accordingly, the Company issued an aggregate of 767,123 shares of common stock in connection with the offering and related warrant exercises, and no pre-funded warrants issued in this offering remained outstanding as of September 30, 2026.
6.Stock-Based Compensation
The following table presents share-based compensation expense on all employee and non-employee awards included in the accompanying condensed statements of operations as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
(in thousands) |
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Research and development |
$ |
106 |
|
|
$ |
168 |
|
|
$ |
142 |
|
|
$ |
169 |
|
General and administrative |
|
69 |
|
|
|
133 |
|
|
|
420 |
|
|
|
384 |
|
Stock-based compensation expense |
$ |
175 |
|
|
$ |
301 |
|
|
$ |
562 |
|
|
$ |
553 |
|
The grant date fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
|
|
|
|
|
|
|
For the Three and Nine Months Ended September, |
|
|
2025 |
Risk-free interest rate |
|
3.86-4.13% |
|
4.05-4.15% |
Expected life in years |
|
5.00-6.06 |
|
5.04-6.06 |
Expected volatility |
|
119.26-127.03% |
|
119.26-127.03% |
Expected dividend yield |
|
—% |
|
—% |
Stock option activity under the Company’s stock option plans for the nine months ended September 30, 2026 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share and per share data) |
|
Number of Shares |
|
|
Weighted- Average Exercise Price |
|
|
Weighted- Average Contractual Term (Years) |
|
|
Aggregate Intrinsic Value |
|
Outstanding, December 31, 2025 |
|
|
222,485 |
|
|
$ |
23.98 |
|
|
|
9.04 |
|
|
$ |
31 |
|
Granted |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
Exercised |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
Cancelled |
|
|
(3,085 |
) |
|
|
168.52 |
|
|
|
|
|
|
|
Outstanding, September 30, 2026 |
|
|
219,400 |
|
|
$ |
21.38 |
|
|
|
8.36 |
|
|
$ |
— |
|
Options exercisable, September 30, 2026 |
|
|
133,233 |
|
|
$ |
32.66 |
|
|
|
8.11 |
|
|
$ |
— |
|
Options available for future grant, September 30, 2026 |
|
|
484,156 |
|
|
|
|
|
|
|
|
|
|
At September 30, 2026, total unrecognized compensation costs related to unvested stock options outstanding amounted to $282 and are expected to be recognized over a weighted-average period of 1.42 years.
The following is a summary of the Company's warrant activity for the nine months ended September 30, 2026:
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share and per share data) |
|
Number of Shares |
|
|
Weighted- Average Exercise Price |
|
|
Weighted- Average Contractual Term (Years) |
|
Outstanding, December 31, 2025 |
|
|
106,452 |
|
|
$ |
9.63 |
|
|
3.73 |
|
Granted |
|
|
386,654 |
|
|
|
0.001 |
|
|
|
|
Exercised |
|
|
(386,654 |
) |
|
|
0.001 |
|
|
|
|
Outstanding, September 30, 2026 |
|
|
106,452 |
|
|
$ |
9.63 |
|
|
|
2.98 |
|
The Chief Operating Decision Maker (“CODM”) for the Company is the Chief Executive Officer (the "CEO"). The Company’s CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. This decision-making process reflects the way in which financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources. Accordingly, the Company has determined that it has a single reportable and operating segment related to biopharmaceutical research and development.
The Company’s CODM assesses financial performance and allocates resources based on operating results which are also reported on the accompanying condensed statements of operations. The measure of segment assets is reported on the balance sheet as total assets. The CODM utilizes operating results by comparing actual results against budgeted amounts. As part of this process, net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development.
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
Shares issued for Services
Subsequent to September 30, 2026, the Company issued an aggregate of 116,103 shares of its common stock, par value $0.001 per share, to members of the Board of Directors, consultants and an employee in consideration for board service fees, services rendered and salary compensation, respectively, with an aggregate fair value of approximately $86.
Asset Acquisition
On October 13, 2026, the Company acquired Velaris Therapeutics, Inc., a Delaware corporation (“Pre-Acquisition Velaris”), in accordance with the terms of the Agreement and Plan of Merger, dated October 13, 2026 (the “Acquisition Agreement”), by and among the Company, Valkyrie Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), Valkyrie Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Pre-Acquisition Velaris. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Pre-Acquisition Velaris, pursuant to which Pre-Acquisition Velariswas the surviving corporation and became a wholly owned subsidiary of the Company (the “First Merger”). Immediately following the First Merger, Pre-Acquisition Velaris merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity (together with the First Merger, the “Asset Acquisition”). The Asset Acquisition is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
Under the terms of the Acquisition Agreement, following the closing of the Asset Acquisition (the “Closing”), the Company issued to the stockholders of Pre-Acquisition Velaris (i) 105,286 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) and (ii) 33,054 shares of Series C Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), each share of which is, in each case, convertible into 1,000 shares of common stock of the Company, subject to certain conditions. In addition, shares of Series C Preferred Stock issued in respect of outstanding unvested restricted shares of Velaris common stock remain subject to the same vesting terms, and each outstanding option to purchase shares of Velaris common stock was assumed by the Company and converted into an option to purchase shares of common stock, with the number of shares and exercise price adjusted based on the exchange ratio in the Merger Agreement. Following satisfaction of the applicable conditions, Series B Preferred Stock is convertible at the holder’s option and Series C Preferred Stock converts automatically. If the required approvals are not obtained, holders may request cash settlement of conversions beginning six months after issuance, subject to applicable waivers.
Private Placement Financing
In connection with the Asset Acquisition, the Company also entered into a significant private investment in public equity (“PIPE”) transaction. The Company agreed to sell (i) 687,789 shares of common stock at a price of $1.4357 per share and (ii) 243,063 shares of Series C Preferred Stock at a price of $1,435.70 per share in the PIPE for approximately $350 million in gross proceeds. The PIPE closed on October 14, 2026. The Series C Preferred Stock are convertible into Common Stock at a ratio of 1,000 shares of common stock per share of Series C Preferred Stock, subject beneficial‑ownership limitations. The proceeds are intended primarily to fund development of the acquired programs and for working capital and general corporate purposes, subject to contractual restrictions on their use.
Related Agreements
In connection with the Asset Acquisition, the Company agreed, subject to required stockholder approval, to repurchase its outstanding Series A-1 and Series A-2 Convertible Preferred Stock, including shares of common stock issued upon conversion, from holders including certain directors and an affiliated entity. The payment, based on liquidation value and accrued dividends, is expected to be approximately $1.6 million if approval occurs before February 2027.
Prior to the effective time of the Asset Acquisition, Velaris entered into a Fusion Protein Discovery and Option Agreement (the “ADOA”) with Paragon Laboratories, Inc. (“Paragon”). Pursuant to the ADOA, Paragon will conduct research programs, overseen by a joint development committee of representatives of each party, directed to the discovery and development of Fc fusion protein candidates, including programs directed to ActRIIA and ActRIIB that were initiated under a prior research letter agreement between Velaris and Paragon, and a program directed to a BMP9/10-sparing ActRIIA fusion protein. The parties may agree to conduct additional research programs under the ADOA. In addition, under the research letter agreement between Velaris and Paragon, Velaris holds options with respect to three research programs directed to antibody candidates, including an anti-PDGF-B monoclonal antibody and a bispecific molecule combining an ActRIIA fusion protein with an anti-PDGF-B antibody, which the parties expect to document in a separate discovery and option agreement. The Company assumed the ADOA and the research letter agreement in connection with
Alaunos Therapeutics, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)
the Asset Acquisition. The ADOA also provide for the issuance of two warrants to Paragon, each representing 1% of the Company’s fully diluted outstanding common stock, with grants scheduled 120 days after closing and twelve months thereafter.
On October 13, 2026, the Company granted two executive officers options to purchase an aggregate of 60,000 shares of common stock under its 2020 Equity Incentive Plan at an exercise price of $1.4357 per share. Of these, 50,000 vest on July 30, 2027, subject to the recipient continuing to lead development of ALN1003 through that date, and 10,000 vest upon the successful filing of both the Company’s 2026 Annual Report on Form 10-K and its Quarterly Report on Form 10-Q for the quarter ending March 31, 2027. Both awards require continued service through the applicable vesting date and expire on October 12, 2036, subject to earlier termination under the award agreements.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial information and related notes included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission, or the SEC, on March 31, 2026, as amended on April 30, 2026, or the Annual Report.
Except for the historical financial information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be deemed to contain forward-looking statements that reflect our plans, estimates and beliefs. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. In this Quarterly Report on Form 10-Q, words such as “may,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.
Our actual results could differ materially from those contained in or implied by any forward-looking statements. Factors that could cause or contribute to these differences include those risks identified under Part I, Item 1A. Risk Factors of our 2025 Annual Report.
All references to “our product candidates,” “our programs” and “our pipeline” in this Quarterly Report on Form 10-Q include the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Paragon Letter Agreement and the Paragon Option Agreement (each as defined below), which we assumed pursuant to the Asset Acquisition. As of the date of this Quarterly Report on Form 10-Q, we have not exercised the option for any of our research programs.
Overview
We are a biopharmaceutical company developing a pipeline of potentially transformative therapies for pulmonary arterial hypertension ("PAH") and related cardiopulmonary disease. In the Asset Acquisition, we bolstered our pipeline with the addition of product candidates for the treatment of PAH and related cardiopulmonary disease, led by VLR199, a proprietary activin receptor type IIA-Fc ("ActRIIA-Fc") ligand trap, and the assumption of the Paragon Option Agreement. VLR199 is designed to replicate the clinically validated pharmacology of Winrevair® (sotatercept), marketed by Merck, but is being developed with elements intended to improve upon its profile, including dosing strategies, presentation and indication selection. Winrevair is the only approved ActRII-Fc ligand trap and has a differentiated mechanism from the traditional vasodilators approved for PAH. We intend to submit an IND or CTA for VLR199 in the second half of 2027, with initial clinical proof-of-concept data from a Phase 1 trial anticipated in 2028. We also intend to pursue additional indications beyond PAH where activin signaling inhibition could benefit patient outcomes.
In addition to VLR199, we are developing VLR247, VLR258 and VLR360. VLR247 and VLR258 are designed to retain the clinical activity of Winrevair but improve upon the safety profile by sparing bone morphogenetic proteins 9 and 10 ("BMP-9/10"). VLR360 is a monoclonal antibody directed to platelet-derived growth factor B ("PDGF-B"), which is designed to be an orthogonal approach from activin signaling to treating PAH and thus has potential as a monotherapy as well as in combination with our other assets. Our pipeline also includes ALN1003, our preclinical oral candidate for obesity and metabolic disease.
PAH is a progressive and ultimately fatal disease caused by narrowing of the pulmonary arteries, making it more difficult for the heart to pump blood to the lungs. Pulmonary vascular resistance (“PVR”) measures how difficult it is for the right side of the heart to pump blood through the pulmonary vasculature. As PVR rises, the right ventricle dilates and fails, and patients progress through a decline in functional class and exercise capacity to right heart failure, lung transplantation or death. Patients typically present with exertional dyspnea, fatigue, chest pain and syncope, which are symptoms that overlap with far more common cardiopulmonary conditions and frequently result in delays in diagnosis by a year or more from the onset of symptoms. The disease is most often identified when patients are in their 50s and affects women approximately three to four times as often as men, with an estimated 30,000 to 50,000 patients in the United States.
PAH carries a high burden of morbidity and mortality despite available therapy. For more than two decades, the approved treatment paradigm for PAH has consisted of vasodilator therapies directed to the endothelin, nitric oxide and prostacyclin pathways, which relieve symptoms but do not directly address the pulmonary vascular remodeling that drives the disease. In contemporary U.S. registry data collected before the introduction of activin signaling inhibitors, survival was approximately 91% at one year and approximately 61% to 65% at five years. Management of PAH commonly requires two or three chronic therapies taken for life, periodic right heart catheterization to reassess risk, and, in more advanced disease, continuous parenteral infusion delivered through an indwelling central catheter or a subcutaneous pump.
The approval of Winrevair in 2024 established activin signaling inhibition as the first mechanism to target pulmonary vascular remodeling directly. In Merck’s Phase 3 STELLAR trial, Winrevair, dosed at 0.7 mg/kg every three weeks on top of double or triple background therapy in 95% of patients, reduced the risk of death or clinical worsening with a hazard ratio of 0.16. Although Winrevair
had a significant impact on outcomes, the vial and syringe dosing is not optimal for patients and Winrevair’s approval is currently limited to PAH. We believe the combination of persistent mortality, escalating treatment burden and the limited ability of the established therapies to address the underlying vascular pathology for patients defines the opportunity for our programs in PAH and other indications. We plan to optimize the dosing regimen, develop an auto-injector for enhanced patient experience and expand into other indications where activin signaling inhibition could benefit patients.
Velaris was launched with assets developed by Paragon Laboratories, Inc. ("Paragon Labs"), an antibody and protein engineering discovery engine founded by Fairmount Funds Management LLC ("Fairmount"), and is the ninth company launched with assets developed by Paragon Labs or Paragon Therapeutics, Inc., its affiliate. We anticipate our existing capital will provide runway through key clinical inflection points, including clinical proof-of-concept data for VLR199 and VLR360 expected in 2028.
Our Strategy
Our goal is to establish a portfolio of optimized ActRII-Fc ligand traps and complementary biologics that together become the backbone of treatment for PAH and related cardiopulmonary disease. Our strategy is to:
•Advance first into PAH, where there is established validation for an ActRIIA-Fc. Winrevair is the only approved agent in a class that has demonstrated the most robust efficacy of any mechanism studied in PAH. We believe that the combination of a validated target and an established regulatory pathway creates an opportunity to capture a meaningful share of Winrevair’s market, which third-party estimates project at approximately $8 billion in PAH alone by 2036.
•Obtain rapid clinical proof of concept by evaluating established biomarkers. Activin signaling inhibition produces specific, measurable pharmacodynamic effects, including dose-dependent reductions in serum follicle-stimulating hormone ("FSH") in healthy postmenopausal women, changes in hemoglobin and increases in serum bone-specific alkaline phosphatase ("BSAP"). We intend to utilize these biomarkers in a small Phase 1 study to confirm we can replicate the effects seen with Winrevair, thereby potentially reducing the risks of later development.
•Improve on the areas where Winrevair may not be fully optimized. We are developing our ligand traps to address dosing and safety limitations of Winrevair. This includes performing a comprehensive dose-ranging study to understand the benefit-risk tradeoff for VLR199, with the possibility of identifying less frequent and more conventional dosing intervals. We also plan to develop an auto-injector, rather than a vial and syringe presentation, for convenience and ease of use. For VLR247 and VLR258, decreasing potency against BMP-9/10 is intended to limit some of the hematological adverse events seen with Winrevair and expand the therapeutic window.
•Develop mechanisms orthogonal to activin signaling. VLR360 is designed to replicate the efficacy observed with imatinib in PAH by selectively inhibiting PDGF-B signaling, but without the toxicity that limited its development. We believe VLR360 has the potential to provide therapeutic benefit as a monotherapy and, because it addresses a distinct driver of pulmonary vascular remodeling, in combination with ActRII-Fc ligand traps.
•Build a portfolio designed for combinations from the outset. Combination therapy is central to the PAH treatment paradigm. VLR199, VLR247 and VLR258 are designed to be optimized both as monotherapies and as foundations for combinations with mechanistically distinct agents, including VLR360.
•Expand rapidly into secondary pulmonary hypertension (“PH”) and other pulmonary indications. PAH patients represent a fraction of those with disease related to pulmonary vascular remodeling. We intend to pursue PH associated with heart failure with preserved ejection fraction ("PH-HFpEF"), where pulmonary vascular remodeling is evident and where Winrevair has established the first efficacy signal of any PAH mechanism. We may also pursue Group 3 PH and pulmonary fibrosis, which also feature pulmonary vascular remodeling and where surrogate endpoints offer rapid paths to signal generation.
•Develop a treatment for obesity and related metabolic disorders. The findings from our recent non-Good Laboratory Practice diet-induced obesity mouse studies support our plan to conduct additional preclinical studies and CMC activities for ALN1003. These planned activities are intended to further characterize ALN1003’s pharmacology, evaluate exposure-response relationships, optimize formulation approaches and support future development planning.
Our Pipeline
Figure 1 summarizes our pipeline of product candidates. We hold options to acquire intellectual property rights with respect to each of the research programs below other than ALN1003 from Paragon, and none of the options has been exercised as of the date of this Quarterly Report on Form 10-Q.

Figure 1: Our pipeline of product candidates.
VLR199 is a new molecular entity comprising the extracellular domain of ActRIIA fused to the Fc domain of human IgG1 and is designed to preserve the balance of Winrevair's inhibitory activity across 16 ligands from the transforming growth factor-beta (“TGF-β”) superfamily, including activin A, activin B, GDF-8, GDF-11, BMP-9 and BMP-10. Because VLR199 is designed to preserve key pharmacological properties of Winrevair, whose clinical benefit has already been demonstrated, we intend to identify a dose that matches the published data for Winrevair’s pharmacodynamic activity in a Phase 1 study. We believe this approach will enable us to more efficiently identify an optimized dose regimen for VLR199.
We are also developing VLR247 and VLR258, ActRIIA-Fc and ActRIIB-Fc ligand traps, respectively, that are engineered to spare BMP-9 and BMP-10 while retaining inhibition of the other key activin signaling ligands. Winrevair is based on an ActRIIA backbone and has demonstrated clinical benefit, but it is unclear if one scaffold offers advantages over the other, so we plan to pursue both, at least initially. Inhibiting BMP-9 and BMP-10 may contribute to undesirable hematological side effects, so this approach may widen the therapeutic window relative to Winrevair, which carries a warning in the United States for elevated risk of bleeding and is dose-constrained due to a risk of hemoglobin elevations. These assets are intended to improve the safety profile, which creates the opportunity for half-life extension and less frequent dosing.
In addition, we are developing VLR360, an Fc-modified monoclonal antibody directed to platelet-derived growth factor-B (“PDGF-B”), a protein that can also drive pulmonary vascular remodeling in a pathway orthogonal to activin signaling. Inhibiting PDGF-B for the potential treatment of PAH is supported by the clinical efficacy observed with imatinib.
Our initial target indication for each of VLR199, VLR247, VLR258 and VLR360 is PAH, with planned expansion, pending positive data, into secondary PH and related cardiopulmonary indications, where the addressable patient populations are substantially larger and where there is mounting evidence for the utility of agents approved in PAH. Winrevair has established proof of concept in patients with PH-HFpEF, a population we estimate at approximately 500,000 patients in the United States, and prostacyclin and other PAH mechanisms have established a path into PH associated with interstitial lung disease ("PH-ILD") and pulmonary fibrosis. We expect to advance either VLR247 or VLR258 into the clinic, and may advance both, based on preclinical data and external catalysts.
Overview of Pulmonary Hypertension
PH is a hemodynamic condition defined by elevated pressure in the pulmonary arteries. It is classified by the World Health Organization into five groups according to underlying etiology. Group 1 PH is PAH, which comprises idiopathic, heritable, drug- and toxin-induced PAH along with other associated diseases of the distal pulmonary arteries. Group 2 contains PH due to left-sided heart disease, including PH-HFpEF. Group 3 comprises PH due to lung disease and hypoxia, including PH-ILD, PH associated with idiopathic pulmonary fibrosis ("PH-IPF"), progressive pulmonary fibrosis ("PH-PPF") and chronic obstructive pulmonary disease ("PH-COPD"). Group 4 comprises patients with chronic thromboembolic pulmonary hypertension (“CTEPH”), which arises from blood clots, while Group 5
encompasses PH that is multifactorial or secondary to other underlying conditions. We do not plan to target Group 4 or Group 5 populations because there is no strong current evidence for activin signaling inhibition as a mechanism of action in these indications. Although the etiologies that give rise to Groups 1 through 3 are distinct, they converge on a shared pathology: remodeling of the distal pulmonary arteries. In the remodeled vessel, the medial and intimal layers thicken and the lumen narrows, the vessel stiffens, and PVR increases. The right ventricle must generate progressively higher pressures to drive blood through the lungs, and right ventricular failure is the usual cause of death. Patients experience dyspnea on exertion, fatigue, syncope and a progressive decline in exercise capacity, measured in clinical trials by the six-minute walk distance ("6MWD").
Figure 2 illustrates the three groups we plan to focus on, which share an underlying pathophysiology of pulmonary vascular remodeling.
Figure 2: Pulmonary hypertension groups and the shared pulmonary vascular pathology. PAH (WHO Group 1) arises in the distal pulmonary arteries. PH associated with left-sided heart disease (Group 2), which includes combined post- and pre-capillary and isolated post-capillary PH-HFpEF, and PH associated with lung disease (Group 3), which includes PH-ILD, PH-COPD, PH-IPF and PH-PPF, arise from disease outside the pulmonary arteries. The vessel cross-sections show the medial and intimal thickening and luminal narrowing that characterize the remodeled artery relative to a healthy vessel. The figure is illustrative and not drawn to scale.
Dysregulated growth-factor signaling is a key driver of pulmonary vascular remodeling in PAH. In healthy individuals, pro-proliferative ligands of the TGF-β superfamily, including activin A, activin B, GDF-8 and GDF-11, signal through the type II activin receptors ActRIIA and ActRIIB, and are counterbalanced by anti-proliferative signaling through BMP-9 and BMP-10. In PAH, pro-proliferative activin signaling overwhelms anti-proliferative BMP signaling, and the resulting imbalance promotes proliferation of smooth muscle and endothelial cells in the vessel wall. Ligand traps comprising the extracellular domain of an ActRII fused to an Fc domain are designed to sequester the excess pro-proliferative ligands and restore that balance.
PDGF-B signaling drives a distinct and complementary proliferative pathway in the same vessels. PDGF-B is released by endothelial cells and platelets and acts on the PDGF receptor beta expressed on pulmonary artery smooth muscle cells and pericytes. Through this receptor, PDGF-B promotes the migration and proliferation of smooth muscle cells into the distal pulmonary arterioles and contributes to the medial thickening and muscularization of small vessels that characterize advanced disease. Expression of PDGF-B and its receptor is increased in the remodeled vessels of patients with PAH, and because PDGF-B signals through a receptor tyrosine kinase rather than through the Smad-dependent pathways engaged by the activin and BMP ligands, it is not addressed by an ActRII-Fc ligand trap. The clinical relevance of this pathway in PAH was implicated by the third-party Phase 3 IMPRES trial of imatinib, a small-molecule inhibitor of several kinases including the PDGF receptor. Imatinib improved exercise capacity and reduced PVR but was not advanced because of an adverse event profile we believe was driven by inhibition of kinases other than the PDGF receptor. A selective antibody directed at PDGF-B may therefore address a driver of remodeling that is both specific to the PDGF pathway and orthogonal to activin signaling.
PAH is a rare disease, with an estimated 30,000 to 50,000 patients in the United States. Secondary PH and related cardiopulmonary disease populations are substantially larger. We estimate, based on published epidemiology, that there are approximately 60,000 to 70,000 patients with PH-ILD, approximately 120,000 with IPF, approximately 180,000 with PPF, approximately 250,000 with PH-COPD, and approximately 500,000 with PH-HFpEF in the United States. We believe PAH represents a compelling first indication in cardiopulmonary disease, and molecules that address pulmonary vascular remodeling have potential across these related populations.
Current PAH Treatments and Their Limitations
Three signaling pathways underpin the approved treatment of PAH. Endothelin receptor antagonists, including ambrisentan, bosentan and macitentan, block endothelin-mediated vasoconstriction and smooth muscle proliferation. Agents acting on the nitric oxide pathway comprise the phosphodiesterase type 5 inhibitors sildenafil and tadalafil and the soluble guanylate cyclase stimulator riociguat. Prostacyclin pathway agents comprise parenteral, inhaled and oral analogs, including epoprostenol, treprostinil and iloprost, together with the oral prostacyclin receptor agonist selexipag. Each of these classes principally acts by dilating the pulmonary vasculature and improving right ventricular afterload.
Contemporary practice combines these agents according to a risk-stratified algorithm. Current treatment guidelines recommend initial combination therapy with an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor for patients with PAH who present at low or intermediate risk of death, and initial triple therapy, adding an activin signaling inhibitor or an intravenous or subcutaneous prostacyclin analog, for patients who present at high risk. In practice, most patients are managed on two or three background agents indefinitely, and participants in contemporary PAH trials are almost uniformly enrolled on top of established double or triple therapy.
These therapies improve symptoms, exercise capacity and hemodynamics, and parenteral prostacyclin has demonstrated a survival benefit in advanced disease. They have meaningfully changed the natural history of PAH; however, they do not directly address the pulmonary vascular remodeling that drives disease progression. Consequently, a meaningful proportion of patients still do not achieve or sustain low-risk status, with risk of progression to right heart failure, transplantation or death remaining high, despite compliance with guideline-directed combination therapy.
The approval of Winrevair in 2024 introduced the first mechanism directed at the underlying remodeling that drives disease rather than at vascular tone. In Merck’s Phase 3 STELLAR trial, Winrevair added to background therapy improved placebo-adjusted 6MWD by 41 meters at 24 weeks and reduced the risk of death or clinical worsening with a hazard ratio of 0.16 in patients with PAH. Activin signaling inhibition has since been incorporated into PAH treatment algorithms on top of the existing vasodilator double or triple therapy for patients at intermediate or high risk.
Winrevair’s benefit-risk leaves room for optimization through improved dosing, presentation and safety:
•Dose selection. Winrevair is titrated from 0.3 to 0.7 mg/kg and administered subcutaneously every three weeks, which is an uncommon interval. Winrevair's Phase 2 doses were selected based on pharmacokinetic modeling from a small study in postmenopausal women and have never been fully optimized in the PAH population. Only two doses were taken into Phase 2 and the doses did not show a difference on multiple endpoints. Therefore, we believe more comprehensive investigations of the relationship between dose level and dosing frequency are warranted, and risk-benefit may identify a regimen that yields a more optimized profile.
•Presentation. Winrevair is administered using a vial and syringe, which requires training on how to reconstitute, prepare, measure and inject the drug. This creates several steps where mistakes can be made, leading to an increased risk of administering an incorrect or even unsafe dose. We plan to develop an auto-injector in an effort to remove several opportunities for error in dosing and improve the patient experience.
•Hematologic and bleeding safety. Winrevair carries a warning in the United States for elevated risk of bleeding and is dose-constrained due to a risk of hemoglobin elevations. In the Phase 3 STELLAR trial, 22% of patients experienced epistaxis and 17% telangiectasia, with 53% of patients exhibiting an increase in hemoglobin above normal levels. Due to these side effects, hemoglobin and platelet levels are monitored before initiating therapy, and periodically thereafter. Delays to treatment are recommended in response to hemoglobin elevations or platelet count decreases. Data suggest these effects are linked to inhibition of BMP-9 and BMP-10, and that a ligand trap engineered to spare those ligands may reduce hematologic adverse events, dose limits and monitoring requirements.
To address these limitations, we have identified multiple avenues to optimize VLR199, VLR247 and VLR258, including a comprehensive dose-ranging study to understand the risk-benefit tradeoff, presentation with an auto-injector rather than as a vial and
syringe, and more conventional and potentially less frequent dosing regimens. For VLR247 and VLR258, reducing BMP-9/10 inhibition is expected to mitigate some of the hematological side effects seen with Winrevair.
VLR199
VLR199 is a proprietary ActRIIA-Fc ligand trap comprising the extracellular domain of ActRIIA, which has broad ligand trapping activity, fused to the Fc domain of human IgG1. VLR199 is designed to leverage the pharmacology of Winrevair, while potentially improving the benefit-risk profile through dose optimization and enhancing the patient experience with an auto-injector. Based on preclinical data generated to date, VLR199 has the potential to achieve a product profile in PAH consisting of the following:
•Pharmacology that matches Winrevair across the relevant ligands. ActRIIA-Fc ligand traps act on ligands of the TGF-β superfamily, including the pro-proliferative activin A, activin B, GDF-8 and GDF-11, and the anti-proliferative BMP-9 and BMP-10. We designed VLR199 to preserve the balance of Winrevair's activity across a panel of 16 ligands, rather than to optimize potency against any one of them, on the view that the clinical activity is attributable to that overall profile.
•Dosing and presentation improvements. We intend to pursue the dosing and presentation initiatives for VLR199, comprising comprehensive dose-ranging, presentation with an auto-injector for increased convenience and potentially less frequent dosing regimens than every three weeks.
Mechanism of Action
Pulmonary vascular homeostasis depends on a balance between two arms of TGF-β superfamily signaling, each transduced through a distinct pair of type 1 and type 2 serine/threonine kinase receptors. Pro-proliferative ligands, comprising the activins and growth differentiation factors, signal through the type 2 receptors ActRIIA and ActRIIB in combination with the type 1 receptors ALK4, ALK5 and ALK7, and propagate a signal through Smad2 and Smad3 that drives proliferation of pulmonary artery smooth muscle and endothelial cells. Anti-proliferative ligands, comprising the bone morphogenetic proteins, signal through the type 2 receptor BMPRII in combination with the type 1 receptors ALK1, ALK2, ALK3 and ALK6, and propagate a signal through Smad1, Smad5 and Smad8 that restrains that proliferation.
In PAH, this balance is disturbed. Loss-of-function mutations in BMPR2, the gene encoding BMPRII, are the most common genetic cause of heritable PAH, and reduced BMPRII signaling is observed in patients with idiopathic disease as well. At the same time, activin and GDF ligand levels are elevated. The result is that pro-proliferative signaling through the activin receptors overwhelms the anti-proliferative BMP signaling that normally opposes it, and the medial and intimal thickening, endothelial dysfunction and occlusive remodeling that characterize the disease proceed unchecked (as shown in Figure 3 below). The approved vasodilator classes act on vascular tone downstream of this process and leave the underlying signaling imbalance in place.

Figure 3: Activin and BMP signaling in the pulmonary vasculature. Pro-proliferative activins and GDFs signal through the type 1 receptors ALK4, 5 and 7 and the type 2 receptors ActRIIA and ActRIIB. Anti-proliferative BMPs signal through the type 1 receptors ALK1, 2, 3 and 6 and the type 2 receptor BMPRII. Solid lines denote strong activity and dashed lines weak activity. Winrevair inhibits activins and GDFs strongly and BMPs weakly, shifting the net balance toward anti-proliferative signaling.
Activin signaling inhibition is designed to restore the balance. An ActRII-Fc ligand trap comprises the extracellular ligand-binding domain of an activin type 2 receptor fused to an immunoglobulin Fc domain. Because it is soluble rather than membrane-bound, the trap binds circulating ligands and sequesters them before they can engage the receptors on the cell surface. Sequestering the pro-proliferative activins and GDFs reduces Smad2 and Smad3 signaling and shifts the net balance back toward the anti-proliferative BMP arm, without supplying an exogenous agonist or acting on vascular tone. This is the mechanism by which Winrevair is understood to reduce PVR and improve hemodynamics in PAH.
An ActRII-Fc trap’s pharmacology is determined, in part, by its relative affinity for multiple TGF-β superfamily ligands. Potency against the activins and GDFs is thought to drive the anti-remodeling effect, while residual activity against BMP-9 and BMP-10 is the element of the profile we believe leads to the hematologic and bleeding effects described above. VLR199 is designed to reproduce the full ligand-binding profile of Winrevair to retain its clinical activity.
Preclinical Data
We have evaluated exemplary VLR199 leads in a panel of in vitro assays measuring binding to 16 ligands and inhibition of downstream signaling for six of them. An exemplary VLR199 lead has a similar binding profile to Winrevair and exhibits a similar inhibitory profile across activin A, activin B, GDF-8, GDF-11, BMP-9 and BMP-10 (as shown in Figure 4 below). These data indicate that VLR199 should preserve the balance of Winrevair's activity across its ligand targets.
Figure 4: In vitro inhibitory profile of an exemplary VLR199 lead compared with Winrevair. Each axis represents inhibition of one ligand of the TGF-β superfamily. Values are half-maximal inhibitory concentrations (“IC50”) plotted on a logarithmic scale, with positions further from the center indicating greater potency. Winrevair was generated recombinantly for comparison and is not the marketed product. Data are from in vitro assays only; no in vivo or clinical comparison has been conducted.
Clinical Development Plans
We intend to submit an IND or CTA for VLR199 in the second half of 2027 and to initiate a Phase 1 study in healthy postmenopausal women, with clinical proof-of-concept data from this study anticipated in 2028. We intend to use pharmacodynamic biomarkers of activin signaling inhibition, including dose-dependent reductions in FSH in postmenopausal women, changes in hemoglobin and increases in BSAP, to establish VLR199’s clinical similarity to Winrevair and to enable dose-matching that is designed to support subsequent Phase 2 and Phase 3 studies.
VLR247 and VLR258
VLR247 and VLR258 are ligand traps designed to inhibit the key activin signaling ligands while sparing BMP-9 and BMP-10, the targets potentially linked to the hematologic adverse events observed with approved and investigational agents in the class. VLR247 comprises an ActRIIA extracellular domain, similar to that of Winrevair, and VLR258 comprises an ActRIIB extracellular domain, similar to that of HS235, a BMP-9/10-sparing ActRIIB-Fc ligand trap acquired by GSK and now known as GSK6792070. Each is fused to the Fc domain of human IgG1. These programs have the potential to achieve a product profile consisting of:
•Lower risk of hematologic adverse events. By sparing BMP-9 and BMP-10, VLR247 and VLR258 are designed to expand the therapeutic window relative to Winrevair.
•Two receptor backbones to optimize activity. By pursuing both ActRIIA and ActRIIB backbones in parallel, we have two distinct opportunities to optimize ligand selectivity and potency. We expect to advance either VLR247 or VLR258 into the clinic, and may advance both, based on preclinical data and external catalysts.
•Half-life extension for less frequent subcutaneous dosing. These candidates are engineered for extended half-life, which, in combination with an expanded therapeutic window, may enable a more convenient dosing regimen than Winrevair, which is dosed every three weeks.
•Presentation. We intend to develop an auto-injector presentation for both VLR247 and VLR258 to improve patient experience.
Rationale for Sparing BMP-9 and BMP-10
BMP-9 and BMP-10 are the principal circulating ligands for ALK1, a receptor expressed largely on endothelial cells, where they signal through the receptor BMPRII to maintain vascular quiescence and the integrity of small vessels. Unlike the activins and growth differentiation factors, which drive proliferation, this arm of the pathway restrains endothelial proliferation and stabilizes the vessel wall. We believe this distinction is what makes the BMP-9 and BMP-10 arm separable from the anti-remodeling effect sought in PAH: the therapeutic benefit of an ActRII-Fc ligand trap is understood to derive from sequestering the pro-proliferative ligands, while activity against BMP-9 and BMP-10 is potentially an incidental consequence of the binding profile of the natural receptor ectodomain rather than a contributor to efficacy.
Human genetics inform what happens when signaling through this arm is reduced. Hereditary hemorrhagic telangiectasia ("HHT") is an autosomal dominant vascular disorder caused by loss-of-function mutations in genes of the BMP-9/BMP-10-ALK1 axis, most commonly ENG, which encodes endoglin, and ACVRL1, which encodes ALK1, with rarer forms attributed to SMAD4 and to GDF2, the gene encoding BMP-9 itself. Patients with HHT develop fragile, dilated small vessels that bleed readily. The cardinal manifestations are recurrent spontaneous epistaxis, mucocutaneous telangiectasia of the lips, oral cavity and fingers, gastrointestinal bleeding from angiodysplastic lesions, and arteriovenous malformations of the lung, liver and brain.
The adverse events reported with ActRII-Fc ligand traps resemble an acquired, partial and reversible form of this phenotype. The adverse reactions reported in the STELLAR Phase 3 trial of Winrevair included epistaxis in 22% of patients and telangiectasia in 17%, each several-fold more frequent than on placebo. In another third-party clinical trial, gingival bleeding and gastrointestinal tract bleeding were reported. In the United States, prescribing information for Winrevair was revised in September 2026 to highlight the increased risk of bleeding and to add post-marketing reports of gastrointestinal bleeding associated with angiodysplasias. These findings closely track with the HHT phenotype and implicate activity against BMP-9 and BMP-10 as potentially related to these adverse events.
Clinical experience with agents directed at BMP-9 and BMP-10 points toward the same conclusion. Dalantercept, a soluble ALK1-Fc ligand trap that preferentially binds BMP-9 and BMP-10, led to telangiectasia and epistaxis in a dose-dependent manner across its clinical program. In a Phase 1 study of dalantercept by Bendell et al. in advanced cancer, telangiectasia was observed as a marker of ALK1 pathway inhibition, and epistaxis was also reported. In the dose-escalation portion of a renal cell carcinoma study, telangiectasia and epistaxis were observed in approximately 21% of patients, with epistaxis increasing at higher dose levels. A separate ActRIIB-Fc ligand trap, ACE-031, was developed by Acceleron to treat muscle disorders with no intended vascular effect. BMP-9 binds ActRIIB approximately 300 times more strongly than it binds ActRIIA, and clinical development of ACE-031 was stopped after epistaxis and telangiectasia were observed. Because dalantercept has no activity against the activins or GDFs, and BMP-9 preferentially binds the ACE-031 backbone, these experiences associate the bleeding and telangiectatic findings with BMP-9 and BMP-10 inhibition specifically, rather than with activin signaling inhibition generally. Together, these data suggest that both a genetic disorder and pharmacologic inhibition of the BMP-9/10 pathway recapitulate unwanted hematological adverse events seen with Winrevair, supporting the rationale for a BMP-9/10-sparing approach.
VLR247 and VLR258 are designed on the rationale that the unwanted side effects of activin ligand traps are associated with BMP-9 and BMP-10 inhibition. Accordingly, VLR247 and VLR258 are engineered to retain inhibition of activin A, activin B, GDF-8 and GDF-11, the ligands believed to drive the clinical benefit seen with Winrevair, while substantially reducing activity against BMP-9 and BMP-10. If the hypothesis holds, a BMP-9/10-sparing trap would separate the efficacy from Winrevair’s principal dose-limiting toxicities, which could permit higher exposures, reduce or eliminate the hemoglobin and platelet monitoring requirements, and lessen the bleeding risk.
Preclinical Data
In vitro assays with an exemplary VLR258 lead exhibited a relative IC50 for BMP-9 approximately 19-fold higher than Winrevair and approximately 5.4-fold higher than HS235, and a relative IC50 for BMP-10 approximately 17-fold higher than Winrevair and approximately 1.3-fold higher than HS235. A higher IC50 is indicative of greater ligand sparing. HS235 showed approximately 3.5-fold and 13-fold higher relative IC50 values for BMP-9 and BMP-10, respectively, than Winrevair. The same VLR258 lead retained inhibition of activin A, activin B, GDF-8 and GDF-11 comparable to Winrevair and HS235. These data are shown in Figure 5 below.

Figure 5: In vitro inhibition of an exemplary VLR258 lead compared with Winrevair and HS235. Left panel: relative IC50 against BMP9 and BMP10, normalized to Winrevair at 1x, where a higher value indicates greater ligand sparing. Right panel: inhibitory profile across six ligands, with IC50 values plotted on a logarithmic scale, with positions further from the center indicating greater potency; the VLR258 exemplary lead and HS235 are drawn inward on the BMP9 and BMP10 axes relative to Winrevair while tracking it on the activin and GDF axes. Winrevair and HS235 were generated recombinantly for comparison and are not the marketed or clinical products. Data are from in vitro assays only; no in vivo or clinical comparison has been conducted.
Clinical Development Plans
We intend to submit an IND or CTA for VLR247 or VLR258 in the first half of 2028. We expect that the design of these programs will be informed by the Phase 1 data generated for VLR199 and by external catalysts.
VLR360
VLR360 is a potentially best-in-class monoclonal antibody targeting PDGF-B, a target in PAH that is mechanistically orthogonal to activin signaling. PDGF-B signaling contributes to vascular remodeling and progression of PAH through a proliferative pathway distinct from that addressed by ActRII-Fc ligand traps. Based on our preclinical data generated to date, we believe VLR360 has the potential to achieve a product profile consisting of:
•Imatinib's PAH efficacy without its off-target kinase side effects. In Novartis’ Phase 3 IMPRES trial, imatinib improved exercise capacity and decreased PVR in PAH, an effect we believe was driven principally by PDGF receptor inhibition. Imatinib's development in PAH was limited by an adverse event profile, which was potentially driven by imatinib’s effects on targets other than the PDGF receptor (“off-target effects”). VLR360 is designed to be highly selective for PDGF-B, with the potential to avoid the off-target effects observed with imatinib.
•Greater potency than the leading antibody in the class. We believe VLR360 has the potential for greater potency than REGN13335, Regeneron's anti-PDGF-B antibody.
•Less frequent subcutaneous dosing. The Fc domain of VLR360 is modified for half-life extension, which we believe may permit less frequent dosing than REGN13335.
•Development as a monotherapy or in combination. We believe VLR360 could be developed as a monotherapy or in combination with ActRII-Fc ligand traps, including VLR199, VLR247 or VLR258.
Clinical Development Plans
We intend to submit an IND or CTA for VLR360 in the second half of 2027, with clinical proof-of-concept data anticipated in 2028.
Combination Strategy
Combination therapy is foundational to the treatment paradigm in PAH. In the Phase 3 STELLAR trial of Winrevair, 95% of patients received Winrevair on top of double or triple background therapy. We have designed our PAH portfolio with combination potential in mind from the outset. Although VLR199, VLR247 and VLR258 are being optimized as monotherapies, whichever ligand trap advances could serve as the foundation for combination with agents addressing distinct proliferative drivers, including VLR360 (as shown in Figure 6 below).

Figure 6: Our portfolio is designed for combination. The figure illustrates combination of a ligand trap (left) with VLR360, a mechanistically distinct agent (right). The molecular structures are illustrative representations of an Fc fusion protein and an antibody and do not depict the structure of any of our product candidates.
ALN1003 for the Treatment of Obesity and Metabolic Disease
We are also advancing ALN1003, which is an internally developed, preclinical small-molecule program for the treatment of obesity and related metabolic disorders. This program is focused on the discovery and development of novel, orally administered therapeutics with the potential to provide a differentiated and complementary profile relative to currently available therapies. While other pipeline therapies for obesity are exploring alternative hormonal pathways, including amylin and dual GIP/GLP-1 receptor agonism, our approach is focused on a non-hormonal mechanism of action.
Obesity and Metabolic Disease Background
Obesity is a chronic metabolic disease associated with insulin resistance, hepatic steatosis and an elevated risk of cardiovascular disease, type 2 diabetes and metabolic dysfunction-associated steatohepatitis ("MASH"). The approved incretin-based therapies, which act on the glucagon-like peptide-1 ("GLP-1") and glucose-dependent insulinotropic polypeptide ("GIP") receptors, have validated pharmacologic treatment of obesity and have become among the most widely prescribed medicines in the United States. Their limitations are, however, well documented. A substantial proportion of patients discontinue treatment, gastrointestinal adverse effects are common and dose-limiting, and the weight lost on these therapies includes a meaningful component of lean muscle mass. We believe significant market share remains available to next-generation therapies that address discontinuation, gastrointestinal tolerability and loss of muscle mass.
Insulin resistance is a shared feature of obesity-related and MASH-relevant metabolic dysfunction and is the central defect in type 2 diabetes. MASH is a rapidly emerging therapeutic area in which metabolic dysfunction drives liver-related morbidity. We believe that a therapy acting on the metabolic dysfunction common to these conditions, rather than on body weight alone, may be relevant across each of them.
ALN1003
In the second half of 2025, we conducted two separate non-Good Laboratory Practice pharmacology studies using a standard diet-induced obesity (“DIO”) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat). In January 2026, we announced we had identified a lead compound for continued preclinical evaluation and had established proof of concept in the DIO mouse model from these two studies, noting that observations from the studies conducted were encouraging and consistent with
statistically significant dose-related reductions in body weight, statistically significant improvements in body composition, specifically percentage fat and relative preservation of percentage lean, alongside favorable changes in metabolic parameters.
In March, May and June 2026, we announced additional details regarding these positive preclinical proof-of-concept data for ALN1003 from the two separate DIO studies conducted. Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, improvement in liver function biomarkers, and improvement in metabolic biomarkers. In the longer-duration 48-day DIO model, ALN1003 was associated with significantly lower fasting insulin and significantly lower Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), a calculated index derived from fasting glucose and insulin. ALN1003-treated animals had significantly lower HOMA-IR scores compared with controls after adjustment for percentage of body fat. Collectively, these findings suggest that ALN1003 may influence multiple components of metabolic syndrome biology in DIO mouse models, including insulin-resistance-related biomarkers, adipose endocrine signaling, and hepatic lipid accumulation. This multi-axis preclinical profile may be relevant to a therapeutic landscape increasingly focused on metabolic health beyond body weight alone, including liver health, cardiometabolic risk, and relative preservation of lean mass.
Discovery Candidates
We are also developing VLR869, a monoclonal antibody, and VLR6109, a bispecific antibody, for undisclosed indications.
Overview of Expansion Opportunities
PH-HFpEF (Group 2 PH)
PH-HFpEF results when left-sided heart failure causes progressive changes in the pulmonary vasculature comparable to those seen in PAH. We estimate the combined post- and pre-capillary PH-HFpEF population in the United States at approximately 500,000 patients, roughly ten times the size of the PAH population. There are no approved therapies, and vasodilator agents developed for PAH have caused harm in this setting.
Activin signaling inhibition is the only PAH mechanism to show efficacy in PH-HFpEF. In the Phase 2 CADENCE trial, Winrevair at the 0.3 mg/kg dose reduced the risk of clinical worsening with a hazard ratio of 0.18 and improved 6MWD and key biomarkers in both the lung and heart, including PVR and wedge pressure. Merck is advancing Winrevair into Phase 3 in PH-HFpEF at the 0.3 mg/kg dose. We believe our ligand trap programs have the potential to advance rapidly into late-stage studies in this indication.
Group 3 PH
Group 3 PH is pulmonary hypertension arising in the setting of chronic lung disease or hypoxia. The two largest subpopulations are PH-ILD and PH-COPD, which we estimate affect approximately 60,000 to 70,000 and approximately 250,000 patients in the United States, respectively. The development of PH in these patients is associated with reduced exercise capacity, greater oxygen requirements and shorter survival than the underlying lung disease alone.
Treatment options are limited for these patient populations. Inhaled treprostinil is the only therapy approved in the United States for PH-ILD, and no therapy is approved for PH-COPD. The systemic vasodilators used in PAH have historically been difficult to apply in Group 3 PH. Non-selective pulmonary vasodilation can aggravate hypoxemia in patients whose lung parenchyma is already diseased, and guidelines have accordingly been cautious about their use.
Given the mechanism and underlying pathology, we believe activin signaling inhibition is well suited to this setting. The mechanism addresses pulmonary vascular remodeling rather than vascular tone, which may allow treatment of the vascular component of Group 3 PH without increasing risk of hypoxia. Investigator-sponsored trials, retrospective analyses and case reports describing the use of Winrevair in Group 3 PH resemble the early clinical signals observed with inhaled treprostinil that preceded formal registrational studies and FDA approval in Group 3 PH.
Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Idiopathic pulmonary fibrosis ("IPF") and progressive pulmonary fibrosis ("PPF") are parenchymal fibrotic lung diseases, which we estimate affect approximately 120,000 and approximately 180,000 patients in the United States, respectively. They are distinct from Group 3 PH, though many patients with advanced fibrosis develop PH. IPF is a progressive and ultimately fatal disease where the approved antifibrotic therapies, nintedanib and pirfenidone, only slow the rate of lung-function decline, demonstrating a high unmet need.
Recent clinical results have established that an inhaled prostacyclin can modify the course of fibrotic lung disease. In the two Phase 3 TETON studies in patients with IPF, nebulized treprostinil improved absolute forced vital capacity ("FVC") by 95.6 mL relative to
placebo over 52 weeks in one study and 130.1 mL in the other, with both studies showing a reduction in clinical worsening events. These results demonstrate that the pulmonary vasculature is a tractable point of intervention in fibrotic lung disease, suggesting activin signaling inhibition could provide benefit in these indications.
Activin signaling inhibition has a mechanistic rationale in fibrosis that is distinct from, and potentially complementary to, its rationale in PAH. Activin A and related TGF-β superfamily ligands have been implicated in fibroblast activation and extracellular matrix deposition in the lung in addition to their roles in vascular remodeling, providing justification for exploring an activin signaling inhibitor in these indications.
Recent Developments
Asset Acquisition and PIPE
On October 13, 2026, we effected the Asset Acquisition to acquire Velaris in accordance with the terms of the Agreement and Plan of Merger, dated as of October 13, 2026 (the “Acquisition Agreement”), by and among the Company, Valkyrie Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), Valkyrie Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Velaris. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Velaris, pursuant to which Velaris was the surviving corporation and became a wholly owned subsidiary of the Company (the “First Merger”). Immediately following the First Merger, Velaris merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity and changed its name to “Velaris Therapeutics, LLC”.
The Asset Acquisition was structured as a stock-for-stock transaction pursuant to which (i) each outstanding share of Velaris common stock was converted into the right to receive a number of shares of Series C Preferred Stock equal to the exchange ratio of 5.2643 divided by 1,000 and (ii) each outstanding share of Velaris preferred stock was converted into the right to receive a number of shares of Series B Preferred Stock equal to the exchange ratio of 5.2643 divided by 1,000, for aggregate consideration of 105,286 shares of Series B Preferred Stock (or 105,286,000 shares on an as-converted-to-Common Stock basis) and 33,054 shares of Series C Preferred Stock (or 33,054,000 shares on an as-converted-to-Common Stock basis), in addition to the assumption of outstanding and unexercised options to purchase shares of Velaris common stock, which were converted into options to purchase 972,432 shares of Common Stock from the Velaris 2026 Equity Incentive Plan.
With respect to the Asset Acquisition, we determined that Alaunos was the acquiror for accounting purposes under ASC 805-10-25-4 and ASC 805-10-55-11. The primary factors considered were (a) the relative voting rights in the combined entity not resulting in a change of control, (b) legacy members of our board of directors maintained control of the board, and (c) the composition of senior management remained the same at the closing of the Transactions. Next, we considered whether the Asset Acquisition should be defined as a business under ASC 805. ASC 805-10-55-5A through 55-5C describe a screen test to determine whether an acquired set of assets and activities is not a business. We determined that substantially all (greater than 90%) of the fair value of the assets acquired were concentrated in a single asset, Velaris’s Option to license intellectual property rights related to certain of its programs pursuant to the Paragon Letter Agreement and the Paragon Option Agreement. Accordingly, we treated the Asset Acquisition as an asset acquisition for accounting purposes. Even if the transaction would have failed the screen test, Velaris lacked the financial resources to have inputs, processes, and outputs to constitute a business under ASC 805. Following the Asset Acquisition, we will need to invest in infrastructure and the continuing research and development being conducted under the Paragon Letter Agreement and the Paragon Option Agreement to be able to have any measurable outputs.
Concurrently with the execution of the Acquisition Agreement, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a PIPE investment with existing and new investors (the “Investors”) to raise approximately $350.0 million, pursuant to which the Investors purchased an aggregate of 687,789 shares of Common Stock at a price of $1.4357 per share and 243,063 shares of Series C Preferred Stock (or 243,063,000 shares on an as-converted-to-Common Stock basis) at a price of $1,435.70 per share (or $1.4357 per share on an as-converted-to-Common Stock basis). The PIPE included participation from Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Wellington Management, Janus Henderson Investors, Access Industries, BB Biotech, TCGX, T. Rowe Price, Deep Track Capital, Blackstone Multi-Asset Investing and Perceptive Advisors. The PIPE closed on October 14, 2026.
The Transactions were approved by our board of directors and the board of directors and stockholders of Velaris. The closings of the Transactions were not subject to the approval of Alaunos stockholders. Subject to the Conversion Approval and certain beneficial ownership limitations set by each holder, each share of Series B Preferred Stock will be convertible at the option of the holder into 1,000 shares of Common Stock and each share of Series C Preferred Stock will automatically convert into 1,000 shares of Common Stock. We expect to file a proxy statement with the SEC to solicit such Conversion Approval, among other matters, at a special meeting of Alaunos stockholders (the “Special Meeting”). Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series B Preferred Stock or the rights of such shares as required by the Delaware General Corporation Law) and the Certificate of
Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the “Series B Certificate of Designation”), the Series B Preferred Stock does not have voting rights. Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series C Preferred Stock or the rights of such shares as required by the Delaware General Corporation Law) and the Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock (the “Series C Certificate of Designation”), the Series C Preferred Stock does not have voting rights. For more information on the Series B Preferred Stock and the Series C Preferred Stock, please refer to the Series B Certificate of Designation and the Series C Certificate of Designation, respectively, which are incorporated by reference herein and attached as Exhibits 3.1 and 3.2 to our Current Report on Form 8-K filed with the SEC on October 13, 2026.
In connection with the execution of the Acquisition Agreement, Alaunos and Velaris entered into stockholder support agreements (the “Support Agreements”) with certain stockholders of Alaunos and its officers and directors (together with affiliated entities), which collectively own an aggregate of approximately 8.0% of the outstanding shares of Common Stock. The Support Agreements provide that, among other things, each of the parties thereto has agreed to vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the Conversion Approval and the other proposals described above at the Special Meeting.
Concurrently and in connection with the execution of the Acquisition Agreement, certain Velaris stockholders as of immediately prior to the Asset Acquisition and certain of the directors and officers and certain stockholders of the Company as of immediately prior to the Asset Acquisition entered into lock-up agreements with the Alaunos and Velaris, pursuant to which each such stockholder will be subject to a 180-day lockup on the sale or transfer of shares of Common Stock held by each such stockholder at the closing of the Asset Acquisition, including those shares received by such Velaris stockholders in the Asset Acquisition.
Our Relationship with Fairmount and Paragon
In connection with the Asset Acquisition, we assumed the rights and obligations of Velaris under the Paragon Letter Agreement and the Paragon Option Agreement. Each of Paragon Laboratories L.P. (“Paragon L.P.”) and Palaris Holding LLC (“Palaris”), an affiliate of Paragon L.P., received 13,161 shares of Series C Preferred Stock in the Asset Acquisition. Neither Paragon L.P. nor Palaris currently beneficially owns more than 5% of a class of our voting securities, and neither is expected to do so following the Conversion Approval. One of our directors, Peter Harwin, is affiliated with Fairmount and was appointed in accordance with the Acquisition Agreement; following the Conversion Approval, three additional directors designated by Fairmount will be appointed to the Board of Directors. We consider Paragon L.P., Palaris and Fairmount to be related parties. See the section titled “Paragon Option Agreement” below for more information on the Paragon Option Agreement.
Paragon Agreements
On July 17, 2026, Velaris entered into the Paragon Letter Agreement, under which Paragon agreed to conduct research programs for Velaris and granted Velaris an exclusive option, on a research program-by-research program basis, to enter into a discovery and option agreement for each program. Velaris exercised that option with respect to the first two research programs under the Letter Agreement, and on October 13, 2026, Velaris and Paragon entered into a Fusion Protein Discovery and Option Agreement (the “Paragon Option Agreement”), which memorializes the continuation of those two programs, supersedes the Letter Agreement with respect to them and establishes a framework for additional research programs. The Letter Agreement remains in effect with respect to its other three research programs, as described below. In connection with the Asset Acquisition, we assumed the rights and obligations of Velaris under the Paragon Option Agreement and the Letter Agreement. Under the terms of the Paragon Option Agreement, Paragon agreed to perform certain research activities to discover, generate, identify and characterize one or more Fc fusion protein candidates that comprise the extracellular domain of a single mutually agreed receptor (each, a “Research Program”). The Paragon Option Agreement includes three Research Programs: Research Program 1, for fusion proteins of activin A receptor type-2A (“ActRIIA”); Research Program 2, for fusion proteins of activin A receptor type-2B (“ActRIIB”); and Research Program 3, for fusion proteins of ActRIIA that spare BMP9/10 signaling. From time to time, we may choose to add additional Research Programs and receptors to the Paragon Option Agreement by mutual agreement with Paragon, and either party may accept or reject a proposed Research Program in its sole discretion.
The Paragon Option Agreement requires us and Paragon to agree on a research plan for each target that includes design, modeling, synthesis, evaluation and other mutually agreed activities (each, a “Research Plan”), which activities primarily include performing preclinical studies. Paragon will use commercially reasonable efforts to perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two representatives designated by us and two representatives designated by Paragon, with us and Paragon each having one vote. Following completion of the fusion protein production activities under a Research Plan, Paragon will deliver to us a data package that includes sequence information for all then-existing fusion proteins for such Research Program, together with samples upon our request and at our expense, to enable us to evaluate our option.
Under the Paragon Option Agreement, we have an option (an “Option”), on a Research Program-by-Research Program basis, to enter
into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a “License Agreement”). Each License Agreement will include (a) an exclusive, worldwide, royalty-bearing license, with the right to sublicense through multiple tiers, under Paragon’s rights in the intellectual property resulting from the applicable Research Program to develop, manufacture and commercialize the fusion proteins of the selected receptor, derivatives thereof and products containing them, and (b) a non-exclusive, worldwide, royalty-bearing license under certain other patents controlled by Paragon that expressly recite the sequence of a licensed fusion protein and are necessary to develop, manufacture or commercialize it. The licenses will be limited to the development and commercialization of the licensed fusion proteins as monospecific Fc fusion proteins; we will have no right under a License Agreement to develop or commercialize any multispecific molecule, antibody-drug conjugate, cell therapy or other modality incorporating a licensed fusion protein or its receptor domain, or to use the Fc domain of a licensed fusion protein other than as part of a licensed fusion protein, and Paragon retains all rights not expressly granted, including the right to use the resulting data for any purpose, subject to the exclusivity described below. The Option with respect to each Research Program is exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending 120 days following our receipt of the data package for such Research Program, or such longer period as the parties agree (an “Option Period”). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreement. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement. As of the date of this Quarterly Report on Form 10-Q, we have not exercised the option for any of our programs.
Upon exercise of an Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 90 days, and if they are unable to do so, either party may require that the form of License Agreement be determined by binding arbitration before an independent licensing expert. Under the terms of a License Agreement, we expect that we will have sole authority over and control of the development, regulatory approval, manufacturing and commercialization of the licensed fusion proteins worldwide, and will own all regulatory approvals. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the Research Program. Following entry into a License Agreement, we expect to control prosecution, defense, maintenance and enforcement of the licensed patents, subject to Paragon’s step-in rights. A License Agreement will continue until the expiration of the last royalty obligation, and may be terminated by either party for the other’s uncured material breach, by Paragon if we challenge the licensed patents, and by us for convenience on 60 days’ notice. However, there is no assurance that we will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this Quarterly Report on Form 10-Q.
Each license agreement under the Paragon Option Agreement will permit Paragon, in its sole discretion, to terminate the license, with the licensed rights reverting to Paragon, upon the occurrence of certain events, including if (i) the Company’s stockholders’ equity, as determined in accordance with the Nasdaq listing rules, does not exceed $200 million as of the end of the second full fiscal quarter following the closing of the Asset Acquisition, or the Company fails to timely file the periodic report including such balance sheet, or (ii) the Company fails to deliver freely tradeable shares of Common Stock within 120 days following an exercise of the warrants held by Paragon. Paragon may exercise this right within 180 days following the occurrence of such an event, and its right is not affected by any subsequent cure. Until Paragon’s reversion right expires, we may not, without Paragon’s consent, sublicense (other than to contractors), assign or grant a lien on the licensed rights, and upon any reversion we must transfer to Paragon the related data, regulatory filings and assignable third-party agreements and grant Paragon an exclusive license under our related intellectual property, in each case without further consideration.
We may terminate the Paragon Option Agreement or any research program for convenience upon 30 days’ prior written notice, subject to payment of accrued costs and non-cancellable obligations. Each party may terminate the Paragon Option Agreement for the other party’s uncured material breach or insolvency, and Paragon may terminate a research program if it is suspended or delayed for four consecutive months as a result of Velaris’s action or inaction. The Paragon Option Agreement also contains customary provisions relating to intellectual property, confidentiality and indemnification.
Unless terminated earlier, the Paragon Option Agreement shall continue in force on a Research Program-by-Research Program basis until the expiration or termination of the research term for such Research Program, which ends upon completion of the activities under the applicable Research Plan or, if earlier, upon the expiration of the Option Period without our exercise of the Option or the expiration of the 90-day License Agreement negotiation period without a License Agreement or a request for arbitration. We may terminate the Paragon Option Agreement or any Research Program at any time for any or no reason upon 30 days’ prior written notice to Paragon; provided, that we must pay Paragon any unpaid development costs accrued prior to termination, any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement or any Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a period of four consecutive months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i) 30 days’ prior written notice of the other party’s material breach (or 10 days’ notice in the case of a payment breach) that remains uncured during such period, (ii) the other party’s bankruptcy and (iii) a force majeure event continuing for more than 90 days.
Under the Paragon Option Agreement and the Paragon Letter Agreement, Velaris is obligated to reimburse Paragon $18.5 million for research and development costs related to VLR199, VLR247, VLR258 and VLR360, other general and administrative costs incurred by Paragon through October 13, 2026 (the “Pre-Effective Date Development Costs”), payable within 30 days after receipt of Paragon’s invoice. The Pre-Effective Date Development Costs include a 20% mark-up on third-party costs paid by Paragon, subject to certain exclusions.
We are also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Paragon Option Agreement, we are required to pay Paragon a one-time, non-refundable research initiation fee of $3.0 million for each of Research Program 1 and Research Program 2, payable within 30 days following the later of finalization of the applicable Research Plan and the first closing of a financing in which Velaris sells equity securities to third parties (other than Paragon or Fairmount) for gross proceeds of more than $50.0 million (a “Qualified Financing”), subject to a $12.0 million cap on aggregate research initiation fees for Research Programs commenced before the first Qualified Financing. Under the Paragon Option Agreement, on a Research Program-by-Research Program basis, we are required to make one-time, non-refundable milestone payments to Paragon of up to a total of $62.5 million per product upon the achievement of certain development and regulatory milestones. As of the date of this Quarterly Report on Form 10-Q, no milestone payments have become payable.
Any License Agreement entered into with respect to a given Research Program will contain the same milestone payment obligations as the Paragon Option Agreement, provided that any milestone set in the Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by us pursuant to the Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, we would also be required to make royalty payments to Paragon in the high single-digit percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.
Additionally, as part of the Paragon Option Agreement, we are obligated to issue to Paragon two warrants, each to purchase a number of shares of our Common Stock equal to 1.00% of our outstanding Common Stock as of the date of the grant on a fully diluted basis, with an exercise price equal to the fair market value of the underlying shares of our Common Stock on the applicable grant date and a term of ten years from the grant date.
As of the closing of the Asset Acquisition on October 13, 2026, Velaris had recognized $18.5 million of expense pursuant to the Paragon Option Agreement and the Letter Agreement, of which $17.9 million is research and development expense and $0.6 million is general and administrative expense. Of the research and development expense, $7.3 million is related to Research Program 1, $5.1 million is related to Research Program 2 and $1.3 million is related to Research Program 3. No payments were made by Velaris to Paragon prior to the closing of the Asset Acquisition. As of the date of this Quarterly Report on Form 10-Q, we have paid Paragon an aggregate of $13.4 million, including $7.1 million related to Research Program 1, $0.9 million related to Research Program 2 and $1.2 million related to Research Program 3.
Nasdaq Stockholders' Equity Deficiency Notice
On April 9, 2026, we received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that our stockholders’ equity, as reported in the 2025 Annual Report, did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. In the 2025 Annual Report we reported stockholders’ equity of $2.2 million, and, as a result, did not satisfy Nasdaq Listing Rule 5550(b)(1) at that time.
Subsequent to September 30, 2026, we completed the PIPE on October 14, 2026, generating approximately $350.0 million in gross proceeds before placement agent fees and other offering expenses. In connection with the PIPE, Fairmount Healthcare Fund II, L.P. provided a limited waiver of cash-settlement rights covering 6,268 shares of Series C Non-Voting Convertible Preferred Stock, representing approximately $9.0 million. Before the PIPE, on October 5, 2026, we had received a written notice from the Listing Qualifications staff of Nasdaq informing us that our securities were subject to delisting due to its continued non-compliance with Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”) unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company had timely submitted a plan to regain compliance and a hearing was scheduled for November 10, 2026. On October 21, 2026, we disclosed Nasdaq’s determination that the PIPE, including the effect of the waiver, had restored compliance with the Stockholders’ Equity Requirement.
On October 22, 2026, we received a letter from Nasdaq’s Office of General Counsel confirming that Nasdaq staff had determined that
we had regained compliance with the Stockholders’ Equity Requirement. Nasdaq closed the matter and cancelled the November 10, 2026 hearing. Our common stock continues to be listed and traded on the Nasdaq Capital Market.
Nasdaq will continue to monitor our compliance. If we do not evidence compliance when we file our Annual Report on Form 10-K for the year ending December 31, 2026, we may be subject to delisting. The September 30, 2026 balance sheet precedes the Asset Acquisition and the PIPE and therefore does not reflect their effects on stockholders’ equity. See Note 9. Subsequent Events and Part II, Item 1A, “Risk Factors,” for additional information.
Results of Operations
Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025
Research and Development Expenses
Research and development expenses during the three months ended September 30, 2026 and 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
($ in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
$ |
227 |
|
|
$ |
469 |
|
|
$ |
(242 |
) |
|
|
(52 |
)% |
|
Research and development expenses for the three months ended September 30, 2026 decreased by $242 when compared to the three months ended September 30, 2025, primarily due to a decrease in stock-based compensation, salary expense and consulting fees incurred in pursuit of our obesity and metabolic disorders program.
General and Administrative Expenses
General and administrative expenses during the three months ended September 30, 2026 and 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
($ in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses |
$ |
533 |
|
|
$ |
718 |
|
|
$ |
(185 |
) |
|
|
(26 |
)% |
|
General and administrative expenses for the three months ended September 30, 2026 decreased by $185 as compared to the three months ended September 30, 2025, primarily due to a decrease in salary expense, insurance costs, filing fees, bank fees, legal fees and travel costs due to our downsized operations.
Other Income (Expense), net
Other income (expense), net during the three months ended September 30, 2026 and 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Change |
|
|
($ in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense), net |
$ |
(12 |
) |
|
$ |
28 |
|
|
|
(40 |
) |
|
|
(143 |
)% |
|
Other income (expense), net, for the three months ended September 30, 2026 decreased by $40 as compared to the three months ended September 30, 2025.
Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025
Royalty Revenue
Royalty revenue during the nine months ended September 30, 2026 and 2025 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, |
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Change |
|
($ in thousands) |
|
|
|
|
|
|
|
|
|
|
|
Revenue |
$ |
— |
|
|
$ |
2 |
|
|
$ |
(2 |
) |
|
|
(100 |
)% |
Research and Development Expenses
Research and development expenses during the nine months ended September 30, 2026 and 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, |
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Change |
|
($ in thousands) |
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
$ |
1,041 |
|
|
$ |
1,002 |
|
|
$ |
39 |
|
|
|
4 |
% |
Research and development expenses for the nine months ended September 30, 2026 increased by $39 when compared to the nine months ended September 30, 2025, primarily due to increases in salary expense and consulting fees incurred in pursuit of our obesity and metabolic disorders program.
General and Administrative Expenses
General and administrative expenses during the nine months ended September 30, 2026 and 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, |
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Change |
|
($ in thousands) |
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses |
$ |
1,683 |
|
|
$ |
2,318 |
|
|
$ |
(635 |
) |
|
|
(27 |
)% |
General and administrative expenses for the nine months ended September 30, 2026 decreased by $635 as compared to the nine months ended September 30, 2025, primarily due to a decrease in salary expense, insurance costs, filing fees, bank fees and legal fees.
Other Income (Expense), net
Other income (expense), net during the nine months ended September 30, 2026 and 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, |
|
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Change |
|
($ in thousands) |
|
|
|
|
|
|
|
|
|
|
|
Other income (expense), net |
|
(6 |
) |
|
|
66 |
|
|
|
(72 |
) |
|
|
(109 |
)% |
Other income (expense), net, for the nine months ended September 30, 2026 decreased by $72 as compared to the nine months ended September 30, 2025.
Liquidity and Capital Resources
Liquidity
Sources of Liquidity
We have not generated any revenue from product sales. Since inception, we have incurred net losses and negative cash flows from our operations. We have operated at a loss since inception in 2003 and have no significant recurring revenue from operations. We anticipate that losses will continue for the foreseeable future. As of September 30, 2026, our accumulated deficit was approximately $927.4 million. Our working capital surplus as of September 30, 2026 was $0.13 million, consisting of $1.08 million in current assets and $0.95 million in current liabilities. Our actual cash requirements may vary materially from those planned because of a number of factors, including changes in the focus, direction and pace of our development programs.
Historically, we have financed our operations primarily through public offerings and private placements of equity securities, including common stock, pre-funded warrants and convertible preferred stock, together with limited historical collaborations.
As of September 30, 2026, we had approximately $0.62 million of cash and cash equivalents.
Subsequent to September 30, 2026, we completed the Asset Acquisition on October 13, 2026 and completed the PIPE financing of common stock and Series C Non-Voting Convertible Preferred Stock on October 14, 2026. The PIPE generated approximately $350.0 million in gross proceeds before placement agent fees and other offering expenses. These transactions are not reflected in our September 30, 2026 balance sheet.
The financing proceeds are intended primarily to support development of our cardiopulmonary programs and provide working capital for general corporate purposes. Their use is subject to contractual restrictions, including limitations on funding our legacy business beyond agreed amounts and certain other uses without the lead investor’s consent. Our historical cash usage does not reflect the expanded development activities resulting from the Asset acquisition.
Based on our updated cash flow forecast, including the net proceeds from the completed PIPE, management believes that our available resources are sufficient to fund planned operations and meet our obligations as they become due for at least one year after the issuance date of these condensed financial statements. Accordingly, management has concluded that the substantial doubt previously identified about our ability to continue as a going concern has been alleviated.
Our future cash requirements will depend on the scope, timing and results of our development programs; manufacturing and regulatory activities; obligations under research and licensing arrangements; transaction and integration costs; and remaining legacy obligations. Our forecasts depend on assumptions that may change, and actual expenditures could materially exceed our estimates.
Our liquidity requirements also include the contemplated repurchase of our Series A-1 and Series A-2 Convertible Preferred Stock and related conversion shares, as described below. In addition, the Series B Preferred Stock and Series C Preferred Stock issued in the Asset Acquisition and PIPE contain cash-settlement provisions that may apply beginning six months after issuance if required stockholder approvals have not been obtained, subject to a limited waiver covering certain Series C shares. If our stockholders do not approve the conversion of the Series B Preferred Stock and Series C Preferred Stock, holders (other than the holder of the 6,268 shares of Series C Preferred Stock covered by the limited waiver) may require us to settle conversions in cash at the fair value of the common stock otherwise issuable. Based on approximately 381.4 million shares of common stock issuable upon conversion, the aggregate amount could exceed our available cash resources. See the “Subsequent Events” note for further information..
We may require additional capital to fund activities beyond our current operating plan, accelerate development or pursue additional opportunities. Such funding may involve equity or debt financings, collaborations or other strategic transactions. Additional capital may not be available on acceptable terms, or at all. See Part II, Item 1A, “Risk Factors,” for further discussion.
Series A-1 and A-2 Preferred Stock Cumulative Dividends
Cumulative dividends on the Company’s Series A-1 and Series A-2 Convertible Preferred Stock accrue at 10% per annum and compound quarterly by increasing the liquidation preference. Undeclared cumulative dividends are not recorded as a liability. Because the Company reported a net loss for the periods presented, cumulative preferred dividends increased the net loss attributable to common stockholders in the earnings-per-share calculation. As of September 30, 2026, undeclared cumulative dividends totaled $78 for Series A-1 and $114 for Series A-2.
On October 13, 2026, we entered into an agreement to repurchase the common shares issued upon conversion of these preferred shares and any preferred shares remaining unconverted. Subject to the agreement’s conditions, repurchase will occur on the second business day after stockholder approval of the Series B and Series C conversion proposal. The payment reflects the original preferred shares’ contractual accreted value, including dividends through the approval date, and is estimated at approximately $1.6 million if approval occurs before February 2027. See Note 9. Subsequent Events.
Cash Flows
The following table summarizes our net increase (decrease) in cash and cash equivalents for the nine months ended September 30, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
($ in thousands) |
|
|
|
|
|
|
Net cash flows from: |
|
|
|
|
|
|
Operating activities |
|
$ |
(1,756 |
) |
|
$ |
(2,317 |
) |
Investing activities |
|
|
— |
|
|
|
(97 |
) |
Financing activities |
|
|
986 |
|
|
|
3,261 |
|
Net increase (decrease) in cash and cash equivalents |
|
$ |
(770 |
) |
|
$ |
847 |
|
Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net loss for:
•Non-cash operating items such as depreciation, amortization, and stock-based compensation; and
•Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.
Net cash flows used in operating activities for the nine months ended September 30, 2026 were $1.76 million, as compared to net cash used in operating activities of $2.32 million for the nine months ended September 30, 2025. The decrease in net cash used in operating activities was primarily related to a decrease in our net loss, offset by an increase in timing of accounts payable and accrued expenses.
Net cash flows used in investing activities for the nine months ended September 30, 2026 were $0, as compared to net cash used in investing activities of $97 for the nine months ended September 30, 2025. The decrease in net cash used in investing activities was directly attributed to an equipment purchase made during the prior period to be used in our obesity program compared to the current period.
Net cash flows provided by financing activities for the nine months ended September 30, 2026 were $0.99 million due to net proceeds from the draw down on our equity line of credit and net proceeds from our registered direct offering. The net cash flows provided by financing activities for the nine months ended September 30, 2025 were $3.26 million directly attributable to proceeds from the issuance of common stock and prefunded warrants, the sale of Series A-1 Preferred Stock, and the sale of Series A-2 Preferred Stock.
Capital Resources
Operating Leases
As of September 30, 2026, we have no lease commitments, other than a short-term lease.
Royalty and License Fees
In June 2022, Solasia Pharma K. K., or Solasia, announced that darinaparsin had been approved for relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the three and nine months ended September 30, 2026, the Company earned no collaboration revenue under the Solasia License and Collaboration Agreement. During the three and nine months ended September 30, 2025, the Company earned collaboration revenue of $0 and $2, respectively under that agreement.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
As a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, we are not required to provide the information under this item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures.
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our principal executive officer and principal financial officer has concluded that as of September 30, 2026, our disclosure controls and procedures were not effective.
Changes in Internal Controls over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities from time to time. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially affect our business, financial condition, results of operations, cash flows and prospects. In addition, regardless of the outcome, litigation could have an adverse impact on us because of defense costs, diversion of management attention and resources and other factors.
We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, be reasonably likely to have a material adverse effect on our business, financial condition, results of operations, cash flows or prospects.
Item 1A. Risk Factors
You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
There is no guarantee that the Asset Acquisition will increase stockholder value.
On October 13, 2026, we completed the Asset Acquisition. We cannot guarantee that implementing the Asset Acquisition, the PIPE and related transactions will not impair stockholder value or otherwise adversely affect our business. The Asset Acquisition poses significant integration challenges between our businesses which could result in management and business disruptions, any of which could harm our results of operation, business prospects, and impair the value of the Asset Acquisition to our stockholders.
We are a preclinical-stage biopharmaceutical company with a limited operating history on which to assess our business; we have no products approved for commercial sale, which may make it difficult to evaluate our current business and likelihood of success and viability.
We are a preclinical-stage biopharmaceutical company with limited operating history. Since our inception, we have incurred operating losses with no corresponding revenue and have utilized substantially all of our resources to identify, license and develop our product candidates, organize and staff our company and provide other general and administrative support for our operations. We have limited experience as a company in initiating, conducting and completing preclinical studies and clinical trials. In part because of this lack of experience, we cannot be certain that our preclinical studies or clinical trials will begin or be completed on time, if at all. In addition, we have not yet demonstrated an ability to obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.
In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with an early research and development focus to a company capable of supporting larger scale clinical trials and eventually commercial activities. We may not be successful in such a transition.
We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research programs or future commercialization efforts.
Developing biotechnology products is a long, time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct preclinical studies and clinical trials of, and seek regulatory approval for our product candidates, advance discovery efforts with respect to our research and research programs, and advance any future programs and product candidates that we may develop or license. Even if one or more of the programs that we
develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities to launch any such product. Our expenses could increase beyond expectations if we are required by the Food and Drug Administration (“FDA”) or other regulatory agencies to perform preclinical studies or clinical trials in addition to or more expansive than those that we currently anticipate. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of funding that will be necessary to successfully complete the development and commercialization of any program we develop. Our future capital requirements depend on many factors, including but not limited to:
•the scope, design, progress, results and costs of discovery, preclinical and clinical development for our product candidates;
•the cost and timing of completion of clinical and commercial-scale manufacturing activities;
•the costs and timing of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property;
•the costs, timing and outcome of the regulatory review of our product candidates and obtaining the requisite regulatory approvals;
•the costs of our future commercialization activities, either on our own or in collaboration with others, including product sales, marketing, manufacturing, and distribution for any product candidate for which we receive regulatory approval;
•the revenue, if any, received from commercial sales of product candidates for which we receive regulatory approval;
•the success of our current or future collaborations, including our collaboration with Paragon pursuant to the Paragon Option Agreement and any future license agreements we enter into with Paragon;
•our ability to establish and maintain additional collaborations on favorable terms, if at all;
•the extent to which we acquire or in-license products, intellectual property and technologies;
•the costs of operational, financial and management information systems and associated personnel; and
•the costs of operating as a public company.
As a result, we will require substantial additional funding to continue our operations. As of September 30, 2026, we had $0.62 million of cash and cash equivalents. We expect that our existing cash and cash equivalents, including the proceeds from the PIPE, will be sufficient to fund our operating expenses and capital expenditure requirements through the expected readout of clinical proof-of-concept data for VLR199 and VLR360 in 2028. We will still need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.
We may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, and adequate additional financing may not be available to us on acceptable terms, or at all. Such financing may dilute our stockholders or the failure to obtain such financing may restrict our operating activities. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our business. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect the rights of our stockholders. Debt financing may result in the imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to current or future collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. Our ability to raise additional capital may be adversely impacted by global macroeconomic conditions and volatility in the credit and financial markets in the United States and worldwide. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy,
and we may have to delay, reduce the scope of, suspend or eliminate one or more of our product candidates, clinical trials or future commercialization efforts or cease our operations.
We expect to continue to incur losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products approved for sale, have not generated any revenue from our product candidates and may never generate revenue or become profitable.
Investment in biotechnology product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risks that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale, have not generated any revenue from product sales to date, and continue to incur significant research and development and other expenses related to our ongoing operations. We do not expect to generate product revenue unless or until we successfully complete preclinical and clinical development and obtain regulatory approval of, and then successfully commercialize, at least one of our product candidates. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we are unable to raise sufficient additional capital to advance a product candidate to commercialization or generate sufficient revenue through the sale of any approved products, we may be unable to continue operations without additional funding.
We have incurred significant net losses in each period since our inception in 2003. For the three and nine months ended September 30, 2026, we had net losses of $0.8 million and $2.7 million, respectively. As of September 30, 2026, we had an accumulated deficit of $927.4 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:
•advance our existing and future product candidates through preclinical and clinical development;
•seek to identify additional product candidates;
•maintain, expand, enforce, defend and protect our intellectual property portfolio;
•seek, obtain and maintain regulatory and regulatory approvals for our product candidates;
•seek to identify, establish and maintain additional collaborations and license agreements;
•make milestone payments to Paragon under the Paragon Option Agreement and under any additional future collaboration or license agreements that we enter into;
•ultimately establish a sales, marketing and distribution infrastructure to commercialize any drug products for which we may obtain regulatory approval, either on our own or in collaboration with others;
•generate revenue from commercial sales of product candidates for which we receive regulatory approval, if any;
•hire additional personnel including research and development, clinical and commercial personnel;
•add operational, financial and management information systems and personnel, including personnel to support our product development;
•acquire or in-license products, intellectual property and technologies;
•establish clinical and commercial-scale current good manufacturing practices (“cGMPs”) capabilities through a third-party or our own manufacturing facility; and
•integrate Velaris into our operations following the Asset Acquisition.
In addition, our expenses will increase if, among other things, we are required by the FDA or other regulatory authorities to perform clinical trials or studies in addition to, or different than, those that we currently anticipate, there are any delays in completing our clinical trials or the development of any of our product candidates, or there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim.
Even if we obtain regulatory approval for, and are successful in commercializing, one or more of our product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.
Our failure to become profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our stock could also cause stockholders to lose all or part of their investment.
Risks Related to Our Discovery, Development and Commercialization
We face competition from entities that have developed or may develop product candidates for the diseases addressed by our product candidates.
The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies. If approved for the treatment of pulmonary arterial hypertension (“PAH”), our product candidates would compete with approved therapies across the endothelin, nitric oxide and prostacyclin pathways, marketed by companies including United Therapeutics, Johnson & Johnson, Bayer, Merck and Liquidia, and with Merck’s Winrevair® (sotatercept), the only approved ActRII-Fc ligand trap and our most direct competitor. In addition, we are aware of several companies with product candidates in development for the treatment of PAH and related cardiopulmonary diseases, including HS235 (GSK6792070), a BMP-9/10-sparing ActRIIB-Fc ligand trap acquired by GSK; REGN13335, an anti-PDGF-B monoclonal antibody in development by Regeneron Pharmaceuticals; ralinepag, an oral prostacyclin receptor agonist in development by United Therapeutics; seralutinib, an inhaled PDGFR, CSF1R and c-Kit inhibitor in development by Gossamer Bio; IKT-001Pro, an oral imatinib prodrug in development by Inhibikase Therapeutics; treprostinil palmitil inhalation powder in development by Insmed; L606, a liposomal treprostinil in development by Liquidia; and mosliciguat, an inhaled soluble guanylate cyclase activator in development by Roivant. We also compete with academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do, and are further along in the clinical development and/or commercialization process. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, raising capital, patient registration for clinical trials, establishing and defending rights to intellectual property, as well as in acquiring technologies complementary to, or necessary for, our product candidates.
Our competitors have developed or are developing, and may in the future develop, product candidates or products competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any potential new treatments, including those currently under clinical development. Our success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop competing products or biosimilars that enter the market more quickly than we do and are able to gain market acceptance. Conversely, the lack of commercial success of other competing therapies may raise concerns about the financial viability of our product candidates.
In addition, because of the competitive landscape for PAH indications, we may also face competition for establishing trial sites and clinical trial enrollment. Patient enrollment will depend on many factors, including if potential clinical trial patients choose to undergo treatment with approved products or enroll in competitors’ ongoing clinical trials for product candidates that are under development for the same indications as our product candidates. An increase in the number of approved products for the indications we are targeting with our product candidates will likely further exacerbate this competition. Our inability to enroll a sufficient number of patients could, among other impacts, delay our development timeline, which may further harm our competitive position.
Our programs are in the preclinical stages of development and may fail in development or suffer delays that materially and adversely affect our viability. If we or our current or future collaborators are unable to complete development of or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.
We have no commercially approved products. Our programs are in the preclinical stages of development, and we have not completed any clinical trials for these product candidates. As a result, we expect it will be many years before we commercialize any product candidate, if ever. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, our product candidates, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our product candidates. We have not yet demonstrated our ability to obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of any product candidate, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of the product candidate.
We or our collaborators may experience delays in initiating or completing preclinical studies or clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, any future preclinical studies or clinical trials that we could conduct that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:
•regulators, such as the FDA, institutional review boards (“IRBs”) or comparable foreign regulatory authorities may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
•we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective clinical research organizations (“CROs”), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
•clinical trial sites may deviate from the trial protocol, fail to conduct trials in a compliant manner or drop out of a trial, which may require that we add new clinical trial sites or investigators or otherwise negatively impact the timing or integrity of our clinical trial(s);
•clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon a product research program;
•the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, and enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;
•our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or suffer other quality or performance issues that negatively impact the timing or integrity of our clinical trial(s);
•we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks;
•the cost of clinical trials of any of our product candidates may be greater than we anticipate;
•the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or successfully complete a given clinical trial;
•we may be unable to manufacture sufficient quantities of our product candidates for use in clinical trials;
•reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates;
•we may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as our product candidates; and
•the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.
Commencing clinical trials in the United States is subject to acceptance by the FDA of an Investigational New Drug (“IND”) and finalizing the trial design based on discussions with the FDA. Commencing clinical trials in jurisdictions outside of the United States is similarly subject to acceptance by the applicable regulatory authority of clinical trial documentation following discussions with such authority. In the event that the FDA or other applicable regulatory authority requires us to complete additional preclinical studies or we are required to satisfy other FDA or foreign regulatory authority requests, respectively, prior to commencing clinical trials, the start of our first clinical trial for a product candidate may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree as to whether we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are analogous processes and risks applicable to clinical trial applications in other countries, including but not limited to Canada, New Zealand, Australia, countries in the EU and countries in Asia.
We may not have the financial resources to continue development of our product candidates if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates. We or our current or future collaborators’ inability to complete development of, or commercialize our product candidates, or significant delays in doing so, could have a material and adverse effect on our business, financial condition, results of operations and prospects.
We are substantially dependent on the success of VLR199, and our anticipated future clinical trials of such product candidate may not be successful.
Our future success is substantially dependent on our ability to timely obtain regulatory approval for, and then successfully commercialize, VLR199. We are initially investing a majority of our efforts and financial resources into the research and development of this program. We intend to file an IND or a clinical trial application (“CTA”) for VLR199 in the second half of 2027 and generate clinical proof-of-concept data in 2028. The success of VLR199 is dependent on our ability to demonstrate in our planned Phase 1 clinical trial that VLR199 replicates the pharmacodynamic effects of Winrevair, which we intend to use to establish VLR199’s clinical similarity to Winrevair and to enable dose-matching for subsequent clinical trials. To the extent we do not observe dose-dependent reductions in serum follicle-stimulating hormone (“FSH”) in healthy postmenopausal women, changes in hemoglobin and increases in serum bone-specific alkaline phosphatase (“BSAP”) comparable to those seen with Winrevair in our Phase 1 clinical trial of VLR199 or in additional clinical trials, it would significantly and adversely affect the clinical and commercial potential of VLR199.
Our product candidates will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote these product candidates, or any other product candidates, before we receive regulatory approval from the FDA and comparable foreign regulatory authorities, and we may never receive such regulatory approvals.
The success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights, potential threats from the intellectual property rights of third parties and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of these product candidates, even if approved. If we are not successful in obtaining regulatory approval and commercializing VLR199 or our other or future product candidates, or are significantly delayed in doing so, our business will be materially harmed.
If we do not achieve our projected development objectives in the time frames we announce and expect, the commercialization of our product candidates may be delayed which may harm our reputation and prospects, increase our expenses and cause our stock price to decline.
From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the initiation of our Phase 1 clinical trial of VLR199, the timing for receipt of clinical data, and the timing for the submission of regulatory filings. From time to time, we may publicly announce the
expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, our prospects and reputation may be adversely affected and our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones.
The target patient population for the treatment of PAH is small and has not been definitively determined, and if estimates of the number of treatable patients are lower than expected, our potential revenues from sales of our product candidates, if approved, and our ability to achieve profitability would be compromised.
The estimates of both the number of patients who have PAH and related cardiopulmonary diseases, as well as the subset of patients with the disease in a position to receive treatment from VLR199 (i.e., patients at intermediate or high risk of death who are receiving background double or triple therapy), if approved, may prove to be incorrect. These estimates have been derived from a variety of sources, including scientific literature, input from physicians that treat patients with the diseases we are targeting, patient foundations and secondary market research databases. For example, our estimate that there are approximately 30,000 to 50,000 patients with PAH in the United States is based in part on published epidemiology. Further, new studies may change the estimated incidence or prevalence of PAH, and any regulatory approvals may be for a narrower patient population. Similar considerations would apply to estimates of patient population for target indications we select for our other product candidates. Accordingly, our target patient populations may turn out to be lower than expected, in which case the potential revenues from sales of our product candidates, if approved, would be lower than expected.
Our approach to the discovery and development of VLR199 and our other product candidates is unproven, and we may not be successful in our efforts to build a pipeline of product candidates with commercial value.
Our approach to the discovery and development of our product candidates leverages ActRII-Fc ligand traps, including BMP-9/10-sparing ligand traps, and a PDGF-B antibody designed to overcome limitations of existing therapies. Our product candidates, including our ActRII-Fc ligand traps and our anti-PDGF-B antibody, are designed to address the growth-signaling imbalances that drive pulmonary vascular remodeling. However, the scientific research that forms the basis of our efforts to develop VLR199 and our other product candidates is ongoing and may not result in viable product candidates. We have no clinical data on our product candidates demonstrating whether they are safe or effective for long-term treatment in humans. The long-term safety and efficacy of VLR199 and our other product candidates compared to currently approved products is unknown.
We may ultimately discover that our product candidates do not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data regarding the in vitro ligand-binding and signaling-inhibition profile of VLR199 and our other product candidates. In addition, our product candidates may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Our product candidates may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. Many product candidates that appeared highly promising in preclinical studies or in early-stage clinical trials have failed when advanced into, or further in, clinical development.
In addition, other companies are developing drug products that utilize similar mechanisms of action in other targets and indications. The failure of those companies to demonstrate the safety and efficacy of their product candidates may be harmful to our business, financial condition, results of operations and prospects.
In addition, we may in the future seek to discover and develop product candidates that are based on novel targets and technologies that are unproven. If our discovery or business development activities fail to identify novel targets or technologies for drug development, or such targets or technologies prove to be unsuitable for treating human disease, we may not be able to develop viable additional product candidates. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from our product candidates prove to be ineffective, unsafe or commercially unviable, our product candidates and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.
Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.
Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process.
Moreover, enrolling patients in clinical trials for PAH may be challenging because PAH is a rare disease, with an estimated 30,000 to 50,000 patients in the United States, and participants in contemporary PAH trials are almost uniformly enrolled on top of established double or triple background therapy. If we are unable to initiate or adequately enroll our clinical trial sites, our clinical trials may be delayed.
Furthermore, a failure of one or more clinical trials can occur at any clinical trial phase. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. In addition, we expect to rely on patients to provide feedback on measures such as measures of disease and quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control and can vary widely from day to day for a particular patient, and from patient to patient and from site to site within a clinical trial.
We cannot be sure that the FDA or comparable foreign regulatory authorities will agree with our clinical development plans. In addition, there is no guarantee that the data from our planned Phase 1 trial of VLR199 will support additional trials. If the FDA or comparable foreign regulatory authorities require us to conduct additional trials or enroll additional patients, our development timelines may be delayed. We cannot be sure that submission of an IND or similar foreign application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval or positive ethics committee opinions at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA’s or any other regulatory authority’s good clinical practice (“GCP”) requirements or regulatory guidelines; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements, guidance or clinical trial plans that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to new or larger-scale facilities and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to us.
We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations would be adversely affected.
We may find it difficult to enroll participants in our clinical trials, particularly in later clinical trials in PAH given the relatively small patient population. If we encounter difficulties enrolling participants in our planned Phase 1 clinical trial of VLR199 or patients in our future clinical trials of VLR199 or our other programs, our clinical development activities could be delayed or otherwise adversely affected.
We may experience difficulties in patient enrollment in our current or future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until our conclusion.
We plan to conduct our Phase 1 clinical trial of VLR199 in healthy postmenopausal women. We may experience difficulties enrolling a sufficient number of eligible participants in a timely manner, including as a result of the eligibility criteria for the trial, competition from other clinical trials for the same population and the availability of qualified clinical trial sites. Our later clinical trials in patients with PAH or other cardiopulmonary diseases will present additional enrollment challenges, including those described below.
Currently, patients with PAH are generally treated with vasodilator therapies directed to the endothelin, nitric oxide and prostacyclin pathways, commonly in combinations of two or three chronic therapies, and, more recently, the activin signaling inhibitor Winrevair. Patients may decide, or physicians may recommend, to use such treatments instead of enrolling in clinical trials.
The enrollment of patients in future trials for any of our product candidates will depend on many factors, including:
•size and nature of the patient population;
•severity of the disease under investigation;
•availability and efficacy of approved drugs for the disease under investigation;
•patient eligibility and exclusion criteria for the trial in question;
•patients’ and clinicians’ perceived risks and benefits of the product candidate under study;
•if patients choose to enroll in clinical trials, rather than using approved products, or if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients instead enroll in such clinical trials;
•efforts to facilitate timely enrollment in clinical trials;
•patient referral practices of physicians;
•the ability to monitor patients adequately during and after treatment;
•proximity and availability of clinical trial sites for prospective patients; and
•continued enrollment of prospective patients by clinical trial sites.
Additionally, the number of patients required for clinical trials of our product candidates may be larger than we anticipate. Even if we are able to enroll a sufficient number of patients for our future clinical trials, we may have difficulty maintaining patients in our clinical trials. Our inability to enroll or maintain a sufficient number of patients would result in significant delays in completing clinical trials or receipt of regulatory approvals and increased development costs or may require us to abandon one or more clinical trials altogether, which could cause our value to decline, limit our ability to obtain additional financing and otherwise harm our prospects.
Preliminary, “topline” or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures.
From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.
Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes
may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments. Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and of us as a company. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. As a result, you or others may have reached different conclusions based on such extensive information in comparison to our publicly disclosed conclusion regarding a particular preclinical study or clinical trial. If the preliminary, topline or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.
Our future clinical trials or those of our current or future collaborators may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of our product candidates.
Results of our clinical trials could reveal a high or unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to such trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. For example, other therapies, including Winrevair, dalantercept (an ALK1-Fc ligand trap) and ACE-031 (an ActRIIB-Fc ligand trap), have been associated with treatment-emergent adverse events (“TEAEs”) such as epistaxis, telangiectasia, bleeding events (including gingival and gastrointestinal bleeding) and elevated hemoglobin in clinical trials. In the Phase 3 STELLAR trial of Winrevair, 22% of patients experienced epistaxis, 17% experienced telangiectasia and 53% had an increase in hemoglobin above normal levels. In September 2026, the U.S. prescribing information for Winrevair was revised to highlight the increased risk of bleeding and to add post-marketing reports of gastrointestinal bleeding associated with angiodysplasias. Because VLR199 will have a similar mechanism of action, it is possible that patients in our future clinical trials could exhibit similar TEAEs as well. We, the FDA or other applicable regulatory authorities, or an IRB or ethics committee, may suspend any clinical trials of any product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to our tolerability versus other therapies. In addition, the extended half-life we are engineering into VLR247, VLR258 and VLR360 could prolong the duration of undesirable side effects, which could also inhibit market acceptance. TEAEs could also affect patient recruitment or the ability of enrolled subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly.
In addition, the anticipated clinical trials of our product candidates may include patients with advanced PAH or other cardiopulmonary diseases whose health is deteriorating. The inclusion of such patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients’ illnesses.
In addition, even if we successfully advance our product candidates or any future product candidate through clinical trials, such trials will only include a limited number of patients and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using our product candidates over a multi-year period.
If any of the foregoing events occur or if one or more of our product candidates prove to be unsafe, our entire pipeline could be affected, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects.
We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example, we are focused primarily on VLR199. As a result, we may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on
viable commercial products or profitable market opportunities. Our spending on current and future research and development of product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we select product candidates amongst a variety of potential product candidates from Paragon, and the product candidates we select may fail to be viable commercial products or the product candidates we do not select may have a greater likelihood of success.
Any approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products.
Even if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, we may not gain market acceptance among physicians, healthcare professionals, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. Market acceptance will depend on many factors, including factors that are not within our control. There are numerous approved products and additional product candidates in clinical development for the treatment of PAH, including Winrevair, HS235, REGN13335, ralinepag, seralutinib and the other agents described under “Business—Competition”. However, VLR199 is designed to replicate the clinically validated pharmacology of Winrevair while improving upon its dosing strategy and presentation, including through an auto-injector and potentially less frequent dosing. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt VLR199 for our targeted indication, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. Market acceptance of our product candidates may be negatively impacted by potential poor performance of our competitors, including the occurrence of serious adverse events in such competitors’ clinical trials or failure by such competitors to obtain and maintain regulatory approval for their product candidates. Additionally, although we believe that the improved dosing, convenience and, for VLR247 and VLR258, safety profile we expect our product candidates to provide will improve market acceptance of such product candidates and that our candidates will have a competitive efficacy profile, our predictions may not be accurate and other competitive products may instead gain and hold the applicable market. Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians’ organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any current or future product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.
Our strategy to differentiate VLR199, VLR247 and VLR258 depends in part on developing an auto-injector presentation. If we are unable to successfully develop, obtain regulatory approval for and manufacture an auto-injector, or if it does not perform as intended or is not valued by patients, physicians and payors, the commercial potential of these product candidates could be reduced.
A key element of our strategy for VLR199, VLR247 and VLR258 is to offer an auto-injector presentation in place of the vial and syringe presentation currently used for Winrevair, which requires users to be trained to reconstitute, prepare, measure and inject the drug and which we believe creates several steps where errors in dosing can occur. We have not yet developed an auto-injector for any of our product candidates. Developing an auto-injector is a complex, expensive and time-consuming process that could take longer or cost more than we expect.
An auto-injector combined with a drug is regulated as a combination product. In the United States, the FDA will determine which of its centers has primary jurisdiction, and we will be required to satisfy applicable requirements for both the drug and the device constituent parts, including design controls, human factors and other usability data, and quality system requirements. Comparable foreign regulatory authorities impose their own requirements for drug-device combination products, which differ from those in the United States and may be more burdensome. If our auto-injector fails to meet these requirements, or if regulators require changes to its design after our clinical trials, the approval of the associated product candidate could be delayed or denied, or we may need to commercialize it with a vial and syringe presentation, which would eliminate a planned point of differentiation.
We expect to rely on third parties to design, develop and manufacture the auto-injector and its components and to assemble and fill the combined product. We will have limited control over these third parties, and the supply of auto-injectors and their components may be limited to one or a small number of suppliers. Disruptions in their operations, quality issues, failure to comply with applicable regulations, or an inability to scale manufacturing to commercial volumes could delay development or approval or interrupt supply. Auto-injectors may also malfunction, fail to deliver the full dose or be misused, which could cause patient injury, lead to product complaints, recalls or regulatory action and expose us to product liability claims. The cost of an auto-injector will also increase our cost of goods.
Even if we successfully develop and obtain approval for an auto-injector, we cannot be certain that patients, physicians or payors will perceive it as a meaningful advantage. They may prefer the presentation of Winrevair or other products, or may be unwilling to pay more for an auto-injector. Merck or other competitors may also develop or introduce improved presentations of their products, including prefilled syringes or auto-injectors, which would reduce or eliminate the differentiation we expect. In addition, third parties hold patents covering auto-injector designs and components, and we could be subject to claims that our auto-injector infringes their intellectual property or be required to obtain licenses on unfavorable terms. Any of these events could reduce the commercial potential of our product candidates, if approved, and harm our business.
Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue.
We are developing VLR199 for the treatment of PAH and intend to develop our other product candidates for PAH, secondary pulmonary hypertension and other cardiopulmonary diseases, and we may in the future develop programs for additional cardiopulmonary indications. However, developing multiple product candidates for related indications may negatively impact our business if the product candidates compete with each other. For example, if multiple product candidates are conducting clinical trials at the same time, they could compete for the enrollment of patients. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit our future revenue.
We plan to conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.
We are planning to conduct our Phase 1 clinical trial of VLR199 in several geographies, including potentially the United States and Australia, and we may choose to conduct one or more of our future clinical trials outside the United States in whole or in part. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on our determination that the trials also complied with all applicable U.S. laws and regulations. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the relevant jurisdiction, as applicable. If the FDA or any comparable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates or delay or prevent regulatory approval for commercialization in the applicable jurisdiction. Even if the FDA or any comparable foreign regulatory authority accepted such data, it could require us to modify our planned clinical trials to receive clearance to initiate such trials in the United States or the relevant jurisdiction, as applicable, or to continue such trials once initiated.
Further, conducting international clinical trials presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.
Risks Related to Our Reliance on Third Parties
We rely on collaborations and licensing arrangements with third parties, including Paragon. If we are unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, our business could be negatively impacted.
We rely on our collaboration with a third party, Paragon, for a substantial portion of our discovery capabilities and for the option to acquire the rights necessary to develop and commercialize our product candidates. In the future, we could also rely on additional licensing arrangements with third parties. For example, we have assumed the Paragon Option Agreement and the Paragon Letter Agreement pursuant to the Asset Acquisition. Under the Paragon Option Agreement and the Paragon Letter Agreement, we hold options to acquire exclusive, worldwide intellectual property license rights with respect to VLR199, VLR247, VLR258 and VLR360, none of which we have exercised. However, Paragon could terminate these agreement under certain circumstances, including our failure to make any payments owed to Paragon under the agreement or any uncured material breach of the agreement by us, in which event we may lose
our option to acquire intellectual property rights and may not be able to develop or commercialize the product candidates covered by that agreement, including VLR199 and our other research programs.
Collaborations or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of our collaborators or licensors experiences delays in performance of, or fails to perform, its obligations under its agreement with us, disagrees with our interpretation of the terms of such agreement or terminates their agreement with us, our pipeline and product candidates and development timeline could be adversely affected. If we fail to comply with any of the obligations under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with them, leading to the potential invalidation of our intellectual property, or they may even infringe upon our intellectual property rights, any of which could subject us to litigation or arbitration, which would be time-consuming and expensive and could harm our ability to commercialize our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.
As part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or add development or commercialization capabilities. We may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.
We may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies may be unwilling to assign or license rights to us, whether they perceive us to be a competitor or for other reasons. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market.
Risks associated with the in-licensing or acquisition of product candidates could cause substantial delays in the preclinical and clinical development of our product candidates.
We have relied and continue to rely on Paragon, and expect to rely on our future licensing partners, to (i) conduct research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, (ii) accurately report the results of all preclinical trials conducted prior to our licensing or acquisition of the relevant product candidates and (iii) correctly collect and interpret the data from these trials. If the research and development processes or the results of the research programs prior to our licensing or acquisition of our product candidates prove to be unreliable, this could result in increased costs and delays in the development of our product candidates, which could adversely affect any future revenue from such product candidates, if approved.
We may also acquire or in-license additional product candidates for preclinical or clinical development in the future as we continue to build our pipeline. The risks associated with acquiring or in-licensing product candidates could result in delays in the commencement or completion of our preclinical studies and clinical trials, if they are ever commenced or completed, and our ability to generate revenues from our product candidates may be delayed. Please see the section titled “Risk Factors—Risks Related to Our Intellectual Property—If we are unable to obtain or maintain necessary rights to our programs through acquisitions and in-licenses, our business may be materially harmed” below for additional information regarding such risks.
We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we
control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP. In addition, our clinical trials must be conducted with products manufactured in accordance with cGMPs. Our failure to comply with these requirements may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws, and foreign equivalents.
Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may encounter challenges hiring and retaining sufficient qualified personnel or they may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our current or future product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates.
In addition, we plan to rely on foreign CROs and CMOs,including WuXi Biologics (Hong Kong) Limited (“WuXi Biologics (Hong Kong)”), for formulation and manufacturing of our Phase 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. WuXi Biologics (Hong Kong) is a subsidiary or affiliate of WuXi Biologics, which was named as a biotechnology “company of concern” in earlier versions of the BIOSECURE Act. In December 2025, a revised version of the BIOSECURE Act was enacted as Section 851 of the National Defense Authorization Act for Fiscal Year 2026. The law prohibits U.S. executive agencies from (i) procuring biotechnology equipment or services provided by a biotechnology company of concern, (ii) entering into, extending or renewing contracts with entities that use such equipment or services in performing a federal contract, and (iii) using loan or grant funds to obtain such equipment or services. The enacted law does not name specific companies. It treats companies on the U.S. Department of Defense’s Section 1260H list as biotechnology companies of concern and requires the Office of Management and Budget to publish a list of additional designated companies by December 2026. The law provides a five-year safe harbor, which begins when implementing regulations are issued, for existing contracts with companies that are later designated, but not for companies that were already on the Section 1260H list when the law was enacted. Depending on which companies are designated, how the BIOSECURE Act is implemented by U.S. federal agencies and how it is interpreted, we could be potentially restricted from pursuing U.S. federal government business or grants in the future if we continue to use WuXi Biologics (Hong Kong) and if WuXi Biologics (Hong Kong) or other parties we contract with are designated as “biotechnology companies of concern” beyond any applicable safe harbor period. Foreign CMOs may be the target of U.S. legislation, including the implementation of the BIOSECURE Act and further legislation, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material, restrict or even prohibit our ability to work with such CMOs, or have an adverse effect on our ability to secure significant commitments from governments to purchase potential therapies.
The biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. In addition, the United States government has imposed significant tariffs on imports from China and other countries and may impose more restrictions on goods, including biologically derived substances, manufactured in or imported from China or other countries or impose other restrictions on companies’ ability to work with Chinese or other foreign counterparties. Evolving changes in China’s public health, economic, political, and social conditions and the uncertainty around China’s relationship with other governments, such as the United States and the United Kingdom (“UK”), could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical research programs. Furthermore, if one or more of our collaborators or vendors in China, including WuXi Biologics (Hong Kong), is designated a biotechnology company of concern under the BIOSECURE Act, our operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while we have established relationships with CROs and CMOs outside of China,
moving to those suppliers in the event of a geopolitical instability affecting our collaborators in China could introduce delays into the research program.
We rely on the use of third-party CMOs to manufacture our product candidates, and we expect to continue to rely on third-party CMOs to produce our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.
We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must rely on CMOs to manufacture our product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved. If there should be any disruption in our supply arrangements, including any adverse events affecting any of our CMOs, or if we experience delays or difficulties in transferring, or are unable to successfully transfer, our manufacturing processes, it could have a negative effect on the clinical development of our product candidates and other operations while we work to identify and qualify an alternate supply source. We have limited control over the manufacturing process of, and may be dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or another applicable regulatory authority does not approve these facilities for the manufacture of our product candidates or withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and delays and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. We, or our future contract manufacturers, any current or future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of member states of the European Union (“EU Member States”) or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMPs. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or products, if approved, and harm our business and results of operations.
Moreover, our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, intellectual property disputes or as a result of labor disputes or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a commercially reasonable cost, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are responsible for transporting temperature-controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our product candidates by the FDA or comparable foreign regulatory authorities, result in higher costs or adversely impact commercialization of our product candidates.
Risks Related to Our Business and Operations
In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.
We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations and regulatory affairs. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our managerial, scientific and medical personnel. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain “key person” insurance for any of our executives or other employees. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key personnel may be difficult and may take an extended period of time. If we do not succeed in attracting and retaining qualified personnel, it could materially adversely affect our business, financial condition and results of operations. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention efforts.
Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
Our future growth may depend, in part, on our ability to develop and commercialize our product candidates, if approved, in foreign markets for which we may rely on collaboration with third parties. Recent and ongoing changes in the United States trade policy with foreign countries, including the continued uncertainty surrounding U.S. tariffs and potential retaliatory measures by foreign governments, may disrupt the global supply chain for biopharmaceutical products. For example, in April 2026, the U.S. government issued a proclamation under Section 232 of the Trade Expansion Act of 1962 imposing tariffs of up to 100% on imports of patented pharmaceutical products and their active pharmaceutical ingredients, which took effect on July 31, 2026 for certain large manufacturers and on September 29, 2026 for all other importers, subject to lower rates for imports from certain countries, reduced rates for companies with approved U.S. onshoring plans and exemptions for certain categories of products. It is not yet clear how these tariffs apply to materials, including active pharmaceutical ingredients and bulk drug products, that are intended for use in clinical trials and not for commercial sale, which could increase the costs of materials for our clinical trials. Any direct tariffs, if imposed on pharmaceutical products, may result in increased costs for raw materials and contract manufacturing services, reduced ability to source critical CMOs, and a delay in our development timelines.
We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable foreign regulatory authority, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, if approved, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable regulatory approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected.
Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.
Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.
Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.
Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.
Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.
Our internal information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants, third party service providers, or existing or future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
In the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, “Process”) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, “Sensitive Information”).
Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs, other contractors (including sites performing our clinical trials), third party service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data.
Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.
To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored.
Our remote workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and technologies.
While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.
We rely on third-party service providers and technologies to operate critical business systems to Process Sensitive Information in a variety of contexts. Our ability to monitor these third parties’ information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised.
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on Processing Sensitive Information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform, deter new customers from products, and negatively impact our ability to grow and operate our business.
Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.
We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect our operating results and business.
We, and third parties we work with, are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. In addition, we are and may become subject to the terms of contractual obligations related to privacy, data protection, and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.
The rules governing U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service (“IRS”) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our stockholders or us. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted.
For example, the United States enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside the United States. On July 4, 2025, the
U.S. Congress enacted the One Big Beautiful Bill Act, which includes a provision restoring the immediate deductibility of domestic research and development expenditures. The impact of this newly enacted law on our tax position will depend on how the provision is implemented and interpreted by the IRS and other regulatory authorities. In addition, we have no assurance as to whether, when and how this provision may be subject to further amendment or repeal. Such changes, among others, may adversely affect our effective tax rate, results of operation and financial condition.
We may acquire businesses, product candidates or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.
We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects.
We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.
Our cash held in non-interest-bearing and interest-bearing accounts exceeds the FDIC insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank in March 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders’ access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business.
Risks Related to Our Intellectual Property
Our intellectual property portfolio is at an early stage. Therefore, our ability to obtain and protect our patent rights, and protect other proprietary rights, is uncertain, exposing us to the possible loss of competitive advantage.
We will rely upon a combination of patents, trademarks, trade secret protection, copyrights and confidentiality agreements, licenses and the Paragon Option Agreement to protect the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with us. Our success depends in large part on our ability to obtain and maintain patent protection for our product candidates and their uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. We do not currently own or license any patents with respect to VLR199 or our other research programs. Paragon has filed patent applications directed to variant ActRIIA-Fc fusion proteins, including applications covering composition of matter, pharmaceutical formulations, and methods of using such fusion proteins, including VLR199, which we have the option to license pursuant to the Paragon Option Agreement In addition, we own 6 patent families relating to our legacy programs, including ALN1003. In the future, we expect to prosecute underlying intellectual property for VLR199 and some or all of the in-licensed or owned product candidates that we develop.
We may not be able to obtain or protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of at least certain patents, trade secrets or other intellectual property. Filing, prosecuting, maintaining and defending patents on product candidates and other related inventions worldwide would be expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, we may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we or our licensor files patent applications to obtain such rights. Our competitors may operate in countries where we do not have patent protection and may be able to freely use our technologies and discoveries in such countries, at least to the extent not forbidden by law.
Our intellectual property portfolio is at an early stage. Except as described above, we do not currently own or license any issued patents or pending patent applications. Our future optioned, in-licensed or owned patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, or invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO. If
we do not obtain patent coverage for the work we are conducting, or if we obtain such rights but they are invalidated or rendered unenforceable, we may be unable to exclude competitors from pursuing and marketing the same or similar product candidates. Other risks we face if we are not able to obtain and maintain patent coverage for our product candidates are the reduction in valuation of our product candidates, and ultimately of us as a company, by potential investors, and our inability to assert claims for infringement against third parties or counterclaim against such third parties or negotiate more advantageous settlement parameters. Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we may own or license may not afford us any meaningful exclusivity period or competitive advantage.
In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while we undertake reasonable efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
If we are unable to obtain or maintain necessary rights to our programs through acquisitions and in-licenses, our business may be materially harmed.
Because our research programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain intellectual property rights we obtain in the future, we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
While we expect to have the right to control prosecution, defense, maintenance and enforcement of patents licensed to us under any license agreements we enter into with Paragon once the trigger for transfer of prosecution control is met, there may be times when rights for patents and patent applications relating to our product candidates are controlled by our future licensors or collaboration partners. For example, Paragon currently has the right to file patent applications and control prosecution with respect to any other inventions that may fall within the Paragon Option Agreement, including those that may apply to VLR199 and our other research programs. If we, Paragon or any of our future licensors or collaboration partners fail to prosecute, defend, maintain and enforce such patents and patent applications in a manner consistent with our best interests, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even if we have the right to control prosecution of patents and patent applications we have licensed to and from third parties, including under future license agreements with Paragon following the point at which such control is assumed, we may still be adversely affected or prejudiced by actions or inactions of Paragon, additional licensees, or licensors and their counsel prior to the date upon which we assume control over patent prosecution. For example, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to VLR199 and our other research programs. Subsequent to entering into such
license agreements, we expect to control patent prosecution over VLR199 and our other research programs following the trigger for transfer of prosecution control for the applicable program to us.
Our future licensors may not be the sole and exclusive owners of all rights in the patents we may in-license. If other third parties have rights to our future in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.
It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates, manufacturing methods or future products or methods resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.
Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including (but not limited to): the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and the priority of invention of patented technology. If we or our future licensors breach the terms of our license agreements, such breach may have a material adverse effect on our business and the commercialization efforts for our programs.
We may be subject to intellectual property lawsuits or may need to file lawsuits to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products.
Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third party rights. If certain of our product candidates are ultimately granted regulatory approval, patent rights held by third parties could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us, and our rights are not held invalid or unenforceable, we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret misappropriation) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that future patents, if filed and issued, owned or licensed by us will not be challenged by others, whether in the course of litigation or in agencies like the USPTO. Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds.
Competitors may infringe or otherwise violate our future patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable.
Further, we may be required to protect our future patents, if filed and issued, through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.
In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees or customers and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees or other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.
Our success will depend in part on our and our current and future licensors’ ability to obtain, maintain and enforce patent protection for our licensed intellectual property.
Our success will depend in part on our and our current and future licensors’ (including Paragon’s) ability to obtain, maintain and enforce patent protection for our licensed intellectual property. Currently, Paragon controls the prosecution, maintenance, enforcement and defense of patents relating to VLR199 and our other research programs. After entry into license agreements with Paragon for VLR199 and our other research programs, and once the trigger for transfer of prosecution control is met, we expect to hold such rights. We, Paragon and our future licensors may not successfully prosecute the patent applications that cover our product candidates. Even if patents are issued in respect of these patent applications, we and our future licensors (including Paragon) may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for any in-licensed intellectual property, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.
We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
As is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.
While we may litigate to defend against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management and other employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.
Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the “Leahy-Smith Act”) could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file
system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation increased the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology.
In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in Amgen, Inc. v. Sanofi (“Amgen”) recently held that Amgen’s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided 26 exemplary antibodies, but the claimed class of antibodies covered a “vast number” of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that we will be granted U.S. patents with composition of matter claims as broad as Amgen’s directed to antibodies functionally defined by their ability to bind a particular antigen. Because Amgen concerned claims to a genus defined by function, its reasoning may similarly limit the breadth of claims we can obtain directed to other protein therapeutics, including ActRII-Fc ligand traps and other Fc fusion proteins, that are defined by their binding or other functional properties. Even if we are granted claims directed to functionally defined antibodies or other protein therapeutics, it is possible that a third party may challenge our patents, when issued, relying on the reasoning in Amgen or other precedential court decisions. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.
In addition, the U.S. Supreme Court’s July 2024 decision to overturn established case law giving deference to regulatory agencies’ interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA’s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. Geopolitical instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. In addition, the Unified Patent Court (“UPC”) entered into force on June 1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated.
Although we do not currently own any European patents or applications, if we obtain or license such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC.
Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain any future patents and patent applications, if filed and issued, covering our product candidates, our competitive position would be adversely affected.
We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent, the patent’s prosecution history and in some cases certain extrinsic evidence of the meaning of terms in a claim. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.
In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our future issued patents or our pending applications, if filed, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our future patent applications or patents, if filed and issued, which could require us to obtain rights to issued patents covering such technologies.
We may become subject to claims challenging the inventorship or ownership of our patents, if issued, and other intellectual property.
We may be subject to claims that former employees, collaborators or other third parties have an interest in our future patents, if filed and issued, or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being invalid or unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.
Patent terms may be inadequate to protect our competitive position of our product candidates for an adequate amount of time.
Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from our earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
Our technology licensed from various third parties may be subject to retained rights.
Our future licensors may retain certain rights under the relevant agreements with us, including the right to use or license the licensed technology outside of the scope of our license, use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and
we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. In addition, while there are certain restrictions on Paragon’s ability to develop products that could be competitive with ours, these restrictions may not prevent the possible future license or development by Paragon of certain technology that could lead to product candidates competitive with ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.
Our rights to VLR199 and our other programs depend on option and license arrangements with Paragon, which may terminate the license if we do not satisfy a $200 million stockholders’ equity condition.
We do not own our product candidates, other than ALN1003. We hold options to obtain exclusive licenses from Paragon under a Fusion Protein Discovery and Option Agreement (and, for antibody programs, under a research letter agreement). Each license under the Fusion Protein Discovery and Option Agreement will permit Paragon, in its sole discretion, to terminate the license, with the licensed rights reverting to Paragon, if our stockholders’ equity, as determined under Nasdaq listing rules, does not exceed $200 million as of the end of the second full fiscal quarter following the closing of the Asset Acquisition (or we fail to timely file the periodic report that includes that balance sheet), or if we fail to deliver freely tradeable shares within 120 days after an exercise of the warrants that we will grant Paragon.
Risks Related to Government Regulation
The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.
The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including VLR199, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective, may prove to have undesirable or unintended side effects, toxicities or other characteristics, or may fail to improve on the applicable standard of care, any of which may preclude our obtaining regulatory approval. The FDA and comparable foreign regulatory authorities have discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for our proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh our safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.
Of the large number of drugs in development, only a small percentage successfully complete the FDA or applicable foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.
If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling
claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, this could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. In addition, the FDA and foreign regulatory authorities may undergo leadership changes, change their policies, issue additional regulations or revise existing regulations, or take other actions, such as those implemented by the recently established Department of Government Efficiency, which may impact our clinical development plans or prevent or delay approval of our product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals and increase the costs of compliance. Since the start of President Trump’s administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. It is difficult to predict how executive actions that may be taken under the current administration may affect the FDA’s ability to exercise its regulatory authority. If any actions impose constraints on the FDA’s ability to engage in routine oversight and product review activities in the normal course, our business may be negatively impacted. Additionally, federal government could adopt legislation, regulations or policies that adversely affect our business or create a more challenging and costly environment to pursue the development, approval and commercialization of our product candidates.
We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates.
In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our contract manufacturing partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved.
Our product candidates for which we intend to seek approval as biologics may face competition from biosimilars sooner than anticipated.
The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or “biosimilar” product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.
We believe that any of our product candidates approved as biologics under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.
Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may impose similar requirements. In addition, if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies
in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. If we or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, delays or restrictions on our ability to conduct clinical trials or delays or refusal to grant a marketing authorization, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, suspension, withdrawal or variation of any marketing authorization that has been granted, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. Similar penalties may apply in case of failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors, to comply with FDA and EU laws and the related national laws of individual EU Member States and other applicable regulatory authorities governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of a marketing authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements, including administrative, civil or criminal penalties. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.
Disruptions at the FDA, the SEC and other government agencies and regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
The ability of the FDA to review regulatory filings and our ability to commence human clinical trials can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies or comparable foreign regulatory authorities may also slow the time necessary for the review and approval of applications for clinical trial or marketing authorization, which would adversely affect our business. For example, in recent years, including in 2018, 2019 and 2025, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Additionally, action by the Trump administration to limit federal agency budgets or personnel may result in reductions to the FDA’s budget, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.
If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
We may face difficulties from healthcare and regulatory legislative reform measures.
Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, the Trump administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription drugs. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained and we may not achieve or sustain profitability.
Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved.
Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.
Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business.
We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor’s product, including a branded or generic/biosimilar product, over our products in an attempt to reduce their costs, which may reduce our commercial opportunity.
We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.
We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Governmental regulation of the import or export of our drug candidates, or our failure to obtain any required import or export authorization for our candidates, when applicable, could harm international operations. Furthermore, export control laws and economic sanctions prohibit the provision of certain items, technology, and services to countries, governments, and persons targeted by sanctions programs. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.
In some countries, particularly EU Member States, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as
part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected.
If we seek and are unable to obtain accelerated approval, the amount, size and duration of our clinical trials could be greater than planned, which could increase the expense, reduce the likelihood, and/or delay the timing of obtaining necessary regulatory approvals. Even if we receive accelerated approval, if confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-approval requirements, such authorities may withdraw accelerated approval.
We may seek accelerated approval, or other expedited development, review or approval status, for our product candidates. Even if granted, there is no guarantee that receiving an expedited development, review or approval status from the FDA will lead to a faster development or regulatory review or approval process, and such status does not increase the likelihood that our product candidates will ultimately receive marketing approval. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. If we choose to pursue accelerated approval, there can be no assurance that the FDA will agree that our proposed primary endpoint is an appropriate surrogate endpoint. Similarly, there can be no assurance that after subsequent FDA feedback that we will continue to pursue accelerated approval or any other form of expedited development, review, or approval, even if we initially decide to do so. Furthermore, if we submit an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting approval of any type. We might not be able to fulfill the FDA’s requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA. Accelerated approval may be contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s predicted effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA may require that any such confirmatory study be initiated or substantially underway prior to the submission of an application for accelerated approval. Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-approval requirements, including submission to the FDA of all promotional materials prior to their dissemination. The FDA could withdraw accelerated approval for multiple reasons, including our failure to conduct any required post-approval study with due diligence, or the inability of such study to confirm the drug’s predicted clinical benefit relative to its risks. A failure to obtain accelerated approval or any other form of expedited review or approval for a product candidate could result in a longer time period prior to commercializing such product candidate, increase the cost of development of such product candidate, and harm our competitive position in the marketplace. Comparable considerations apply outside of the United States.
General Risk Factors
We may become exposed to costly and damaging liability claims, when testing a product candidate in the clinical stage or at the commercial stage, and our product liability insurance may not cover all damages from such claims.
We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims may be made by patients that use the product or product candidate, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for our products or any prospects for commercialization of our products. Although we intend to obtain product liability insurance for our future clinical trials, it is possible that our liabilities could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.
Litigation costs and the outcome of litigation could have a material adverse effect on our business.
From time to time, we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal information, contractual relations with collaborators and licensors and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights that we may have against third parties, could result in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows.
Our business could be adversely affected by economic downturns, inflation, fluctuating interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.
The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, fluctuating interest rates, and uncertainty about economic stability. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs imposed by the U.S. government and potential retaliatory measures by foreign governments and other barriers to trade, especially in light of recent comments and executive orders made by the Trump administration, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), government shutdowns, tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. In addition, the U.S. has imposed and taken action to pause, resume or adjust tariffs on imports from a number of countries. Since February 2025, the United States government has imposed, modified and suspended various tariffs on imports from many countries, including tariffs on imports from China and South Korea. In February 2026, the U.S. Supreme Court invalidated certain of these tariffs, although tariffs imposed under other authorities, including Section 232, remain in effect. In April 2026, the U.S. government issued a proclamation under Section 232 of the Trade Expansion Act of 1962 imposing tariffs of up to 100% on imports of patented pharmaceutical products and their active pharmaceutical ingredients, which took effect on July 31, 2026 for certain large manufacturers and on September 29, 2026 for all other importers, subject to lower rates for imports from certain countries, reduced rates for companies with approved U.S. onshoring plans and exemptions for certain categories of products. It is not yet clear how these tariffs apply to materials, including active pharmaceutical ingredients and bulk drug products, that are intended for use in clinical trials and not for commercial sale, which could increase the costs of materials for our clinical trials. There still remains substantial uncertainty about the duration of existing tariffs and whether additional tariffs may be imposed, modified or suspended. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Uncertainty and political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. After lowering interest rates in late 2025, the Federal Reserve raised its benchmark interest rate in September 2026 in response to persistent inflation, and it may raise interest rates again. High interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.
We may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.
Risks Related to the Ownership of Our Common Stock
If our stockholders do not approve the conversion of the Series B Preferred Stock and Series C Preferred Stock, holders may require us to settle conversions in cash, and, if the conversion is approved, our existing stockholders will be substantially diluted and designees of the lead investor in our financing will constitute a majority of our Board.
In connection with the Asset Acquisition and PIPE, we issued shares of Series B Preferred Stock and Series C Preferred Stock that is convertible into approximately 381.4 million shares of common stock, subject to stockholder approval, an increase in our authorized shares and beneficial ownership limitations. If our stockholders do not approve the conversion, then beginning six months after issuance a holder may require us to settle a conversion in cash at the fair value of the common stock otherwise issuable; only 6,268 shares of Series C Preferred Stock are covered by a limited waiver of that right, and the waiver terminates on the later of that approval and the
effectiveness of the authorized share increase. A cash settlement could materially exceed our available cash resources. If the conversion is approved, our existing stockholders’ ownership will be substantially diluted, three of our directors will resign and designees of the lead investor, Fairmount, together with Mr. Harwin will constitute four of our five directors. Until stockholders approve the conversion, the Series B and Series C Preferred Stock are expected to be classified outside permanent stockholders’ equity, which could affect our ability to satisfy Nasdaq’s stockholders’ equity requirement.
The market price of our Common Stock has been and is expected to continue to be volatile.
The market price of our Common Stock has been and is expected to continue to be subject to significant fluctuations. Some of the factors that may cause the market price of our Common Stock to fluctuate include:
•results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future collaborators;
•failure to meet or exceed financial and development projections we may provide to the public;
•failure to meet or exceed the financial and development projections of the investment community;
•if we do not achieve the perceived benefits of the Asset Acquisition as rapidly or to the extent anticipated by financial or industry analysts;
•announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;
•actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms;
•disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;
•additions or departures of key personnel;
•significant lawsuits, including patent or stockholder litigation;
•if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;
•changes in the market valuations of similar companies;
•general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;
•sales of securities by us or our securityholders in the future;
•if we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates;
•trading volume of our Common Stock;
•announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;
•adverse publicity relating to ActRII-Fc ligand traps and other PAH product candidates, including with respect to other products in such markets;
•the introduction of technological innovations or new therapies that compete with our products and services; and
•period-to-period fluctuations in our financial results.
Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our Common Stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our Common Stock. In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results, financial condition and cash flows.
We are governed by Delaware law and our Certificate of Incorporation and Bylaws, provisions of which have anti-takeover implications.
Provisions that are included in our Certificate of Incorporation and Bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the Company that our stockholders may consider favorable, including transactions in which holders of Common Stock might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock, thereby depressing the market price of our Common Stock. In addition, because the Board of Directors is responsible for appointing our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for our stockholders to replace members of the Board of Directors. Among other things, these provisions:
•provide that the number of directors is fixed from time to time by resolution of the Board of Directors;
•permit newly created directorships and vacancies on the Board of Directors to be filled by a majority of the directors then in office;
•provide for advance notice requirements for nominations for election to the Board of Directors or for proposing matters that can be acted on at stockholder meetings;
•provide that special meetings of stockholders may be called only by the Board of Directors and that business transacted at a special meeting is limited to the purposes stated in the notice;
•authorize the Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Board of Directors; and
•permit the Board of Directors to adopt, amend or repeal the Bylaws without stockholder approval.
Moreover, we and our organizational documents are governed by Delaware law. Section 203 of the Delaware General Corporation Law (“DGCL”) contains provisions that may enable our Board of Directors to discourage, delay or prevent a change in our ownership or in our management. The business combinations with interested stockholders provisions of the DGCL, subject to certain exceptions, restrict our ability to engage in any business combination with an interested stockholder for a three year period following the time that this stockholder becomes an interested stockholder, unless (i) before the stockholder became an interested stockholder, our Board of Directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or (iii) at or after the time the stockholder became an interested stockholder, the business combination was approved by the Board of Directors and authorized
at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. For purposes of the foregoing provisions, “interested stockholder”, with certain exceptions is any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person at any time in the last three-year period.
Additionally, the Series B Certificate of Designation may delay or prevent a change in control of the Company. At any time while at least 30% of the originally issued Series B Preferred Stock remains issued and outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) consummate (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, (ii) increase or decrease the size of the Board of Directors, (iii) adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless such adoption, amendment or repeal has been approved by the unanimous vote of the Board of Directors, (iv) terminate or replace our registered independent public accounting firm, independent compensation consultant or corporate counsel.
Because our Bylaws limit the court in which you may bring an action against us, you may have difficulty obtaining a more favorable judicial forum or you may incur more expense enforcing any rights which you may claim as compared to another forum.
Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery lacks subject matter jurisdiction, another state court located within the State of Delaware or, if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for (i) any derivative claim or cause of action brought on our behalf; (ii) any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any claim or cause of action against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws; (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or Bylaws; (v) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery; and (vi) any claim or cause of action against us or any of our current or former directors, officers or other employees governed by the internal affairs doctrine. Our Bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These provisions do not apply to claims brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. These exclusive forum provisions may limit our stockholders’ ability to obtain what they believe to be a favorable judicial forum for disputes with us and our officers and directors.
Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.
We will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.
We will incur significant legal, accounting and other expenses as a public company, including costs associated with public company reporting obligations under the Exchange Act. Our executive officers and other personnel need to devote substantial time to comply with public company reporting requirements and additional applicable laws and obligations. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the Board of Directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors’ and officers’ insurance, on acceptable terms.
Once we are no longer a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows.
We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. However, as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Exchange Act, in at least the
near term, we may take advantage of exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. In addition, as a smaller reporting company with less than $100.0 million in annual revenue, we are not required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. Once we are no longer a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our Common Stock may be harmed. For example, if we or our independent auditor identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act.
We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.
If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our Common Stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.
We do not anticipate that we will pay any cash dividends in the foreseeable future.
The current expectation is that we will retain our future earnings, if any, to fund the growth of our business as opposed to paying dividends. As a result, capital appreciation, if any, of our Common Stock will be the sole source of gain, if any, for our stockholders for the foreseeable future.
Future sales of shares by existing stockholders could cause our stock price to decline.
If existing securityholders sell, or indicate an intention to sell, substantial amounts of our Common Stock in the public market after legal restrictions on resale in connection with the Asset Acquisition lapse, the trading price of our Common Stock could decline. In addition, shares of Common Stock that are subject to outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of our Common Stock could decline.
Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.
Our executive officers, directors and principal stockholders, in the aggregate, beneficially own a significant portion of our outstanding shares of common stock (on a fully-diluted basis), subject to beneficial ownership limitations. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire.
Conflicts of interest may arise between us and Paragon or us and Fairmount.
In connection with the Asset Acquisition, we assumed the rights and obligations of Velaris under the Paragon Option Agreement. See the section titled “Paragon Option Agreement” for more information on the Paragon Option Agreement. Paragon and Palaris each
received shares of Series C Preferred Stock in the Asset Acquisition, and neither is expected to beneficially own more than 5% of our Common Stock following the Conversion Approval. Fairmount beneficially owns more than 5% of Paragon, appointed Paragon’s board of directors, and has the contractual right to approve the appointment of any executive officers of Paragon. Palaris is an entity formed by Paragon as a vehicle to hold equity in Velaris (and, as a result of the Asset Acquisition, us). Fairmount beneficially owns approximately 16.3% of our outstanding Common Stock and would beneficially own 19.99% of our Common Stock assuming conversion of the Series B Preferred Stock and Series C Preferred Stock into Common Stock held by it (in each case, subject to beneficial ownership limitations and based on the number of shares of Common Stock outstanding as of November 12, 2026, and assuming no exercise of outstanding options). One of our directors, Peter Harwin, is affiliated with Fairmount and was appointed in accordance with the Acquisition Agreement. Upon approval of the Conversion Approval, three of our current directors, Robert W. Postma, Michael A. Jerman and Jaime W. Vieser, will resign from the Board of Directors and three directors designated by Fairmount will be appointed to the Board of Directors, such that Mr. Harwin and the Fairmount designees will constitute four of the five members of the Board of Directors. In addition, following approval of the Conversion Approval, the holders of the Series B Preferred Stock, all of which is held by Fairmount, will be entitled to elect two members of the Board of Directors.
Our relationship with Paragon, Palaris, Fairmount and our non-employee directors may create, or may create the appearance of, conflicts of interest when we are faced with decisions that could have different implications for Paragon or Palaris than the decisions have for us. For example, such conflicts may arise in connection with the selection of additional targets, the exercise of options under the Paragon Option Agreement, the negotiation of the terms of any future license agreements, the allocation of resources and expenses, the enforcement or defense of intellectual property rights, the pursuit of strategic partnerships or transactions, or the resolution of any disputes that may arise between us and Paragon or Palaris. We expect that the decision to amend the Paragon Option Agreement or enter into any similar agreements or license agreements with Paragon will be subject to the approval of the Board of Directors. All directors of the Board of Directors owe fiduciary duties pursuant to Delaware law, and directors of the Board of Directors are expected to comply with their respective fiduciary duties under Delaware law relevant to related party transactions. We have previously adopted a related party transaction approval policy and our audit committee will be responsible for the review, consideration and approval or ratification of related party transactions.
Furthermore, because Paragon and Fairmount have interests in other biotechnology companies that may compete with us or pursue similar or complementary product candidates or technologies, they may have an incentive to favor or support such other companies over us. These potential conflicts of interest may make it more difficult for us to favorably advance our business interests and may adversely affect our competitive position, business, financial condition, results of operations and prospects.
If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, then our stock price and trading volume could decline.
The trading market for our Common Stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our Common Stock, and such lack of research coverage may adversely affect the market price of our Common Stock. In addition, we do not have any control over the analysts or the content and opinions included in their reports. The price of our Common Stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts cease coverage of us or fail to publish reports on us regularly, demand for our Common Stock could decrease, which in turn could cause our stock price or trading volume to decline.
Our ability to use net operating loss (“NOL”) carryforwards and other tax attributes may be limited, including as a result of the Asset Acquisition.
We do not expect to become profitable in the near future and may never achieve profitability. As of December 31, 2025, we had federal and state NOL carryforwards and federal and state research and development credits that may be used to offset future taxable income. Under current law, our U.S. federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, U.S. federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An “ownership change” pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Asset Acquisition or other transactions. Similar rules may apply under state tax laws. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected.
The class structure of our capital stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.
The class structure of our capital stock may limit your ability to influence corporate matters. Holders of Common Stock are entitled to one vote per share, while holders of the Series B Preferred Stock and Series C Preferred Stock have no voting rights, except as required by the DGCL and with respect to the protective provisions and director election rights described below. Nonetheless, following 5:00 p.m. Eastern Time on the third business day after the Stockholder Approval, each share of Series B Preferred Stock may be converted at any time into 1,000 shares of Common Stock at the option of the holder by providing written notice to us, subject to the beneficial ownership limitation described below. Consequently, if holders of the Series B Preferred Stock exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of the Series B Preferred Stock and correspondingly decreasing the voting power of the holders of Common Stock, which may limit your ability to influence corporate matters. At the same time, each share of Series C Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to the beneficial ownership limitation, and any shares of Series C Preferred Stock that are not converted as a result of a holder’s beneficial ownership limitation will remain outstanding and convertible at the option of the holder.
Although Series B Preferred Stock does not have voting rights on proposals presented to our holders of common stock, at any time while at least 30% of the originally issued Series B Preferred Stock remains issued and outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) consummate (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, (ii) increase or decrease the size of the Board of Directors, (iii) adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless such adoption, amendment or repeal has been approved by the unanimous vote of the Board of Directors, (iv) terminate or replace our registered independent public accounting firm, independent compensation consultant or corporate counsel, or (v) use any portion of the proceeds of the PIPE to fund our legacy business in excess of the amounts contemplated by the Acquisition Agreement, to declare or pay any dividend or other distribution on, or to redeem or repurchase, any shares of our capital stock or to repay any indebtedness owed to any of our directors, officers or affiliates, or take any action that would constitute a material deviation from the operating plan contemplated by the Acquisition Agreement.
Additionally, stockholders who hold, in the aggregate, more than 10% of Common Stock, Series B Preferred Stock and Series C Preferred Stock, but 10% or less of Common Stock, and are not otherwise an insider, may not be required to report changes in their ownership due to transactions in the Series B Preferred Stock and Series C Preferred Stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.
A Nasdaq continued listing requirement mandating a minimum Market Value of Listed Securities of $5.0 million is currently stayed and subject to SEC review; if the requirement becomes operative and we fail to comply, trading in our common stock could be suspended and our common stock could be delisted without the customary opportunity to regain compliance.
On July 22, 2026, the Division of Trading and Markets of the Securities and Exchange Commission, acting pursuant to delegated authority, approved a Nasdaq rule change that would require companies listed on the Nasdaq Capital Market to maintain a Market Value of Listed Securities (“MVLS”) of at least $5.0 million. MVLS generally is determined by multiplying the consolidated closing bid price of a company’s listed securities by the number of securities being valued. The new requirement would be codified as Nasdaq Listing Rule 5550(a)(6) and would apply in addition to Nasdaq’s other continued listing requirements.
Under the rule as approved, if our MVLS were to remain below $5.0 million for 30 consecutive business days, Nasdaq Staff would issue a Staff Delisting Determination and our common stock would become immediately subject to suspension and delisting. Unlike many other Nasdaq continued listing deficiencies, we would not automatically receive a cure or compliance period before suspension. In addition, although we could request a hearing before a Nasdaq Hearings Panel, a timely hearing request would not stay the suspension of trading in our common stock. A Hearings Panel could reverse the Staff Delisting Determination if it determined that the determination was made in error or could, in limited circumstances, grant an exception of up to 180 days for us to demonstrate compliance with all applicable initial listing requirements, rather than merely the $5.0 million MVLS requirement. There can be no assurance that a Hearings Panel would grant any such exception or that we would be able to satisfy all applicable initial listing requirements within the period granted.
On July 29, 2026, following the SEC’s receipt of notices of intention to petition for review of the delegated action, the SEC notified Nasdaq that the July 22, 2026 approval order had been automatically stayed pursuant to Rule 431(e) of the SEC’s Rules of Practice and would remain stayed until the Commission orders otherwise. As of the date of this Quarterly Report, the stay remains in effect and the Nasdaq rulebook continues to identify the approval order as stayed. The stay is procedural and does not constitute a final determination regarding the validity or ultimate implementation of the rule. The Commission may affirm, reverse, modify, set aside or remand the
delegated action, in whole or in part, and may terminate or continue the stay. Accordingly, we cannot predict the duration of the stay, the timing or outcome of the Commission’s review, whether the rule ultimately will become operative in its approved or a modified form, or what implementation date, transition provisions or measurement procedures Nasdaq may apply if the stay is lifted. In particular, there is uncertainty regarding when Nasdaq would begin or resume measuring the 30-consecutive-business-day period following any termination of the stay.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Not applicable.
Item 3. Defaults upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Intellectual Property
Overview
We strive to protect the proprietary programs and technologies that we believe are important to our business, including seeking and maintaining patent protection intended to cover the composition of matter of our programs, our methods of use and manufacture, and other inventions.
With respect to VLR199, VLR258 and VLR247, Paragon has filed provisional patent applications directed to fusion proteins comprising variant ActRIIA or variant ActRIIB polypeptides, including applications covering composition of matter, pharmaceutical formulations, and methods of using such fusion proteins. With respect to VLR360, Paragon has filed provisional patent applications directed to anti-PDGF-B antibodies, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies. A provisional patent application is an application filed in the USPTO for the purpose of securing an early date of priority for the applicant’s invention. The provisional application must include a written description of what the inventor has discovered, along with a drawing of the invention, but need not include patent claims, statements concerning or disclosing the prior art, or certain other formalities. A provisional patent application allows for an effective filing date to be established with regard to an invention, but once a provisional patent application is filed, either a corresponding non-provisional patent application or a petition to convert the provisional patent application into a non-provisional patent application must be filed within 12 months or such effective filing date will be lost.
The maximum term of a U.S. patent, excluding extensions and adjustments, begins on the effective filing date of the first non-provisional application claiming the patented invention and ending 20 years from that date. In essence, a provisional patent application provides a patent applicant two principal advantages over filing a non-provisional application. First, it allows the applicant to secure an earlier priority date for its invention than that of an equivalent non-provisional application—up to one year earlier than the filing date of a related non-provisional application. Second, since the term of a patent runs from the effective filing date of the first non-provisional application but does not begin upon filing a provisional application, filing a provisional application provides the applicant an additional year’s time to refine that invention before filing a related non-provisional application without surrendering the earlier priority date. Securing an earlier priority date both ensures that later inventors cannot obtain a patent to the same invention and provides protection against certain arguments that developments in the field arising after the priority date should prevent or invalidate the applicant’s invention.
If the non-provisional patent applications filed for VLR199, VLR258, VLR247, and VLR360 result in issued patents, such patents are expected to expire in 2047, without taking potential patent term adjustment or patent term extension into consideration. If we or Paragon timely file non-provisional patent applications in the United States and in countries outside of the United States with regard to Paragon’s variant ActRIIA- or ActRIIB- fusion protein-related provisional patent applications and/or Paragon’s anti-PDGF-B antibody-related provisional patent applications, and these non-provisional patent applications result in issued patents, such patents are expected to expire in 2047, without taking potential patent term adjustment or patent term extension into consideration.
Other IP Rights
In addition to patents, we rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and know-how can be difficult to protect. We seek to protect our proprietary information, in part by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee, however, that we have executed such agreements with all applicable counterparties, that such agreements will not be breached, or that these agreements will afford us adequate protection of our intellectual property and proprietary rights. For more information, please see the section titled “Risk Factors—Risks Related to Our Intellectual Property” in this Quarterly Report on Form 10-Q.
Commercial
Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution capabilities.
Manufacturing
We do not own or operate, and currently have no plans to establish, any manufacturing facilities. All of our preclinical and clinical drug supply development, manufacturing, storage, distribution and testing are outsourced to third-party manufacturers and facilities. Our manufacturing strategy enables us to more efficiently direct financial resources to the research, development and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities. As our programs advance through development, we expect to enter into longer-term commercial supply agreements with key suppliers and manufacturers to fulfill and secure our supply needs.
Competition
The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our programs, technology, development experience and scientific knowledge provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of the companies with which we are currently competing or will compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, and enrolling patients in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Key competitive factors affecting the success of our product candidates, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level of generic and biosimilar competition, and the availability of reimbursement from government and other third-party payors. Our competitors may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.
There are numerous approved therapies for PAH across the endothelin, nitric oxide and prostacyclin pathways, marketed by companies including United Therapeutics, Johnson & Johnson, Bayer, Merck and Liquidia. Winrevair, marketed by Merck following its acquisition of Acceleron Pharma, is the only approved ActRII-Fc ligand trap and is our most direct competitor. Merck is advancing Winrevair into Phase 3 in PH-HFpEF.
We are aware of several other agents in clinical development for PAH and related indications, including, but not limited to, HS235 (GSK6792070), a BMP-9/10-sparing ActRIIB-Fc ligand trap acquired by GSK; REGN13335, an anti-PDGF-B monoclonal antibody in development by Regeneron Pharmaceuticals; ralinepag, an oral prostacyclin receptor agonist in development by United Therapeutics;
seralutinib, an inhaled PDGFR, CSF1R and c-Kit inhibitor in development by Gossamer Bio; IKT-001Pro, an oral imatinib prodrug in development by Inhibikase Therapeutics; treprostinil palmitil inhalation powder in development by Insmed; L606, a liposomal treprostinil in development by Liquidia; and mosliciguat, an inhaled sGC activator in development by Roivant.
In addition, because our PAH product candidates are biologics, they may in the future face competition from biosimilar products, including any biosimilar versions of Winrevair that may be developed following the expiration of its applicable exclusivities.
Government Regulation
The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory authorities of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. Generally, before a new therapeutic product can be marketed, considerable data demonstrating a biological product candidate’s quality, safety, purity and potency, must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. For biological product candidates, potency is similar to efficacy and is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result.
Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-marketing may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications from the sponsor, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us and our products or product candidates.
U.S. Biologics Regulation
In the United States, biological products (or “biologics”) are subject to regulation under the Federal Food, Drug, and Cosmetic Act (“FDCA”), the Public Health Service Act (“PHSA”) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:
•completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s current Good Laboratory Practices (“GLP”) regulation;
•submission to the FDA of an Investigational New Drug Application (“IND”), which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;
•approval by an independent institutional review board (“IRB”), or ethics committee at each clinical site before the trial is commenced;
•manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (“cGMPs”);
•performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice (“GCP”) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;
•preparation of and submission to the FDA of a biologics license application (“BLA”), after completion of all pivotal clinical trials;
•a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
•satisfactory completion of an FDA Advisory Committee review, if applicable;
•satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product’s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and
•FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.
Preclinical and Clinical Development
Prior to beginning any clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. In April 2025, the FDA published a roadmap to reduce animal testing in preclinical safety studies, including those required in INDs, with scientifically validated new approach methodologies (“NAMs”). An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.
Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.
For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.
•Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
•Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.
•Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.
In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.
A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.
BLA Submission and Review
Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.
In addition, under the Pediatric Research Equity Act (“PREA”), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan (“PSP”) within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted, except that the PREA will apply to an original BLA for a new active ingredient that is orphan-designated if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that the FDA determines to be substantially relevant to the growth or progression of a pediatric cancer.
Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA’s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product’s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.
If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a risk evaluation and mitigation strategy (“REMS”) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the
product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.
Regulation of Combination Products
Certain therapeutic products are comprised of multiple components, such as drug components, biologic components, and device components, that would normally be subject to different regulatory frameworks by the FDA and frequently regulated by different centers at the FDA. These products are known as combination products. Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The determination of which center will be the lead center is based on the “primary mode of action” of the combination product. Thus, if the primary mode of action of a drug/biologic-device combination product is attributable to the drug or biological product, the FDA center responsible for premarket review of the drug or biological product would have primary jurisdiction for the combination product. The FDA has also established the Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. A combination product with a primary mode of action attributable to the drug or biologic component generally would be reviewed and approved pursuant to the drug or biologic approval processes set forth in the FDCA. In reviewing the new drug application (“NDA”) or BLA for such a product, however, FDA reviewers would consult with their counterparts in the FDA’s Center for Devices and Radiological Health to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products with both device and drug/biologic components are subject to cGMP requirements applicable to both drugs and devices, including the Quality Management System Regulation applicable to medical devices.
Post-Approval Requirements
Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer’s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, and potency or effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.
The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:
•restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;
•fines, warning letters or holds on post-approval clinical studies;
•refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;
•product seizure or detention, or refusal of the FDA to permit the import or export of products;
•consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
•mandated modification of promotional materials and labeling and the issuance of corrective information;
•the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or
•injunctions or the imposition of civil or criminal penalties.
The FDA closely regulates the marketing, labeling, advertising, and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.
Biosimilars and Reference Product Exclusivity
The Affordable Care Act (“ACA”) includes a subtitle called the Biologics Price Competition and Innovation Act (“BPCIA”), which created an abbreviated approval pathway for biological products that are highly similar, or “biosimilar,” to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.
Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.
A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA’s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. The FDA has issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA’s interpretation of certain statutory requirements added by the BPCIA.
Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.
A reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant’s favor of a lawsuit challenging the biologics’ patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period.
A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study.
The BPCIA is complex and continues to be interpreted and implemented by the FDA. On December 20, 2020, Congress amended the PHSA as part of the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.
Patent Term Extension
In the United States, after a BLA is approved, owners of relevant drug patents may apply for up to a five-year patent extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as one-half the time between the later of the effective date of an IND and issue date of the patent for which extension is sought, and the submission date of a BLA, plus the time between BLA submission date and the BLA approval date up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14 years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Some, but not all, foreign jurisdictions possess patent term extension or other additional patent exclusivity mechanisms that may be more or less stringent and comprehensive than those of the United States.
Other Healthcare Laws and Compliance Requirements
Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (“AKS”); the federal False Claims Act (“FCA”); the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and similar foreign, federal and state fraud, abuse, and transparency laws.
The AKS prohibits, among other things, persons, and entities from knowingly and willfully soliciting, receiving, offering, or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common commercial activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, for persons in a position to refer or recommend federally reimbursable healthcare business may be alleged to be intended to induce prescribing, purchasing or recommending, and may be subject to scrutiny if they do not qualify for an exception or regulatory safe harbor. Qualifying for a statutory exception or regulatory safe harbor requires satisfying all of the criteria for the exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS, but it does increase the risk of regulatory scrutiny. Ultimately, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
The FCA, which can be enforced through civil whistleblower or qui tam actions, prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.
HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.
The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics, and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.
The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid & Medicare Services (“CMS”) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.
We are also subject to federal price reporting laws and federal consumer protection and unfair competition laws. Federal price reporting laws require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products. Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers.
We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.
Data Privacy and Security
Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information and could apply to our operations or the operations of our partners.
For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (“HITECH”), and their respective implementing regulations impose data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (“PHI”) for or on behalf of such covered entities. These requirements imposed by HIPAA and HITECH on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient’s past, present, or future physical or mental health or condition or information about a patient’s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators.
Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (“HHS”) to settle allegations of HIPAA non-compliance. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys’ fees and costs associated with pursuing federal civil actions. To the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied. In addition, state health information privacy laws, such as California’s Confidentiality of Medical Information Act and Washington’s My Health My Data Act, that govern the privacy and security of health-related information, specifically, may apply even when HIPAA does not and impose additional requirements.
Even when HIPAA and state health information privacy laws do not apply, according to the FTC and state attorneys general, violating consumers’ privacy rights or failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act and state consumer protection laws.
In addition, certain state laws, such as the California Consumer Privacy Act of 2018 (“CCPA”), as amended by the California Privacy Rights Act of 2020, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA in various ways. Numerous other states have passed similar laws, but many differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, and affords rights to California residents in relation to their personal information. Health information falls under the CCPA’s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked, directly or indirectly, with a particular consumer or household and is included under a new category of personal information, “sensitive personal information,” which is offered greater protection.
The CCPA and numerous other comprehensive privacy laws that have passed or are being considered in other states, as well as at the federal and local levels, exempt PHI that is subject to HIPAA; and others exempt covered entities and business associates subject to HIPAA altogether, further complicating compliance efforts, and increasing legal risk and compliance costs for us and the third parties upon whom we rely.
Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence and machine learning, controlling for data bias, and antidiscrimination.
Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.
Coverage and Reimbursement
In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates, if approved, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.
Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product candidate for which we obtain regulatory approval. Sales of any approved product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is:
•a covered benefit under its health plan;
•safe, effective, and medically necessary;
•neither experimental nor investigational.
Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices, and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.
For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.
In addition, the U.S. government, state legislatures, and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The Inflation Reduction Act of 2022 (“IRA”) provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. On August 29, 2023, HHS announced the list of the first ten drugs subject to price negotiations. These price negotiations occurred in 2024. In January 2025, CMS announced a list of 15 additional Medicare Part D drugs that will be subject to price negotiations. The IRA also provides a new “inflation rebate” covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision requires drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition, beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar’s market entry beyond two years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA’s impact on commercialization and competition remains largely uncertain.
In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we may commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.
Finally, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union (“EU”) provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower.
Healthcare Reform
The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.
The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies’ share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.
Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs being covered under Medicare Part D.
Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021. In May 2025, the Trump Administration renewed the idea of international reference pricing through an executive order entitled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” which, among other things, directs the HHS and other agencies to communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for U.S. patients in line with comparably developed nations and to facilitate direct-to-consumer purchasing programs. The HHS subsequently issued guidance indicating the MFN target price will be the lowest price paid in an Organisation for Economic Co-operation and Development country with a gross domestic product (“GDP”) per capita of at least 60% of the U.S. GDP per capita. In addition, in December 2025, CMS proposed new drug payment models to lower drug prices for Medicare beneficiaries; under the models, CMS would explore potential adjustments to Medicare drug inflation rebate calculations by comparison to international drug pricing information. It is currently unclear whether and to what extent these measures will be implemented and what impact any such implementation would have on our business.
Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, we expect government authorities to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.
Individual states in the U.S. have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.
Other Government Regulation Outside of the United States
In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.
Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.
The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.
Regulation in the European Union
European Data Laws
The processing of personal data, including health-related personal data in the European Economic Area (“EEA”) is mainly governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (“GDPR”), and related data protection laws in individual EEA countries. In the United Kingdom (“UK”), the processing of personal data is mainly governed by the GDPR as incorporated into UK law pursuant to the European Union (Withdrawal) Act 2018 (the “UK GDPR”). The GDPR and UK GDPR impose a number of strict obligations and requirements for the processing, including collecting, analyzing and transferring, of personal data of individuals in the EEA or in the UK, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR and UK GDPR include requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the personal data breaches which may have to be notified to the national data protection authorities and data subjects, the measures to be taken when engaging processors, and obligations relating to the security and confidentiality of the personal data. EEA countries may also impose additional requirements in relation to the processing of health, genetic and biometric data through their national legislation.
In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the EEA that are not considered by the European Commission (“EC”) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (“SCCs”). When relying on the appropriate safeguards, data exporters, with the assistance of the data importers, are also required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the safeguards in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential equivalence. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. With regard to the transfer of data from the EEA to the United States, on July 10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework. With regard to the transfer of data from the EEA to the UK, based on the EC’s adequacy decision of June 28, 2021 and subsequent renewals, personal data may continue to flow freely from the EEA to the UK on the basis that the UK is deemed to provide an adequate level of data protection until December 27, 2031. The adequacy decisions will automatically expire unless renewed.
With respect to transfers from the UK to other countries, these transfers are also subject to specific transfer rules under the UK regime. These UK international transfer rules broadly mirror the EU GDPR rules.
On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (“IDTA”) and the international data transfer addendum to the EC’s standard contractual clauses for international data transfers (“UK Addendum”) and a document setting out transitional provisions. The IDTA and UK Addendum came into force on March 21, 2022 and are the primary UK-approved mechanisms for putting in place appropriate safeguards for UK restricted transfers, subject to transitional arrangements for legacy SCCs. Regarding transfers from the UK to the EEA, the UK Information Commissioner’s Office (“ICO”) guidance indicates that organizations do not need new arrangements. With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the UK Extension to the EU-US Data Privacy Framework, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection where the recipient is a U.S. organization certified to the EU-US Data Privacy Framework and participating in the UK Extension to the EU-US Data Privacy Framework.
Failure to comply with the requirements of the GDPR or UK GDPR and the related national data protection laws of the EEA countries may result in significant monetary fines for noncompliance of up to €20 million or £17.5 million (as applicable) or 4% of the total worldwide annual turnover (for higher-tier infringements). This is enforced by ICO and is entirely separate from fines under EU GDPR. In addition, violations of national laws can trigger additional administrative penalties, investigations, corrective orders, temporary or definitive bans, and, in some jurisdictions, a number of criminal offenses for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EEA countries may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EEA.
Furthermore, there are specific requirements relating to processing health data from clinical trials, including public disclosure obligations provided in the EU Clinical Trials Regulation No. 536/2014 (“CTR”), European Medicines Agency (“EMA”) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results.
Drug and Biologic Development Process
Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (“MA”) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC (“Clinical Trials Directive”) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU.
Under the CTR, a sponsor is able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the Clinical Trials Information System or “CTIS”). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an “opt-out” from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU database, including a layperson’s summary. Since January 31, 2023, submission of initial clinical trial applications via CTIS is mandatory and CTIS serves as the single entry point for submission of clinical trial-related information and data. As of January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive need to comply with the CTR and have to be transitioned to CTIS.
Under the CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (“ICH”) guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the National Competent Authority and to the Ethics Committees of the EU member state where they occur.
During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (“CHMP”) on the recommendation of the Scientific Advice Working Party (“SAWP”). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (“MAA”) of the product concerned.
Drug Marketing Authorization
In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA. To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.
To be used or sold in the UK, a drug must have an effective MA granted by the Medicines and Healthcare Products Regulatory Agency (“MHRA”) under the Human Medicines Regulations 2012 (SI 2012/1916), as amended. MA applications are submitted electronically
via the MHRA Submissions Portal. Under the MHRA’s national assessment procedure, the MHRA generally aims to reach a decision within 210 “clock-on” days, excluding any “clock-stops” while the applicant prepares responses to MHRA questions.
On August 30, 2023, the MHRA published detailed guidance on its recently announced new International Recognition Procedure (“IRP”) for MAAs. The IRP applies since January 1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g., Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK. Applicants can submit initial MAAs to the IRP, but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations, and renewals.
Centralized Authorization Procedure
The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional EEA Member States (Norway, Iceland, and Liechtenstein). The centralized procedure is compulsory for specific medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy, or tissue engineered medicines) and medicinal products with a new active substance indicated for the treatment of certain diseases (HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune diseases and other immune dysfunctions, and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure.
Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA’s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety, and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion.
Decentralized Authorization Procedure
Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state’s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure).
The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.
Risk Management Plan
All new MAAs must include a Risk Management Plan (“RMP”) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national competent authority, or (ii) whenever the risk-management system is modified, especially as the result of
new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.
MA Validity Period
MAs have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.
Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.
For the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA. Following Windsor Framework changes, which became effective January 1, 2025, European Commission Union authorizations are no longer valid in Northern Ireland and centrally authorized products are instead authorized by the MHRA under UK-wide marketing authorizations; existing licenses for product licensed by the MHRA that covers Great Britain only become geographically valid UK-wide while retaining their license number/prefix.
On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January 31, 2020 and ending on December 31, 2020 (the “Brexit Transition Period”) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining member states of the EU, the three-year period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.
Exceptional Circumstances/Conditional Approval
Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. Once a conditional MA has been granted, the MA holder must fulfil specific obligations within defined timelines. A conditional MA is valid for one year and must be renewed annually, but it can be converted into a standard MA once the MA holder fulfils the obligations imposed and the complete data confirm that the medicine’s benefits continue to outweigh its risks.
Data and Market Exclusivity
As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor’s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder’s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. Innovative medicinal products, referred to as New Chemical Entities (“NCEs”) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity.
An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.
The data exclusivity period begins on the date of the product’s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder’s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the
eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).
Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU’s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.
On April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation and negotiations are still ongoing. The timing for finalization of these negotiations and entry into force are unclear.
The current drafts envisage:
•a shortening of the periods of data exclusivity from eight to six years (with transferrable vouchers for an additional year of market protection as an incentive for the development of new antibiotics),
•earlier regulatory guidance and extension of market exclusivity for orphan medicines (depending on certain conditions),
•four-year data exclusivity for additional indications of existing products, and
•rules governing the availability of products (including shortage prevention plans and some supply obligations for manufacturers).
Pediatric Development
In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a paediatric investigation plan (“PIP") together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA’s Pediatric Committee (“PDCO”). Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted a MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two-year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.
In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. From January 1, 2025, EU pediatric requirements are addressed via Windsor Framework categorization: for Category 2 products, both UK and EU pediatric requirements apply, and an EU-agreed PIP must also be in place (unless waived).
PRIME Designation
In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (“PRIME”) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from the Committee for Advanced Therapies (“CAT”) are appointed facilitating increased understanding of the product at EMA’s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.
Post-Approval Regulation
Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.
Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors, to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal, or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties.
The holder of a MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.
These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine’s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (“PSURs”) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn, or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC’s decision provides can undermine the ongoing validity of the MA.
More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension, or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.
The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC (repealed by Directive 2017/1572 on January 31, 2022), Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (“GMP”). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. Amendments or replacements of at least Directive 2001/83/EC and Regulation (EC) No 726/2004 are part of the reform proposal for European pharmaceutical legislation. Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations, and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.
On October 27, 2025, the Council of the EU approved a framework for compulsory licensing of crisis-relevant products (including medicinal products) in crisis situations. While the proposal focuses on voluntary agreements with intellectual property rights holders, it includes rules on compulsory licensing as a measure of last resort upon activation / declaration of a crisis or emergency mode. The European Parliament has not yet voted on the proposal.
Sales and Marketing Regulations
The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising, and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product’s summary of product characteristics (“SmPC”) as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines, and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on our promotional activities with healthcare professionals.
EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern Ireland.
Anti-Corruption Legislation
In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.
Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician’s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.
In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act 2010. Due to the Bribery Act 2010’s far-reaching territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person’s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed. The Bribery Act 2010 is comprised of four offenses that cover (i) individuals, companies and partnerships that give, promise, or offer bribes, (ii) individuals, companies, and partnerships that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships that bribe foreign public officials, and (iv) companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten years and in some cases both.
Regulations in the UK and Other Markets
The UK formally left the EU on January 31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement, which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.
The UK government has adopted the Medicines and Medical Devices Act 2021 (the “MMDA”) to enable the UK’s regulatory frameworks to be updated following the UK’s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines, and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK.
For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.
If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.
Regulation of Medicinal Products in Australia
The Australian Therapeutic Goods Administration (“TGA”) and the National Health and Medical Research Council (“NHMRC”) set the GCP requirements for clinical research in Australia.
Compliance with the regulations, standards and codes set by the TGA and NHMRC is mandatory. Under the Therapeutic Goods Act 1989 (Cth) and the Therapeutic Goods Regulations 1990 (Cth), it is a condition (amongst other conditions) of all clinical trials involving investigational medicinal products to comply with the National Statement on Ethical Conduct in Research Involving Humans, published by the NHMRC (the “National Statement”), and the Guideline for Good Clinical Practice published by the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (“ICH Guidelines”). The ICH Guidelines have been adopted in Australia and must be complied with across all fields of clinical research involving therapeutic goods, including those related to pharmaceutical quality, nonclinical and clinical data requirements, and trial designs. The basic requirements for preclinical data to support a first-in-human trial under ICH Guidelines are applicable in Australia. Requirements related to adverse event reporting in Australia are generally similar to those required in other major jurisdictions, although reporting timeframes may differ to other jurisdictions.
Clinical trials conducted using “unapproved therapeutic goods” in Australia, being those which have not yet been evaluated by the TGA for quality, safety, and efficacy (and including unapproved indications of therapeutic goods which have otherwise been approved for use in Australia) must occur pursuant to either the Clinical Trial Notification Scheme (“CTN Scheme”) or the Clinical Trial Approval Scheme (“CTA Scheme”). In each case, the trial is supervised by a Human Research Ethics Committee (“HREC”), an independent review committee constituted in accordance with the National Statement that ensures the protection of rights, safety and well-being of human subjects involved in a clinical trial. An HREC reviews, approves and provides continuing oversight of trial protocols (including any amendments), methods and materials intended to be used in obtaining and documenting informed consent of the clinical trial subjects.
The CTN Scheme broadly involves:
•submission to an HREC, of all material relating to the proposed clinical trial, including the trial protocol;
•the HREC reviews the scientific validity of the trial design, the balance of risk versus harm of the therapeutic good, the ethical acceptability of the trial process, and approves the trial protocol. The HREC is also responsible for monitoring the conduct of the trial;
•the institution or organization at which the trial will be conducted (the “Approving Authority”) giving final approval for the conduct of the trial at the site, in terms no less restrictive to those advised by the HREC; and
•the investigator submitting a ‘Notification of Intent to Conduct a Clinical Trial’ form (“CTN Form”) to the TGA. The CTN Form must be signed by the sponsor, the principal investigator, the chairman of the HREC and a person responsible from the Approving Authority. The TGA does not review any data relating to the clinical trial however CTN trials cannot commence until the trial has been notified to the TGA. It is the responsibility of the sponsor to ensure that all relevant approvals are in place before supplying the “unapproved” therapeutic goods in clinical trials in Australia.
Under the CTA Scheme:
•a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment, which includes payment of relevant fees;
•the TGA will undertake a preliminary assessment to ensure that there is sufficient data to begin evaluation. If critical data is missing, the TGA may request further information;
•a sponsor must forward any comments made by the TGA delegate to the HREC(s) at the sites where the trial will be conducted;
•the HREC is responsible for considering the scientific and ethical issues of the proposed trial protocol.
A sponsor cannot commence a trial under the CTA Scheme until written advice has been received from the TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted.
Approval for inclusion in the Australian Register of Therapeutic Goods (“ARTG”) is required before a therapeutic good (including pharmaceutical product) may be marketed (or supplied, imported, exported, or manufactured) in Australia. Exceptions apply to therapeutic goods/pharmaceutical products that are supplied, imported, and exported to and from Australia for the purposes of a clinical trial, on the basis that certain conditions are met (e.g., the trial is conducted in accordance with the CTN or CTA Scheme).
Once a sponsor decides to register a therapeutic good/pharmaceutical product in Australia, in order to obtain registration of the product on the ARTG, it is required that (amongst others):
•the sponsor submits appropriate documentation, including the outcomes of clinical trials and studies, to allow the TGA to assess the quality, safety, and efficacy of the therapeutic product/pharmaceutical product; and
•the sponsor submits evidence which demonstrates that the manufacture of the therapeutic product/pharmaceutical product complies with the applicable GMP requirements.
The TGA has the ultimate discretion to decide whether to include the therapeutic product/pharmaceutical product in the ARTG.
Additional Regulation
In addition to the foregoing, local, state, and federal laws, including in the United States, regarding such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical, and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous or biohazardous substances, we could be liable for damages, environmental remediation, and/or governmental fines. We believe that we are in material compliance with applicable environmental laws and occupational health and safety laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. We may incur significant costs to comply with such laws and regulations now or in the future.
Employees and Human Capital Resources
As of October 31, 2026, we had one full time employee. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good.
Legal Proceedings
From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 6. Exhibits
|
|
Exhibit Number |
Description |
|
|
2.1* |
Agreement and Plan of Merger, dated as of October 13, 2026, by and among Alaunos Therapeutics, Inc., Valkyrie Merger Sub I, Inc., Valkyrie Merger Sub II, LLC and Velaris Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed on October 13, 2026). |
|
|
3.1 |
Third Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, SEC File No. 001-33038, filed July 17, 2024). |
|
|
3.2 |
Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on July 10, 2025). |
|
|
3.3 |
Second Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, SEC File No. 001-33038, filed February 1, 2024). |
|
|
3.4 |
Certificate of Designation of Series A-1 Convertible Preferred Stock of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on April 14, 2025). |
|
|
3.5 |
Certificate of Designation of Series A-2 Convertible Preferred Stock of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on June 26, 2025). |
|
|
3.6 |
Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on October 13, 2026). |
|
|
3.7 |
Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on October 13, 2026). |
|
|
4.1 |
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on September 22, 2026). |
|
|
4.2 |
Form of Registration Rights Agreement, by and among Alaunos Therapeutics, Inc. and the investors signatory thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on October 13, 2026). |
|
|
4.3 |
Form of Share Repurchase and Voting Agreement, by and among Alaunos Therapeutics, Inc., Velaris Therapeutics, Inc. and the holders party thereto (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on October 13, 2026). |
|
|
10.1 |
Form of Securities Purchase Agreement, dated as of September 18, 2026 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 22, 2026). |
|
|
10.2 |
Placement Agency Agreement, dated September 18, 2026, between the Registrant and Dawson James Securities, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on September 22, 2026). |
|
|
10.3 |
Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on September 22, 2026). |
|
|
|
|
10.4* |
Securities Purchase Agreement, dated as of October 13, 2026, by and among Alaunos Therapeutics, Inc. and each investor listed on Exhibit A thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on October 13, 2026). |
|
|
10.5* |
Fusion Protein Discovery and Option Agreement, dated as of October 13, 2026, by and between Paragon Laboratories, Inc. and Velaris Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-3 filed on November 12, 2026). |
|
|
10.6* |
Research Letter Agreement, dated as of July 17, 2026, by and between Paragon Laboratories, Inc. and Velaris Therapeutics, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-3 filed on November 12, 2026). |
|
|
31.1+ |
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
32.1++ |
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|
|
101.INS+ |
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
|
|
101.SCH+ |
Inline XBRL Taxonomy Extension Schema Document |
|
|
104+ |
Cover Page Interactive Data File—the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments |
|
|
+ |
Filed herewith. |
++ |
This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
* |
Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. |
|
Certain portions of this exhibit (indicated by “[***]”) have been omitted because they are both (i) not material and (ii) customarily and actually treated as private or confidential. |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ALAUNOS THERAPEUTICS, INC.
|
|
By: |
|
/s/ Holger Weis |
Holger Weis |
Chief Executive Officer |
(On Behalf of the Registrant and as Principal Executive Officer and Principal Financial Officer) Dated: November 16, 2026 |
|
|
By: |
|
/s/ Ferdinand Groenewald |
Ferdinand Groenewald |
Vice President, Finance |
(Principal Accounting Officer) Dated: November 16, 2026 |